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Summary
High resolution MR images acquired at multiple time points of the brain allow quan-
tification of localized changes induced by external factors such as maturation, ageing
or disease progression/recovery. High-dimensional warping of such MR images incor-
porates changes induced by external factors into the accompanying deformation field.
Deformation fields from high dimensional warping founds tensor based morphome-
try (TBM), and provides unique opportunities to study human brain morphology and
plasticity. In this thesis, specially adapted image processing streams utilizing several
image registration techniques to characterize differences between brains, demonstrate
the versatility and specificity of the employed voxel-wise morphometric methods.
More specifically TBM is used to study neurodegenerative changes following severe
traumatic brain injuries. Such injuries progress for months, perhaps even years post-
injury. Little information is known about the spatial distribution and the clinical signif-
icance of this late atrophy. TBM revealed a large coherent cluster of significant atrophy
consisting of the brain stem and cerebellar peduncles extending bilaterally through the
thalamus, internal and external capsules, putamen, inferior and superior longitudinal
fasciculus, corpus callosum and corona radiata. This indicates that the long-term at-
rophy is attributable to consequences of traumatic axonal injury. Despite progressive
atrophy, remarkable clinical improvement occurred in most patients.
ii
The other study utilized TBM and voxel based morphometry (VBM) in two separate
papers concerning antipsychotic-naı¨ve first episode schizophrenia. Volume reductions
of hippocampal and caudate regions were found in patients compared to controls using
VBM. Six months later, TBM revealed continued volume loss in striatum and hippocam-
pus, despite treatment with quetiapine. The mechanisms underlying these progressive
brain dynamics, specific antipsychotic compounds and clinical symptoms warrant fur-
ther clarification.
Resume´
MR billeder af den menneskelige hjerne som er optaget med høj rumlig opløsning og
pa˚ flere tidspunkter giver mulighed for at kvantificere lokale tidslige forandringer som
følge af eksterne faktorer sa˚som modning, aldring eller sygdomsprogression. Billed-
registrering med millioner af frihedsgrader af sa˚danne MR billeder kvantificerer foran-
dringerne som følge af eksterne faktorer i det tilhørende deformationsfelt. Sa˚danne
deformationsfelter danner grundlag for tensor baseret morfometri (TBM), og giver en-
esta˚ende muligheder for at studere morfologi og plasticitet i menneskets hjerne. Specielt
tilpassede billedbehandlingsmetoder, der benytter sig af mange forskellige teknikker til
billedregistrering for at karakterisere forskelle mellem hjerner, viser alsidigheden og
specificiteten af de anvendte voxel-vise morfometriske metoder i to kliniske studier .
I første studie anvendes TBM til at undersøge neurodegenerative forandringer efter al-
vorlige traumatiske hjerneskader. Sa˚danne hjerneskader udvikles over flere ma˚neder,
endsige a˚r efter skadestidspunktet. Der eksisterer kun fa˚ studier om den rumlige fordel-
ing og den kliniske betydning af disse sene atrofiske hjerneskader. I dette studie afslører
TBM en stor sammenhængende klynge af atrofi, besta˚ende af hjernestammen, de cere-
bellare pedunklers forlængelse bilateralt gennem thalamus, capsula interna og eksterna,
putamen, inferior og superior longitudinal fasciculus, corpus callosum og corona radi-
ata. De regioner som udviste størst volumentab var strukturer, der er særlig udsatte for
traumatisk aksonal skade og resulterende Wallersk degeneration. Dette indikerer at den
progressive atrofi betinges af konsekvenserne af aksonal skade.
iv
Andet studie udgøres af to seperate artikler om antipsykotika-naive første-episode ski-
zofrene, hvor ba˚de TBM og voxel baseret morfometri (VBM) anvendes. Her blev vol-
umentab i striatum og hippocampus regioner afsløret hos patienter i forhold til kon-
trolgruppen ved baseline. Seks ma˚neder senere, viste TBM fortsat volumentab i ba˚de
striatum og hippocampus, pa˚ trods af behandling med anti-psykotika stoffet quetiapin.
Mekanismerne bag disse progressive hjerne forandringer, samt de strukturelle æn-
dringers relation til den antipsykotiske behandling og de kliniske symptomer berettiger
yderligere MR undersøgelser.
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Scientific contributions
This thesis is based on three papers [27, 28, 102] concerning longitudinal studies of
brain morphometry. Below is a full list including abstract of all peer-reviewed scientific
contributions made in the years 2006–2010 in order of publication; 9 Journal papers,
and 17 conference proceedings.
Conference proceedings [48–51, 105] are all derivatives of [47] concerning the devel-
opment of a gradient insensitive, generic technique for recording of non-MR signals by
use of surplus scanner bandwidth. However, due to my many other engagements the
project never really gained momentum, and my focus was redirected towards statistics
and image analysis. My scientific contributions to these publications was the devel-
opment and testing of methods to extract the recorded non-MR signals from the MR
signal.
Design of image processing methods, statistical design and analysis of functional MRI
(fMRI), was my scientific contribution to papers [68, 92] and conference proceedings
[77, 79, 89, 90, 93]. These papers address widely different neuroscientific questions,
such as recovery from acute optic neuritis, healthy aging, MDMA abuse and modulation
of the serotonin system.
Diffusion tensor imaging (DTI) and related image processing techniques, including im-
age distortion correction, were the focus of my involvement in the papers [78, 120]
and conference proceedings [46, 80]. Both papers revolve around the HUBU (”Hjer-
nens Udvikling hos Børn og Unge”) project, addressing brain maturation of typically
developing children and adolescents.
viii Scientific contributions
The papers [27, 28, 102, 134] concern studies on brain morphometry, and related con-
ference proceeding [106] constitutes the scientific work of the latter part of my PhD
project. My scientific contributions to these publications were design, development
and implementation of complex image processing streams, statistical design and anal-
ysis, as well as supervision.
The toolbox for correction of image distortions due to non-linearities in the scanner
gradient system (see section 2.1) was used in [27, 28, 75, 78, 120] and conference
proceedings [46, 80, 103, 104], and development and testing of the toolbox was part of
my scientific contributions to these.
Journal papers
[68] Korsholm, K., Madsen, K. H., Frederiksen, J. L. , Skimminge, A. and Lund, T.
E.; Recovery from optic neuritis: an ROI-based analysis of LGN and visual
cortical areas Brain. 2007 May;130(Pt 5):1244-53.
Optic neuritis (ON) is the first clinical manifestation in approximately 20% of patients
with multiple sclerosis (MS). The inflammation and demyelination of the optic nerve
are characterized by symptomatic visual impairment and retrobulbar pain, and asso-
ciated with decreased visual acuity, decreased colour and contrast sensitivity, delayed
visual evoked potentials and visual field defects. Spontaneous recovery of vision typi-
cally occurs within weeks or months after onset, depending on the resolution of inflam-
mation, remyelination, restoration of conduction in axons which persist demyelinated
and neuronal plasticity in the cortical and subcortical visual pathways. To assess where
recovery takes place along the visual pathway, visual activation was studied in the lat-
eral geniculate nucleus (LGN), the main thalamic relay nucleus in the visual pathway
and in three areas of the visual cortex: the lateral occipital complexes (LOC), V1 and
V2. We conducted a longitudinal functional magnetic resonance imaging (fMRI) study
of regions of interest (ROI) of activation in LGN and visual cortex in 19 patients with
acute ON at onset, 3 and 6 months from presentation. With fMRI we measured the
activation in the ROIs and compared activation during monocular stimulation of the
affected and unaffected eye. In the acute phase the activation of LGN during visual
stimulation of the affected eye was significantly reduced (P ¡ 0.01) compared to the
unaffected eye. This difference in LGN activation between the affected and unaffected
eye diminished during recovery, and after 180 days the difference was no longer sig-
nificant (P = 0.59). The decreased difference during recovery was mainly due to an
increase in the fMRI signal when stimulating the affected eye, but included a compo-
nent of a decreasing fMRI signal from LGN when stimulating the unaffected eye. In
LOC, V1 and V2 activation during visual stimulation of the affected eye in the acute
phase was significantly reduced (p < 0.01) compared to the unaffected eye, and during
recovery the difference diminished with no significant differences left after 180 days.
As the pattern of activation in LOC, V1 and V2 resembled the development in LGN we
found no evidence of additional cortical adaptive changes. The reduced activation of
the LGN to stimulation of the unaffected eye is interpreted as a shift away from early
Journal papers ix
compensatory changes established in the acute phase in LGN and may indicate very
early plasticity of the visual pathways.
[102] Sidaros, A., Skimminge, A., Liptrot, M.G., Sidaros, K., Engberg, A.W., Hern-
ing, M., Paulson, O.B., Jernigan, T.L. and Rostrup, E.; Long-term global and
regional brain volume changes following severe traumatic brain injury: a longi-
tudinal study with clinical correlates Neuroimage. 2009 Jan 1;44(1):1-8.
Traumatic brain injury (TBI) results in neurodegenerative changes that progress for
months, perhaps even years post-injury. However, there is little information on the spa-
tial distribution and the clinical significance of this late atrophy. In 24 patients who
had sustained severe TBI we acquired 3D T1- weighted MRIs about 8 weeks and 12
months post-injury. For comparison, 14 healthy controls with similar distribution of
age, gender and education were scanned with a similar time interval. For each sub-
ject, longitudinal atrophy was estimated using SIENA, and atrophy occurring before
the first scan time point using SIENAX. Regional distribution of atrophy was evaluated
using tensor-based morphometry (TBM). At the first scan time point, brain parenchy-
mal volume was reduced by mean 8.4% in patients as compared to controls. During the
scan interval, patients exhibited continued atrophy with percent brain volume change
(%BVC) ranging between -0.6% and -9.4% (mean -4.0%). %BVC correlated signif-
icantly with injury severity, functional status at both scans, and with 1-year outcome.
Moreover, %BVC improved prediction of long-term functional status over and above
what could be predicted using functional status at approximately 8 weeks. In patients
as compared to controls, TBM (permutation test, FDR 0.05) revealed a large coher-
ent cluster of significant atrophy in the brain stem and cerebellar peduncles extending
bilaterally through the thalamus, internal and external capsules, putamen, inferior and
superior longitudinal fasciculus, corpus callosum and corona radiata. This indicates
that the long-term atrophy is attributable to consequences of traumatic axonal injury.
Despite progressive atrophy, remarkable clinical improvement occurred in most pa-
tients.
[78] Madsen, K. S., Baare´, W. F., Vestergaard, M., Skimminge, A., Ejersbo, L.R.,
Ramsøy, T. Z., Gerlach, C., A˚keson, P., Paulson, O.B. and Jernigan, T.L.; Re-
sponse inhibition is associated with white matter microstructure in children, Ac-
cepted in Neuropsychologia, available as E-publication
Cognitive control of thoughts, actions and emotions is important for normal behaviour
and the development of such control continues throughout childhood and adolescence.
Several lines of evidence suggest that response inhibition is primarily mediated by a
right-lateralized network involving inferior frontal gyrus (IFG), presupplementary mo-
tor cortex (preSMA), and subthalamic nucleus. Though the brain’s fibre tracts are
known to develop during childhood, little is known about how fibre tract development
within this network relates to developing behavioural control. Here we examined the
relationship between response inhibition, as measured with the stop-signal task, and in-
dices of regional white matter microstructure in typically-developing children. We hy-
pothesized that better response inhibition performance would be associated with higher
fractional anisotropy (FA) in fibre tracts within right IFG and preSMA after control-
ling for age. Mean FA and diffusivity values were extracted from right and left IFG
and preSMA. As hypothesized, faster response inhibition was significantly associated
with higher FA and lower perpendicular diffusivity in both the right IFG and the right
preSMA, possibly reflecting faster speed of neural conduction within more densely
x Scientific contributions
packed or better myelinated fibre tracts. Moreover, both of these effects remained sig-
nificant after controlling for age and whole brain estimates of these DTI parameters.
Interestingly, right IFG and preSMA FA contributed additively to the prediction of per-
formance variability. Observed associations may be related to variation in phase of
maturation, to activity-dependent alterations in the network subserving response inhi-
bition, or to stable individual differences in underlying neural system connectivity.
[92] Ramsøy, T.Z., Liptrot, M.G., Skimminge, A., Lund, T.E., Sidaros, K., Chris-
tensen, M. S., Baare´, W., Paulson, O. B. and Jernigan, T. L.; Regional activation
of the human medial temporal lobe during intentional encoding of objects and
positions,Neuroimage. 2009 Oct 1;47(4):1863-72.
The medial temporal lobe (MTL) consists of several regions thought to be involved in
learning and memory. However, the degree of functional specialization among these
regions remains unclear. Previous studies have demonstrated effects of both content
and processing stage, but findings have been inconsistent. In particular, studies have
suggested that the perirhinal cortex is more involved in object processing than spa-
tial processing, while other regions such as the parahippocampal cortex have been
implicated in spatial processing. In this study, functional magnetic resonance imag-
ing (fMRI) optimized for the MTL region was used to probe MTL activation during
intentional encoding of object identities or positions. A region of interest analysis
showed that object encoding evoked stronger activation than position encoding in bi-
lateral perirhinal cortex, temporopolar cortex, parahippocampal cortex, hippocampus
and amygdala. Results also indicate an unexpected significant correlation in activation
level between anterior and posterior portions in both the left parahippocampal cortex
and left hippocampus. Exploratory analysis did not show any regional content effects
during preparation and rehearsal stages. These results provide additional evidence for
functional specialization within the MTL, but were less clear regarding the specific
nature of content specificity in these regions.
[27] Bjørn H. Ebdrup, Birte Glenthøj, Hans Rasmussen, Bodil Aggernaes, Annika
R. Langkilde, Olaf B. Paulson, Henrik Lublin, Arnold Skimminge, William
Baare´; Hippocampal and Caudate Volume Reductions in Antipsychotic-Naı¨ve
First Episode Schizophrenia, Journal of Psychiatry and Neuroscience. 2010;35(2):95-
104
Enlarged ventricles and reduced hippocampal volumes are consistently found in first
episode schizophrenia Studies investigating brain structure in antipsychotic-naı¨ve pa-
tients generally focused on the striatum. Here we examined whether ventricular en-
largement, hippocampal and caudate volume reductions are morphological traits in
antipsychotic-naı¨ve first episode schizophrenia.
High-resolution 3D T1-weighted magnetic resonance imaging scans were obtained in
38 antipsychotic-naı¨ve first episode schizophrenia patients and 43 matched healthy
control subjects on a 3 Tesla scanner. Brain images were warped to each other using a
high-dimensional inter-subject registration algorithm. Voxel-wise group comparisons
were performed with permutation tests. Small volume correction was performed for
the hippocampus, the caudate and the ventricles, using a FDR-correction (p¡0.05) to
control for multiple comparisons. Brain structure volumes estimates were derived and
analyzed. Patients were divided into those with (N=9) or without (N=29) any lifetime
substance abuse diagnosis to examine the possible effects of abuse.
Journal papers xi
As hypothesized, hippocampal and caudate volumes were decreased in patients. Ven-
tricular enlargement was absent. No differences in global volumes were found and no
significant associations between tissue volumes and duration of untreated illness and
psychopathology, respectively, were observed. The hippocampal reductions appeared
influenced by a history of substance abuse. Exploratory analyses indicated reduced
nucleus accumbens volumes in the patients.
This study was not designed to test for differences a priori between schizophrenia pa-
tients with or without lifetime substance abuse and the sub-group comprising abusing
patients was small.
Hippocampal and caudate volume reductions may constitute a morphological trait in
antipsychotic-naı¨ve first episode schizophrenia patients. However, the clinical implica-
tions of these findings are still unclear. Moreover, past substance abuse may accentuate
hippocampal volume reductions. MRI studies explicitly addressing the potential ef-
fects of substance abuse in antipsychotic-naı¨ve first episode schizophrenia patients are
warranted.
[28] Bjørn H. Ebdrup, Arnold Skimminge, Hans Rasmussen, Bodil Aggernaes, Bob
Oranje, Henrik Lublin, William Baare´, Birte Glenthøj; Regional brain changes in
antipsychotic-naı¨ve first-episode schizophrenia patients treated with quetiapine:
Relation to dose and psychopathology Published in The international journal of
neuropsychopharmacology, August 2010.
MRI studies have shown progressive brain alterations in the course of schizophrenia.
Whereas first- generation antipsychotics have been associated with striatal volume in-
creases, the effects of second- generation antipsychotics (SGA) on striatal volumes
are unclear. Neuroprotective effects of SGA’s have been suggested on hippocampal
volumes, whereas ventricular enlargement may be associated with clinical outcome.
Dose-dependent volumetric effects of individual SGA’s have been scarcely investi-
gated. Here we examined structural brain changes in initially antipsychotic-naA˜¯ve
first-episode schizophrenia patients after six months treatment with quetiapine.
High-resolution 3D T1-weighted magnetic resonance imaging scans were obtained on
a 3 Tesla scanner at baseline and after six months in 22 antipsychotic-naı¨ve first-episode
schizophrenia patients and 28 matched healthy control subjects. Baseline and follow-
up brain images were analyzed using tensor based morphometry (TBM). Voxel-wise
group comparisons were performed with SPM5. Small volume correction was per-
formed for striatum, hippocampus and the ventricles, using a FDR-correction (p¡0.05)
to control for multiple comparisons. Additionally, volumetric estimates were derived
and analyzed. Effects of medication, including dose-dependent effects, and associa-
tions with psychopathology (PANSS-scores) were assessed.
Patients had significant striatal and hippocampal volume loss over the six months treat-
ment period. The striatal volume loss was most pronounced in low quetiapine doses
and less apparent in high doses. Conversely, hippocampal volume loss appeared more
pronounced in high quetiapine doses than in than low doses. Clinically, higher base-
line positive symptoms were associated with more striatal and hippocampal volume
loss over time. Although patients’ ventricles did not change significantly, ventricular
increases correlated with less improvement on negative symptoms.
Progressive regional volume loss in quetiapine-treated first-episode schizophrenia pa-
tients may be dose-dependent and clinically relevant. The mechanisms underlying
progressive brain changes, specific antipsychotic compounds and clinical symptoms
warrant further clarification.
xii Scientific contributions
[75] H. Lundell, D. Barthelemy, A. Skimminge, T.B. Dyrby, F. Biering-Sørensen,
J.B. Nielsen; Independent spinal cord atrophy measures correlate to motor and
sensory deficits in individuals with spinal cord injury accepted for publication
Spinal Cord
The aim of this study was to present anatomically consistent and independent spinal
cord atrophy measures based on standard MRI material and analyze their specific rela-
tions to sensory and motor outcome in individuals with chronic incomplete spinal cord
injury (SCI).
We included 19 individuals with chronic incomplete SCI and 16 healthy controls. Par-
ticipants underwent MRI and a neurological examination including sensory testing for
light touch and pinprick, and muscle strength. Antero-posterior width (APW), left-
right width (LRW) and cross- sectional spinal cord area (SCA) were extracted from
MRI at the spinal level of C2. The angular variation of the spinal cord radius over the
full circle was also extracted and compared with the clinical scores.
The motor score was correlated to LRW and the sensory scores were correlated to APW.
The scores correlated also well with decreases in spinal cord radius in oblique angles in
coherent and non-overlapping sectors for the sensory and motor qualities respectively.
APW and LRW can independently be used to assess sensory and motor function inde-
pendently. The finding is corresponding well with the respective locations of the main
sensory and motor pathways.
[120] Martin Vestergaard, Kathrine Skak Madsen, William F.C. Baare´, Arnold Skim-
minge, Lisser Rye Ejersbo, Thomas Z. Ramsøy, Christian Gerlach, Per A˚keson,
Olaf B. Paulson, Terry L. Jernigan; White matter microstructure in superior
longitudinal fasciculus associated with spatial working memory performance in
children submitted to Jounal of Cognitive Neuroscience
During childhood and adolescence ongoing white matter maturation in the fronto-
parietal cortices and connecting fiber tracts is measurable with diffusion weighted
imaging. Important questions remain, however, about the links between these changes
and developing cognitive functions. Spatial working memory (SWM) performance im-
proves significantly throughout the childhood years and several lines of evidence im-
plicate the left fronto-parietal cortices and connecting fiber tracts in SWM processing.
Here we report results from a study of 76 typically developing children, 7 to 13 years
of age. We hypothesized that better SWM performance would be associated with in-
creased fractional anisotropy (FA) in a left fronto-parietal network comprised of the su-
perior longitudinal fasciculus (SLF) and regional white matter underlying the dorsolat-
eral prefrontal cortex (DLPFC), and posterior parietal cortex (PPC). As hypothesized,
we observed a significant association between higher FA in the left fronto-parietal net-
work and better SWM skills, and the effect was independent of age. This association
was mainly accounted for by variability in left SLF FA and remained significant when
FA measures from global fiber tracts or right SLF were included in the model. Further,
the effect of FA in left SLF appeared to be mediated primarily by decreasing perpen-
dicular diffusivity. Such associations could be related to individual differences among
children in the architecture of fronto-parietal connections and/or to differences in the
pace of fiber tract development. Further studies are needed to determine the contribu-
tions of intrinsic and experiential factors to the development of functionally significant
individual differences in fiber tract structure.
Conference proceedings – peer reviewed xiii
[134] Xingchen Wu, Lars G. Hanson, Arnold Skimminge, Per Soelberg Sørensen, Olaf
B. Paulson, Morten Blinkenberg, Henrik Kahr Mathiesen Cortical N-acetyl as-
partate is a predictor of long-term clinical disability in newly diagnosed relapsing-
remitting multiple sclerosis submitted to Multiple Sclerosis
Sixteen patients with newly diagnosed RRMS were studied by serial MRI and MR
spectroscopic imaging (MRSI) once every 6 months for 24 months. Clinical exam-
inations, including the Expanded Disability Status Scale (EDSS), were performed at
baseline, month 24, and year 7.
Baseline cortical NAA/Cr correlated inversely with EDSS at month 24 (r = −0.61,
p < 0.05), and follow-up at month 24 showed that patients with EDSS ≥ 4 had a
lower baseline cortical NAA/Cr compared to those with EDSS less than 4 (p < 0.05).
Baseline cortical NAA/Cr also correlated inversely with EDSS at year 7 (r = −0.60,
p < 0.05), and follow-up at year 7 revealed that patients with EDSS ≥ 4 had a lower
baseline cortical NAA/Cr compared to those with EDSS less than 4 (p< 0.05). Base-
line brain parenchymal fraction (BPF) correlated inversely with EDSS at month 24
(r =−0.62, p< 0.05), but not with EDSS at year 7.
Cortical NAA/Cr in early RRMS correlated with clinical disability in 2 and 7 years and
may be used as a predictor of long-term disease outcome.
Conference proceedings – peer reviewed
2006
[51] Lars G Hanson, Arnold Skimminge, Torben E Lund and Christian G Hanson,
Encoding of EEG in MR images in Proceedings of the 12th Annual Meeting of
the Organization for Human Brain Mapping, Florence, 2006
It was previously shown in that electrophysiology and other non-MR signals can be
measured by MR equipment after modulation to frequencies close to those of the MR-
signals. The signals are encoded in the oversampled region of the field-of-view nor-
mally discarded by the image reconstruction. Using surplus sampling and storage ca-
pacity of the scanner, non-MR signals can thereby be recorded without affecting the
acquired images. In addition, imaging-induced distortions are largely avoided, and
residuals are simple to filter away due to intrinsic perfect synchronization of MR- and
non-MR recordings. Here we present the first EEG recordings made with the new
technique.
[105] A. Skimminge, C.G. Hansonand L.G. Hanson, A simple approach to electro-
physiological recording during fMRI in Proceedings of the 12th Annual Meeting
of the Organization for Human Brain Mapping, Florence, 2006
A simple technique involving only an MR-scanner and a standard signal generator
demonstrates how any non-MR signal can be embedded in an MR-image using similar
principles as soundtrack encoding in movies. The presented method largely avoids
gradient artifacts normally compromising EEG/fMRI. The method uses off-the-shelf
xiv Scientific contributions
hardware but requires specialised software to extract the embedded signals. However
it may be attrative to implement if only a few channels are needed.
[89] K. Nielsen, K. H. Madsen, J. L. Fredriksen, A. Tsakiri, A. Skimminge and T.
E. Lund, LGN activation in patients recovering from acute optic neuritis, in
Proceedings of the 12th Annual Meeting of the Organization for Human Brain
Mapping, Florence, 2006
Optic neuritis (ON) is a disease characterized by decreased visual acuity, visual field
defects and abnormal VEP (visual evoked potentials). Inflammation and demyelination
of the optic nerve are the major causes of the symptoms in ON. To further elucidate the
mechanisms behind the recovery process in ON, we conducted a longitudinal fMRI
study of LGN (lateral geniculate nucleus) activation in patients recovering from acute
ON. There is a clear tendency towards smaller differences in LGN activation between
the affected and the unaffected eyes over time.
[48] Hanson, Lars G. and Skimminge, Arnold and Hanson, Christian G., Strategies
for Avoiding Image Artefacts When Scanner is Used for Recording of Non-MR
Signals, in Proceedings 14th Scientific Meeting, International Society for Mag-
netic Resonance in Medicine, Seattle, 2006
Surplus sampling capacity of MR scanners can be used to record non-MR signals as has
been demonstrated previously. If the non-MR signals are encoded in the oversampled
frequency range of the scanner, i.e. outside the field of view, such signals are invisible
in the images but can be extracted from the imaging raw data, a technique resembling
”mag stripe” encoding of soundtracks in movies. Even though the non-MR-signals are
encoded at frequencies corresponding to positions outside the field of view, there may
be ringing artefacts appearing in the MR images. Two strategies for eliminating such
artefacts are presented.
[90] Nielsen, Kirsten and Madsen, Kristoffer Hougaard and Frederiksen, Jette Lautrup
and Tsakiri, Anna and Skimminge, Arnold and Lund, Torben Ellegaard, Inves-
tigations of LGN Activation During Recovery from Acute Optic Neuritis, in
Proceedings 14th Scientific Meeting, International Society for Magnetic Reso-
nance in Medicine, Seattle, 2006
To further elucidate the mechanisms of recovery of vision in acute optic neuritis (ON),
we conducted a longitudinal fMRI-study at 3T of activation of the lateral geniculate
nucleus (LGN) during visual stimulation of patients with ON. Sixteen patients were
examined acutely, and two weeks, three and six months later.At each time-point we
calculated the average BOLD signal change in LGN during stimulation of affected
and unaffected eyes. We found a clear tendency towards smaller differences in LGN
activation between affected and unaffected eyes over time, indicating that the amount
of signals reaching LGN from affected eyes increases during recovery.
Conference proceedings – peer reviewed xv
2007
[107] Skimminge, Arnold and Sidaros, Karam and Liptrot, Matthew and Sidaros, An-
nette, Partial Volume Effects in DTI, in Proceedings 15th Scientific Meeting,
International Society for Magnetic Resonance in Medicine, Berlin, 2007
We present a method for analysing and correcting for partial volume effects in DTI
acquired with large voxels, using a high resolution MPRAGE and its corresponding
SPM2 tissue segmentation. The analysis shows that voxels with mixed tissue types
contributes to a broadened profile of ADC and FA values within an ROI of the sple-
nium. Furthermore a correction scheme is devised which is robust with respect to
mixed tissue voxels.
[49] Hanson, Lars G. and Skimminge, Arnold and Hanson, Christian G., Encoding
of EEG in MR Images, in Proceedings 15th Scientific Meeting, International
Society for Magnetic Resonance in Medicine, Berlin, 2007
It was shown earlier that electrophysiology and other non-MR signals can be measured
by MR equipment after modulation to frequencies close to those of the MR-signals.
After wireless transmission to the scanner, MR and and non-MR signals were recorded
together. The technique is somewhat similar to the ”mag stripe” technique used for
encoding soundtracks in movies: The signals are encoded in the oversampled region
just outside the field-of-view. Here we demonstrate 6 channel simultaneous ECG, EOG
and alpha-EEG, all recorded by the scanner during fast echo planar imaging at 3 tesla
2008
[86] Mikkelsen, I. and Ziegelitz, D. and Kjølby, B. and Starck, G. and Skimminge, A.
and Widmark, M. and Tullberg, M. and Holta˚s, S. and Wikkelsø, C. DSC-MRI
perfusion imaging: which input function? – A comparison to CT perfusion imag-
ing in Proceedings 16th Scientific Meeting, International Society for Magnetic
Resonance in Medicine, Toronto, 2008
The choice of artery for input function (AIF) measurement in dynamic susceptibility
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CHAPTER 1
Computational
neuroanatomy
Neuroanatomical structures show extraordinary morphological variability, and specific
neuroanatomical features, such as volume, cortical shape and area, and gyrification
patterns often need to be compared within and between groups of individuals. Com-
putational neuroanatomy harnesses the vastly growing computational power of modern
large-scale computer systems to characterize differences between brains, using sophis-
ticated mathematical models sensitive to subtle changes in the size, position, shape,
and tissue characteristics of brain structures. Advanced statistical methods are then
employed to make inferences about the structural characteristics of health and disease
while taking into account factors such as age, sex, genetic background, and disease
state of individual subjects.
Magnetic resonance imaging non-invasively provides highly detailed images of brain
anatomy. 3D high-resolution (∼ 1mm3 voxels) scans of the entire brain can be ob-
tained in less than 10 minutes. This type of rapidly acquired high-resolution images is
described in detail in chapter 2. Furthermore techniques for correcting scanner specific
artifacts are demonstrated.
Acquired brain scans are generally placed in a common coordinate system such as
Talairach[113] and MNI (Montreal Neurological Institute)[29, 30], to allow comparison
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of neuroanatomical characteristics within and between individuals. To this end many
different registration techniques, with varying levels of complexity, are employed. Lin-
ear techniques are generally used to correct for rotation and translation (i.e. 6 param-
eter rigid body registration) and global size differences between subjects (i.e. 9 or 12
parameter affine registration entailing scaling and scaling plus shears, respectively).
Non-linear techniques are used to compensate for local neuroanatomical differences
within or between subjects and differ in the amount of degrees of freedom [66]. Non-
linear techniques with millions degrees of freedom allow discerning neuroanatomical
dynamics not only within single subjects but also between different subjects. The dif-
ferent registration techniques that are employed in this thesis are described in chapter 3.
Two morphometric methods are used in this thesis, voxel- and tensor based morphom-
etry. Voxel based morphometry (VBM) allows assessing voxel-wise anatomical dif-
ferences throughout the brain and generally compares gray matter concentrations or
volumes. Tensor based morphometry (TBM) uses the gradients of deformations fields
obtained from high-dimensional non-linear registration techniques to identify local
neuroanatomical differences(e.g shape, volume) in neuroanatomy. Both methods have
been passionately discussed in the literature, especially regarding anatomical speci-
ficity as well as interpretation of results. Both methods are introduced and discussed in
chapter 4.
The statistical methods employed in this thesis are general linear models, with the
added complexity of the multiple comparisons problem as well as non-normality of the
underlying probability distributions. The general linear model is discussed in chapter 5.
The papers [27, 28, 102] concerning studies of brain morphometry, and related confer-
ence proceeding [106] are discussed in chapters 6 and 7.
Final remarks are given in chapter 8.
CHAPTER 2
Magnetic resonance imaging
Computational neuroanatomy relies heavily on good quality high-resolution MR im-
ages, generally obtained using a fast T1-weighted imaging technique. An example
is the Magnetization Prepared Rapid Gradient Echo (MPRAGE) sequence, a fast 3D
gradient echo pulse sequence using a magnetization preparation pulse for contrast en-
hancement. MPRAGE is designed for rapid acquisition with T1 weighted dominance in
the image contrast, thus providing good contrast between different tissue types in the
brain. Fast gradient echoes are characterized by their rapid sampling time, high signal
intensity and good image contrast. The rapid speed of the acquisition makes it an in-
valuable sequence in every MR research protocol for anatomical reference. A typical
MPRAGE image of a normal subject is shown in figure 2.1 with 3 axial slices, 3 sagittal
slices and 3 coronal slices.
The pulse sequence timing diagram for the MPRAGE sequence is shown in figure 2.2.
The diagram illustrates the steps of basic hardware activity that are played out dur-
ing image acquisition. Time during pulse sequence execution is indicated along the
horizontal axes. Important timing parameters are
TE Echo time represents the time between the application of the excitation RF pulse
and the peak of the MR signal during readout.
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Figure 2.1: A typical conventional 3D high resolution T1 weighted image of a normal
subject. Here shown with 3 axial slices, 3 sagittal slices and 3 coronal slices.
TR Repetition time represents the time between successive RF pulses sequences ap-
plied to the same slice.
TI Inversion time represents the time period between the inversion pulse and the
excitation pulse.
TD Delay time: After the acquisition, for all rows a delay time is used to prevent
saturation effects.
Typical scanning parameters are: Echo time (TE) 3.04 ms, repetition time (TR) 1550
ms, inversion time (TI) 800 ms, flip angle 9◦, field of view 256 mm, matrix 256 x 256,
1 x 1 x 1 mm voxels, 192 slices with a total acquisition time of ∼6.38 minutes.[45]
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Figure 2.2: MPRAGE pulse sequence timing diagram. The diagram illustrates the steps
of basic hardware activity that are played out during image acquisition. Time during
pulse sequence execution is indicated along the horizontal axes. Each line represents
a different hardware component, thus one line is needed for the radio frequency trans-
mitter and one for each imaging gradient (SLC = slice selection gradient (x), PH =
phase encoding gradient (y), RO = frequency encoding gradient (z), also called readout
gradient). The MR signal is sampled during the positive RO gradient. Brackets indicate
repetition.
2.1 Imaging artifacts
MRI images exhibit intensity and geometric distortion artifacts affecting various mor-
phometric measures, depending on the sequence, vendor-specific gradient design ge-
ometry and patient anatomy.
An artifact often seen in MRI images is a smooth variation of the signal intensity across
images. This artifact is variously referred to as RF inhomogeneity, shading artifact,
bias field, or B1 intensity non-uniformity. The artifact is usually attributed to several
factors, such as poor radio frequency (RF) field uniformity, eddy currents driven by the
switching of field gradients, and patient anatomy both inside and outside the field of
view. There are several approaches to correct for intensity non-uniformity in MRI data
that achieves high performance without requiring supervision. Correction of intensity
non-uniformity in MRI data for has been shown to substantially improve the accuracy
of anatomical analysis techniques such as tissue classification, registration and cortical
surface extraction.[13, 108]
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Before engaging in longitudinal analyzes it is important to correct for scanner-specific
image distortions thereby allowing a more accurate comparison of quantitative mor-
phometry results. Multi-modal and multi-site studies also requires correction of image
distortions, as well as studies of populations where image distortions are likely to be
systematic between groups, e.g. head size of children induces systematic image dis-
tortions which will covary with age. Although, cross-sectional studies also suffer from
such distortions, the distortions can be considered stochastic and just add to the vari-
ance of the measurements. Image distortions can potentially affect the accuracy of
quantitative morphometric measures such as volume [33], shape [87] and boundaries
of sub-cortical structures[14].
A prominent source of distortions in structural MRI arises from imaging gradient non-
linearities, which degrades both geometry and image intensities. The distortions arise
because spatial localization is usually achieved using Fourier encoding. The encoding
is realized by applying a magnetic field gradient along the dimension of interest, which
is assumed to create a linear correspondence between the resonance frequency and
spatial location following the Larmor equation. Any non-linearities in the magnetic
field gradient will result in distorted images.[45] The distortion field specific to the
Siemens sonata gradient coil is visualized in figure 2.3.
Figure 2.4 shows examples of the effect of gradient non-linearity distortions on one
subject scanned several times at different positions within the scanner. It is worth
noting that most of the intensity differences with low spatial frequencies are due to
differences in radio wave inhomogeneities. The effect of the gradient non-linearities is
the geometric distortions, which are apparent near the rim of features. The top images
show the first scan from the scanning session, and the four subsequent images show the
scaled absolute differences between the first scan and the subsequently acquired scans.
All the scans have been coregistered using rigid body transformations to account for
the different positions(see section 3.2).
Figure 2.3: Geometric distortion field due to gradient non-linearities specific to the
Siemens sonata gradient coils. Color indicate direction with red, green and blue color
components corresponding to x, y and z directions respectively. The largest distortions
within the image shown is about 6mm, and these are located furthest away from the
centre of the bore. The top image shows the MNI template image.
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Two main 3D correction methods have been developed. a) direct 3D measurements of
the geometric distortions using specially designed imaging phantoms[69, 121, 122]. b)
3D calculations of the geometric displacements from the spherical harmonic expansion
for the representation of the magnetic fields generated by the gradient coils[57, 61,
99]. The methods described in [61], have been extended reimplemented in a SPM
toolbox. The new implementation relies on the same principles and algorithms, but has
more flexible output, such as retaining the original voxel sizes in the images, and can
be combined with other geometric distortion corrections. Images corrected using the
toolbox are shown in figure 2.5. All the scans have been coregistered after correction
using rigid body transformations to account for the different positions.
Gradient non-linearity correction was found crucial in the paper about spinal cord at-
rophy measures[75], for reducing the effect of subject positioning and vendor-specific
gradient design geometry. Specifically, as a consequence of the gradient non-linearity
correction, the coefficient of variance was reduced from 8.05 to 1.01% for the spinal
cord area, 4.33 to 0.95% for the left-right widths and 4.03 to 0.93% for the anterior-
posterior widths.
Homogeneity of the main magnetic field, B0 is another important prerequisite for accu-
rate spatial localization in magnetic resonance imaging. In the presence of B0 inhomo-
geneities along any dimension, the linear mapping prescribed by the Larmor equation
does not hold and spatial distortions arise in the acquired images. B0 inhomogeneities
are particularly pronounced at borders between low and high magnetic susceptibility,
e.g. the interface of tissue and air. Spatial distortions at such interfaces increase with
field strength, and will affect the accuracy of morphometric measures locally.
8Figure 2.4: The top images shows the first MPRAGE scan of a scanning session out
of five scans with different positions. The remaining images show the squared differ-
ences between the first scan and the subsequent scans, when not corrected for gradient
non-linearities. The intensity differences with low spatial frequency are due to B1 in-
homogeneities. The intensity differences located near the rim of features are due to
gradient non-linearities.
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Figure 2.5: The top images shows the first MPRAGE scan of a scanning session out
of five scans with different positions. The remaining images show the absolute dif-
ferences between the first scan and the subsequent scans, when corrected for gradient
non-linearities. The intensity differences with low spatial frequency are due to B1 in-
homogeneities.
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CHAPTER 3
Image registration
Every MR image has a 4×4 spatial transformation matrix M associated with it, which
maps voxel coordinates x to real world coordinates y. The mapping is a simple matrix
multiplication, y = Mx, or more elaborate:
y1
y2
y3
1
=

m11 m12 m13 m14
m21 m22 m23 m24
m31 m32 m33 m34
0 0 0 1


x1
x2
x3
1
 (3.1)
This mapping of coordinates allows reorienting images without resampling, and also
allows comparison of images with arbitrary resolutions and acquisition orientations.
Any spatial transformation matrix can be written as a product of a number of linear
transformations; translations, rotations, scalings and shears. Each of these linear trans-
formations is parametrized by three parameters, one for each spatial direction. Trans-
lations are the simplest, as it defines the mapping of origin between the coordinate
systems 
1 0 0 t1
0 1 0 t2
0 0 1 t3
0 0 0 1
 (3.2)
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Rotations roll, pitch and yaw about the x, y and z axes respectively, are written as
follows 
1 0 0 0
0 cos(u1) −sin(u1) 0
0 sin(u1) cos(u1) 0
0 0 0 1
 (3.3)

cos(u2) 0 sin(u2) 0
0 1 0 0
−sin(u2) 0 cos(u2) 0
0 0 0 1


cos(u3) −sin(u3) 0 0
sin(u3) cos(u3) 0 0
0 0 1 0
0 0 0 1
 (3.4)
Scalings or Zooms, and finally shears
q1 0 0 0
0 q2 0 0
0 0 q3 0
0 0 0 1
 and

1 s1 s3 0
0 1 s3 0
0 0 1 0
0 0 0 1
 (3.5)
Any combination of translations and rotations defines a rigid body transformation,
while adding scaling and shears defines a full affine transformation.[35]
Image transformation matrices are usually implicitly defined when positioning scans
during image acquisition. The mapping of the transformation matrices is therefore
from the individual images voxel coordinate systems to the scanner coordinate system.
The scanner coordinate system is a right handed cartesian coordinate system with the
z axis directed along the B0 field, x along left/right, y along up/down, and has origin in
the center of the bore.1
3.1 Optimization
Image registration (linear or non-linear) is really a non-linear optimization problem
in that there is some function O(q,x) that depends in some non-linear fashion on a
set of parameters q and the input data x, and optimization determines the values of q
that minimizes O(q,x) given x. Methods for finding the parameters q come in many
flavors, some require only the ability to calculate O(q,x) while other methods relies on
the first, and possibly second, derivatives with respect to the parameters q. Methods
dependent on derivatives are usually faster and sometimes more robust, something that
is especially important when there are a large number of unknown parameters.[88]
1The scanner coordinate system is defined in the DICOM standard, and the statement is only true for
scanners conforming to these. [1]
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The simplest and most used cost function is the ”sum-of-squared differences” men-
tioned in section 3.2. Its use is limited to cases where the image intensities are very
similar, as opposed to other cost-functions like e.g. normalised mutual information
which are less sensitive to differences in contrast, also mentioned in section 3.2. How-
ever, the sum-of-squared differences cost-function has important computational advan-
tages when searching for the parameters that minimize its value.[35]
Any image registration technique attempts to find a compromise between minimising
the specified cost function, i.e. between making the images look as similar as possi-
ble, and making the deformations ”reasonable”. This compromise is formalised by a
regularising function, which are functions of only the parameters q and not the data.
The cost function is thereby split into a penalty function, that depends on both data
and parameters, and a regularization function, only depending on the parameters.[88]
The regularization function formalizes ”reasonable” deformations, and are often based
on concepts borrowed from mechanics, such as ”membrane energy” and ”bending en-
ergy”. These are functions of the deformations themselves, that have a high value for
sharp deformations and a small value for smooth deformations.
Newton’s method for optimizations and related methods, such as Gauss-newton and
Levenberg-Marquardt methods, utilizes the Taylor expansion of the cost function O(q,x)
with respect to the parameters q. Thus, provided that O(q,x) is twice-differentiable,
and a reasonable starting estimate q(0), the sequence defined by
q(k+1) = q(k)− γ
[
HO(q(k),x)
]−1
∇O(q(k),x) (3.6)
will converge towards an extremum of O(q(k),x). H denotes the Hessian, and related
algorithms use different approximations of this to obtain a solution, as its exact calcu-
lation and inversion can be computationally intensive and numerically unstable.[88]
3.2 Coregistration
The scanner coordinate system is not optimal for voxel-wise statistical analysis of im-
ages due to differences in subject position during and between acquisitions. Therefore
it is essential to obtain point correspondence between images by ensuring that the trans-
formation matrices of all images of subjects refer to the same anatomical coordinate
system. The process of determining these transformation matrices is generally called
coregistration. In neurosurgery and neurological research one generally uses the Carte-
sian coordinate system known as stereotaxic space as an external, three-dimensional
frame of reference. The most prominent stereotaxic space is most likely the Talairach
coordinate system(see section 3.3)[113].
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There are two steps involved in registering a pair of images together. There is the
registration itself, whereby the optimal transformation is determined, and then there
is the transformation which involves resampling the images in a new voxel coordi-
nate system. Resampling of the images at arbitrary voxel coordinates is fundamen-
tal to the registration process, both in order to evaluate any objective function during
optimization, and also to write the images once the optimal transformation has been
determined. A common method for interpolation of images is to represent the voxel in-
tensities as a linear combination of basis functions, typically b-splines of three or more
degrees. Resampling then involves determining the parameters for the basis functions
once, and evaluation at new points is an appropriate linear combination of the basis
function. Resampling is then expressed as a simple convolution of the basis function
coefficients.[35, 88]
Images of the same subject with similar contrasts between tissue types, can be coreg-
istered by minimizing the mean squared difference between each of the images. The
objective function being optimized is
λ1∑
i
( f (Mxi)−qg(xi))2 +λ2∑
i
(
g
(
M−1xi
)−q−1 f (xi))2 (3.7)
q is an intensity scaling parameter accounting for the arbitrary scaling of MT image
intensities. The objective function is made symmetric, to obtain more robust solu-
tions [125, 126]. Gauss-Newton optimization algorithm has proven a good algorithm
for rigid registration of images with similiar contrast. f and g are the resampling func-
tions able to evaluate image intensities at arbitrary voxel positions in the respective
images.[35]
Coregistration of images with different contrasts between tissue types, requires a differ-
ent objective function derived from information theoretical measures such as entropy
of joint probability distributions. This approach is required since there need not be
a linear relationship between the image intensities. The entropy of joint probability
distributions is written as
H (f,g) =−
∫ ∞
−∞
∫ ∞
−∞
P(f,g) log(P(f,g))dfdg (3.8)
While the the marginalized entropies are given as
H (f) = −
∫ ∞
−∞
P(f) log(P(f))df and (3.9)
H (g) = −
∫ ∞
−∞
P(g) log(P(g))dg (3.10)
These enable the definition of normalized mutual information
I˜ (f,g) =
H (f)+H (g)
H (f,g)
(3.11)
3.3 Spatial normalisation 15
These equations are easily discretized using histograms, and appropriate summations.
The optimal rigid body transformation is then found using a Levenberg-Marquardt op-
timization algorithm, a stabilized version of the Gauss-Newton method used for the
mean squared difference measure.[35] These methods for coregistration have been
implemented in a number of freely available toolboxes, including FSL[58, 59] and
SPM[5, 8, 63].
3.3 Spatial normalisation
Individual coordinate systems of different subjects are not immediately comparable,
as a set of coordinates rarely will correspond to the same underlying neuroanatomi-
cal feature. When matching multiple subjects it is often more convenient to coregister
each subjects brain to a common template using affine transformations, thus accounting
for differences in size and global skewness. Either of the above mentioned objective
functions can be appropriate depending on quality and contrast of the common tem-
plate. Many studies rely on this simple approach of spatial normalisation for reporting
neuroanatomical locations. More often spatial normalisation rely on additional non-
linear registration techniques, potentially requiring millions of parameters to describe
the nonlinear transformations that warp an image into a standard space.[96]
The problem of spatial normalization, i.e. how to map a single subject’s brain image
into another brain or a template, is indeed not a trivial one. In practice it is often mean-
ingless to even attempt an exact match between brains beyond a certain resolution.
There is no one-to-one relationship between the cortical structures of one brain and
those of another, so any registration method that attempts to match brains exactly must
fold the brain to create artificial sulci and gyri. Even if an exact match is obtained,
the solutions obtained by high-dimensional warping techniques may not be truly opti-
mal. Hence any solution to the spatial normalization problem has to be a compromise
between an exact match and warp complexity in order to obtain a valid point corre-
spondence between subjects.[66]
Spatial normalization facilitates a wide range of statistical analyses, either voxel-based
or via appropriate representations of neuroanatomical features derived from shape or
geometric properties. Once a set of meaningful euclidian coordinates within a stan-
dard reference space has been obtained, results are readily incorporated into existing
literature, brain atlases and databases.[82]
The most commonly adopted coordinate system within the brain imaging community
is that described by the atlas of Talairach and Tournoux, 1988[113]. Use of the Ta-
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lairach coordinate system and the accompanying atlas is heavily discussed[118], as it
is based upon postmortem sections of a 60-year-old french female with a smaller than
average brain size. This means that most other brains need to be considerably warped
to conform to the small size of the atlas, introducing both bias and error. Furthermore,
anatomical labeling of Brodmann areas was done visually using inconsistent slices[67].
Nonetheless, the Talairach atlas has proved an invaluable tool in modern neuroimag-
ing, and has paved the way for more representative brain atlases including the MNI atlas
from the Montreal Neurological Institute, used throughout this thesis.[29, 30]
Registering one image volume to another involves estimating a vector field (deforma-
tion field) that maps from coordinates of one image to those of the other. In this thesis,
one image (the template image) is considered as fixed, and a mapping from this image
to the second image (the source image) is estimated. The intensity at the i’th voxel of
the template image is denoted g(xi), where xi is a vector describing the coordinates of
the voxel. The deformation field spanning the domain of the template is denoted by yi
(or y(xi)) at each point, and the intensity of the source image at this mapped point by
f (yi). The source image is transformed to match the template by resampling it at the
mapped coordinates.[8]
Solutions to the very high dimensional spatial normalisation problem can be obtained
in many ways. Often methods are tailored to specific features, such as subcortical struc-
tures or the cortical surface or tailored to specific types of analysis, fMRI or VBM[9, 32].
The approach used in the SPM software is based on a parametrization of the deforma-
tion field using cosine basis functions, see figure 3.1. In short the spatial transformation
variables are written as
y1 (x,α) = x1 +
M
∑
m=1
αm1φm (x) (3.12)
y2 (x,α) = x2 +
M
∑
m=1
αm2φm (x) (3.13)
y3 (x,α) = x3 +
M
∑
m=1
αm3φm (x) (3.14)
with
φ1 (i) =
1√
I
, φm (i) =
√
2
I
cos
(
pi (2i−1)(m−1)
2I
)
i= 1 . . . I,m= 2 . . .M (3.15)
Deformations are thus only defined by a few hundred parameters, forfeiting the poten-
tial precision of other non-linear registration methods. Deformations with high spatial
frequencies cannot be modeled, since the deformations are restricted to the lowest spa-
tial frequencies of the basis functions. This approach is unsuited for exact matches
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Figure 3.1: The lowest frequency two-dimensional cosine basis functions.[6]
between fine cortical structures, and does not encompass the whole range of detailed
shape variability of neuroanatomical features found within the general population.[6,
10]
3.4 DARTEL
The DARTEL (”Diffeomorphic Anatomical Registration using Exponentiated Lie alge-
bra”) procedure utilizes a more sophisticated registration model, described in [9], to
obtain a better spatial normalisation, with a higher degree of neuroanatomical corre-
spondence between subjects. This model uses in the order of 6 000 000 parameters,
providing plenty degrees of freedom to achieve much more precise intersubject align-
ment, and was developed specifically to counter the criticisms pertaining voxel based
morphometry(see section 4.2). It has been shown that DARTEL outperforms ROI-based
registration algorithms[135] and a number of other widely used and fully automated
intersubject registration algorithms[66].
The DARTEL procedure is an iterative procedure initiated with rigidly aligned gray and
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white matter segmentations of brain images. DARTEL creates a ”flow field” for each
of the subjects encoding how the individual images should be warped. The algorithm
alternates between computing templates based on the average tissue probability maps
from all subjects and subsequently updating the flow fields to best match the individ-
ual images to the latest template. As the images gradually become better aligned, the
average tissue probability maps become increasingly sharp and gradually less smooth-
ing is applied to the templates. Gray and white matter tissue maps are simultaneously
aligned.
The computed average template need not be appropriately registered with the Talairach
coordinate system nor MNI space, thus requiring further spatial normalisation to report
the location of differences within a more established coordinate system. This can be
achieved by using the spatial normalisation procedure described in section 3.3 on the
average tissue probability maps.
3.5 High-dimensional warping
In the case of multiple images from the same subjects, it is often possible to obtain an
one-to-one match between the images using non-linear registration, of at least some
parts of the brain. The deformation field will in this case incorporate the dynamics
of the subject’s neuroanatomy during growth, aging, maturation, disease progression
or treatment. Any singularities in the deformation field will occur due to localized
neuroanatomical changes, such as disappearance or occurence of hemorrhagic lesions,
occurrence of ’black hole’ lesions often found in multiple sclerosis patients, or even as a
result of surgical intervention. This quantitive and potentially very localized approach
to the dynamics of neuroanatomy is at the core of the publications composing this
thesis.
A high dimensional model has been implemented in SPM’s high dimensional warping
(HDW) toolbox, where a finite element approach is employed to estimate translations
of each voxel. The toolbox uses bayesian statistics to obtain a maximum a posteriori
(MAP) estimate of the deformation field describing the differences between the images.
Priors describing the probability distributions of the deformation, are in this imple-
mentation assumed to have symmetric properties. This implies that the probability of
obtaining a particular deformation field, is the same as obtaining its inverse. The details
of the implementation can be found in [8, Chp. 4] and [4].
An example of a deformation field obtained using this toolbox is shown in figure 3.2.
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Figure 3.2: The deformation field illustrating the warping of one image to another.[101]
SPM’s HDW toolbox was chosen because, it has been developed specifically with this
purpose in mind, it computes a deformation field in reasonable time and has been suc-
cessfully deployed in a number of studies[19, 31, 65]. There are a plethora of non-
linear image registration techniques, related algorithms and implementations(see [66]
for an evaluation of 14 non-linear deformation algorithms), many of which are equally
applicable to detect localized neuroanatomical changes as SPM’s HDW toolbox.
3.6 Smoothing
It is customary to smooth spatially normalized images by convolving with a 3D Gaus-
sian kernel having FWHM ∼ 4-12mm. Smoothing of images both enhances statistics
by noise cancellation, and somewhat compensates for imperfect anatomical correspon-
dence between subjects. Furthermore, the fact that Gaussian random field theory is
often used to control the family-wise error in mass-univariate hypothesis tests for sig-
nificant effects require that data exhibit smoothness over several millimeters to become
in agreement with the assumptions usually made in Gaussian random field theory[131].
Drawbacks of smoothing include compromized spatial resolution.
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CHAPTER 4
Morphometry
A large number of approaches for morphometric analysis, i.e. characterization of neu-
roanatomical variability, exists, both within and between subjects. A simple approach
involves subtracting images of single subjects acquired at different time points[11].
Most changes detected with this method will be related to pathology, provided that
the images are properly coregistered (see section 3.2). Interpretation of results can be
straight-forward for localized pathological changes, however many neurodegenerative
diseases induce neuroanatomical changes that are too mild, diffuse, or topologically
complex to be interpreted or even detected by this method (see figure 4.1 for an exam-
ple).
The following sections cover two morphometry methods for quantitative and voxel-
wise comparison of neuroanatomy throughout the brain, tensor-based morphometry
(TBM) and voxel-based morphometry (VBM). Furthermore two methods for whole
brain measures of morphometry are discussed.
22 Morphometry
Figure 4.1: Subtraction of images detect pathological changes. This subject sustained
a severe traumatic brain injury, and has both diffuse and focal injuries.
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4.1 Tensor-based morphometry (TBM)
Tensor based morphometry encodes any structural differences within a deformation
field obtained from high-dimensional image registration, which can be further char-
acterized by a number of statistical procedures. Methods utilizing these deforma-
tion fields to quantify neuroanatomical differences at each voxel are termed deforma-
tion based morphometry (DBM), or tensor based morphometry (TBM).[8] Deformation
based morphometry refers to methods that identify differences in relative positions
within subjects brains. Tensor based morphometry uses the deformation fields to iden-
tify differences in the local shape of brain structures.[35]
The deformation fields describe the spatial transformation that matches individual brains
to each other or to a common template. The deformation fields that describe the spatial
transformation to match individual brains to a common template, can also be studied on
their own right. The deformation fields contain information about the individual image
shapes, however the enormous neuroanatomical variability between normal subjects,
makes interpretations less straight-forward.
Once an appropriate deformation field has been obtained, any further analysis is usually
based upon the accompanying jacobian matrices. Each voxel contains information
about the local stretching, shearing and rotation involved in the deformation, in the
Jacobian matrix which is defined by:
J =

∂y1
∂x1
∂y1
∂x2
∂y1
∂x3
∂y2
∂x1
∂y2
∂x2
∂y2
∂x3
∂y3
∂x1
∂y3
∂x2
∂y3
∂x3
 (4.1)
The determinant of the jacobian matrices is directly related to local volume changes,
before and after warping, and often appears as a normalization factor in differential
geometry. If a region shrinks to half its original volume during the warping, then
the intensity should be doubled so that the total signal is conserved. Analysis of the
deformation fields is not limited to volumes, lengths, areas and other invariant tensor
measures are potentially useful for localizing neuroanatomical changes or variability.
Jacobian matrices of the deformation field can also be transformed in various ways, for
example, by calculating strain tensors [4] or by the matrix logarithm [71, 127].
Spatial normalization of Jacobian determinant maps needs to be interpolated using log-
arithmic interpolation. This is achieved by simply taking the logarithm of the Jacobian
determinants prior to spatial normalization, and exponentiating in normalized space.
Furthermore the logarithmic of jacobian determinants is more symmetric and thus more
appropriate for classical statistical analysis.[70]
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The simplest form of TBM involves voxel-wise comparison of relative volumes derived
from the Jacobian determinants of the deformation fields. Stastical inferences are made
voxel-wise through use of spatial normalisation of such Jacobian determinant maps, as
described in section 5, creating statistical parametric maps showing regional volume
differences among poulations. This type of morphometry specifically looks at whether
local growth or volume loss has occured between the time points of the scanning. The
first paper discussed in chapter 6 uses this method. Alternatively the jacobian determi-
nants can be combined with a VBM analysis to quantify local volume changes in units
of gray matter tissue, as discussed in chapter 7.
TBM has been successfully utilized in studies of multiple sclerosis [116], matura-
tion [54], HIV/AIDS [71, 72], Ageing and age-related diseases [19, 53, 55], and many
others. The methods for TBM are not as standardized as methods for VBM. Each choice
of intra-subject non-linear registration method spawns a new TBM method [20, 54, 85].
4.2 Voxel-based morphometry (VBM)
The direct voxel-wise comparison of local gray matter concentrations between sub-
jects is termed voxel-based morphometry (VBM), and was introduced as a standardized
method by John Ashburner & Karl Friston in [7].
The basic procedure for a VBM analysis involves the serial application of image in-
tensity non-uniformity correction, tissue classification, spatial normalization of gen-
erated tissue probability maps, modulation with Jacobian determinants of the applied
deformation field and finally spatial smoothing. Statistical inferences are then made
upon resulting images of gray matter concentrations. Results obtained from a VBM
analysis are heavily dependent on the specific image processing techniques employed,
as well as good consistent image quality[12, 17]. The choice of tissue classification
algorithm, spatial normalization method and statistical procedures all influence both
anatomical specificity and statistical sensitivity.[10] To complicate matters further the
entire procedure for VBM analysis is inherently circular.[13] Methods for tissue clas-
sification almost always rely on prior probability maps, which needs to be warped
using spatial normalization methods. Spatial normalisation methods benefit greatly
from the use of gray and white matter segmentations. Finally both methods rely on
image intensity non-uniformity correction, which again benefit from both segmenta-
tions and spatial normalization. The circularity is resolved in SPM5, which implements
a combined generative model for tissue classification, spatial normalisation and im-
age intensity non-uniformity correction.[13] Estimation of the model parameters is an
alternation between tissue classification, bias correction, and non-linear registration
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Figure 4.2: This illustrates how findings from a VBM study of gray matter could be
interpreted. The top row shows situations where there would be less gray matter in
a cortical region compared to the situation shown below it. From left to right, dif-
ferences could be attributed to folding, thickness, misclassification or misregistration.
Generally, the objective is to interpret differences in terms of thickness or folding.[10]
steps. This approach provides significantly better results than serial applications of
each component.[13, 130] In order to preserve the volume of tissue from each struc-
ture, the warped images are multiplied, voxel-by-voxel with the Jacobian determinants
of the deformations. Jacobian determinants encode relative volumes of tissue, before
and after warping. For example, if a region shrinks to half its original volume during
the warping, then the intensity would be doubled so that the total signal from that re-
gion is conserved. Figure 4.2 shows possible interpretations of findings in a VBM study
of gray matter.
VBM has been successfully utilized in studies of ageing [42], age related diseases [22,
43], schizophrenia [60, 132, 133] and many other. The validity of VBM has been much
discussed [12, 17, 84, 96], especially in relation to the employed spatial normalization
routine. One of the criticisms of VBM has been that the precision of non-linear inter-
subject registration using spatial basis functions is insufficient. For example, if the reg-
istration procedure systematically has problems with one population type, eg. elderly
people with large ventricles, the anatomical differences detected by VBM may be real,
but their localization and explanation in terms of gray matter volumetry may be incor-
rect. Specifically, any voxel-wise statistics are uninformative about group differences
wherever the spatial normalization algorithm fails to register on robustly appearing im-
age gradients. The method introduced in [7] is only valid far from all image gradients.
These discussions has led to the development of the DARTEL procedure discssued in
section 3.4.
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4.3 Whole brain measures
Quantitative measurement of global changes in brain size and shape, especially to esti-
mate atrophy in patients, provides a clinically useful measure. Structural Image Evalu-
ation, using Normalisation, of Atrophy (SIENA) for longitudinal studies [110] and the
cross-sectional variant SIENAX [111] has proven both robust and accurate. SIENA uses
two brian images taken at different points in time, to estimate of percentage brain vol-
ume change (%BVC). SIENA works automatically by segmenting brain from non-brain
in each image, and the external surface of the skull is used for rigid intra-subject regis-
tration. The surface of each brain is then estimated and the surface motion is estimated
upon these. The mean perpendicular edge motion across the entire brain surface can
then be converted into a percentage brain volume change estimate with subvoxel accu-
racy. Measurement error of %BVC has been reported to be approximately±0.2% [111].
The cross-sectional variant, SIENAX, utilizes the same procedures as SIENA, however
the second image is always the standard MNI template. Furthermore, it is not meaning-
ful to report %BVC, instead global estimates of gray and white matter are reported.[111]
These methods were employed in [102, 134].
CHAPTER 5
Statistics
Statistical inference in neuroimaging studies typically relies on classical/Fisher statis-
tics testing using the hypothesis testing framework.[131] Hypothesis testing is gener-
ally done voxelwise using a mass-univarate approach, with significance levels suffi-
ciently adjusted for multiple comparisons. A general linear model is fitted to the data
in each voxel, thus obtaining statistical parameters which can be mapped into a stereo-
taxic space.[35]
5.1 Bayes’ Theorem
Bayes’ Theorem relates the direct probability of a generative modelMwith parameters
θ conditional on a given body of data Y, p(M,θ|Y), to the inverse probability of the
data conditional on the generative model, p(Y|M,θ) denoted the likelihood.
p(M,θ|Y) = p(Y|M,θ) p(M,θ)
p(Y)
(5.1)
Despite its mathematical triviality, Bayes’ Theorem is of great value in calculating con-
ditional probabilities because inverse probabilities are typically both easier to ascertain
and less subjective than direct probabilities. The probability of the model p(M,θ) ex-
presses the expectations about the model and parameters prior to observing the data
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(hence typically denoted the prior). The probability of the data p(Y) in the denomina-
tor is constant given Y, and thus only serves as a normalisation factor and its direct cal-
culation is most often avoided. p(Y) can be calculated directly by summing/integrating
the likelihood over all possible models and parameters involving substantial computa-
tional complexity.[52, 81]
5.2 The General Linear Model
The linear model is a pillar of modern statistics and is prominent in the analysis of
neuroimaging data [18, 36, 37]. Given a set of input/predictor vectors Xᵀ=(X1,X2, . . . ,XK),
the following model in matrix notation is used to predict the output Y at each voxel
Y = Xβ+ (5.2)
Where Y denotes a T ×N matrix containing the observed data series (of length T ) as
columns for each of the N voxels. X is a T ×K matrix, denoted the design matrix, and
β is a K×N parameter matrix (to be estimated). Finally, the  is the T ×N residual
matrix.
Assuming spatial independence and normally distributed residuals, ie. the spatially in-
dependent matrix variate normal distribution (∼ NT×N(0,I,Σ)), the probability den-
sity is written as follows
p(|Σ) = (2pi)−TN2 |Σ|−N/2 exp
(
−1
2
Tr
[
ᵀΣ−1
])
(5.3)
Substituting Y−Xβ for  in the expression above, the probability is maximized by dif-
ferentiating with respect to the each of parameters and equating to zero. The maximum
likelihood estimate for the parameters βML thereby becomes
XᵀΣ−1XβML = XᵀΣ−1Y⇒ βML = (XᵀΣ−1X)−1XᵀΣ−1Y (5.4)
This estimate is also known as the generalized least squares (GLS) or pre-whitened
maximum likelihood estimate.[52] In the special case Σ= I, this maximum likelihood
estimate is known as the ordinary least squares solution(OLS).[52]
The above expressions describe a multivariate model, however the assumed spatial in-
dependence essentially makes parameter estimation univariate. The remaining problem
is to determine a good estimate of the covariance matrix Σ. An often used estimate uti-
lizes the residuals of the OLS solution, such that
Σ =
1
1−K 
ᵀ
OLS⊗OLS (5.5)
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This estimate only has full rank and hence is invertible when N >= T +K. When
N < T +K, the estimation of the covariance becomes an ill-posed problem due to the
many free parameters. A specific structural form or a regularized version of Σ is often
used to reduce this problem and handle such cases.[74, 128, 129]
Proper construction of the design matrix and the accompanying contrasts (see section
5.3) is essential for the application and interpretation of the general linear model. The
design matrix is assumed to be deterministic, and each column represents independent
variables which potentially describe the observed data in terms of other explanatory
variables. Each column in the design matrix can come from a number of different
sources
• Quantitative inputs; Age and weight are good examples.
• Transformations of quantitative input; log or square-root to model specific non-
linear effects.
• Basis expansions, eg polynomial representation of quantitative inputs.
• Numeric coding of non-numeric inputs, eg binary encoding of gender. Factors
with multiple levels are represented with an equal number of columns using bi-
nary encoding, eg. subjects in a repeated measures experiment.
• Interactions between variables, eg. Age×Gender.
A column of ones is almost always included to model the intercept. In the case where
XᵀX is singular, the above expressions are modified by replacing the inverse by a
pseudo inverse and K with the rank of X. However, in this case the parameters of
the model are not unique (in the sense that other parameters can produce the same
residual) and interpretation of the parameters may be hampered.[23]
5.3 Hypothesis Testing
In the hypothesis testing framework, a null hypothesis is constructed reflecting how a
test statistic would behave if the effect of interest was not present. If the test statistic is
sufficiently extreme compared to the expected behavior, then the data does not support
the null hypothesis and the alternative hypothesis is accepted. The most commonly
used statistic is the student’s t-test
t =
x̂−µ
σ̂/
√
n
(5.6)
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Where x represents the quantity to be tested, µ is the value of x defined by the null
hypothesis, σ̂ is the sample standard deviation and n is the residual degrees of freedom.
The residual degrees of freedom is the total number of samples minus the degrees of
freedom used to estimate the model. The t-test statistic is distributed according to the
T-distribution with n degrees of freedom under the null hypothesis (no effect, Gaussian
uncorrelated noise). When x is based on two samples (two-sample T-test/paired T-
test) the denominator needs to be calculated assuming either equal sample size and
variances (pooled-variance estimate), different sample sizes and equal variances, or
different sample sizes and unequal variance through the Welch-Satterthwaite equation
[97, 123].
An alternative test useful for testing the significance of a combination of effects is the
F-test, here the ratio between the variance explained by two competing models (the null
model and the alternative model) is tested.
F =
(RSS0−RSS1)/(K−K0)
RSS1/(T−K−1)
(5.7)
RSS0 and RSS1 denotes the residual sum of squares for least squares fit of general linear
models with K0 (the null model) and K (the alternative model) parameters respectively.
The general linear model allows for testing of linear combinations of effects through
the contrast vector. A contrast vector c (1×K) defines the explanatory variables of
interest, with which the voxel-wise t-test becomes
ti =
cβi
σ̂i(cβi)/
√
n
, (5.8)
The voxel-wise standard deviation estimate σ̂i(cᵀβi) for this particular choice of con-
trast vector and covariance matrix is determined by
σ̂i(cβi) =
√
σ̂i2c(XᵀΣ−1X)†cᵀ (5.9)
X† denotes the Moore-Penrose generalized/pseudo inverse of the matrix X. More gen-
erally, c can be also a (K−K0)×K matrix thereby defining an F-test. The voxel-wise
F-test statistic is written
Fi =
(cβ)ᵀ
(
c(XᵀΣ−1X)†cᵀ
)
(cβ)/(K−K0)

ᵀ
11/(T−K−1)
(5.10)
The voxelwise T- and F-statistics can be compared to the tabularized distributions to
obtain a p-value, ie. the probability of observing an effect when the null hypothesis is
true, commonly referred to as the uncorrected p-value.
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5.4 Multiple comparisons
The uncorrected p-value from voxel-wise procedure for T- and F-tests attempt to con-
trol the voxel-wise false positives. However, when many voxels are considered this
is not desirable as even a quite low false positive rate can result in many voxels be-
ing reported significant. The simple method of adjustment named after Bonferroni is
based firmly within the classical tradition in applied statistics. Under the assumption
that all tests are independent, the Bonferroni adjustment allow control of the so called
family-wise error by simply multiplying the uncorrected p-value by the number of (in-
dependent) tests (The family-wise error refers to the probability of making one or more
type-I errors). The Bonferroni adjustment is generally considered too conservative for
neuroimaging studies, due to the fact that all voxels exhibit strong spatial dependence
(especially after spatial smoothing).[130]
Spatial dependence can be taken into account through the use of Gaussian random field
theory, which utilizes euler characteristics of regions above the statistical threshold
to approximate proper statistical thresholds[130]. Alternatively the spatial extent of re-
gions of significant voxels can be used to approximate a proper statistical threshold[38].
Another alternative is to control the expected overall false discovery rate (FDR), ie. the
proportion of voxels declared significant which on average can be expected to be false
positives[16, 39, 94]. Benjamini and Hochberg (1995) first proposed the notion of false
discovery rate in [15], and here they showed a testing procedure which bounds FDR at
a user-defined level α . The Benjamini-Hochberg procedure is based on p-values, and
is calculated using the following algorithm
1. Fix the false discovery rate α and let p(1) ≤ p(2) ≤ ·· · ≤ p(N) denote the or-
dered p-values
2. Define L= max{ j : p( j)< α · j/N}
3. Reject all hypotheses H0 j for which p j ≤ p(L), the FDR rejection threshold.
Note that the FDR is not the same as type-I error, for which 0.05 is the customary
threshold. The false discovery rate is the expected proportion of false positive among
all the voxels that passes the threshold, thus α > 0.05 might still be useful, especially
if the study is exploratory in nature.[24].
The strong emphasis put on the null hypothesis unfortunately has a tendency to make
hypothesis testing quite sensitive to the explicit assumptions made such as for exam-
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ple normality. For instance variance estimates are quite sensitive to outliers making
assumption of Gaussian residuals/normality important in especially F-tests.
5.5 Resampling methods for statistical inference
Classical parametric tests, as they are described in the previous sections, compare the
observed statistics to their repective theoretical distributions, thereby indicating evi-
dence of the experimental effect of interest. Resampling methods depart from theoreti-
cal distributions, instead inference is based upon estimates of the distributions obtained
by resampling the data many times. The resampling method is closely tied to Monte
Carlo simulations, which provides a solid theoretical background.[52]
Resampling in statistics comprises a number of different procedures with different ob-
jectives. Examples are, the randomization exact test also known as the permutation
test, cross-validation techniques including leave one out cross-validation and bootstrap
methods.[52] The permutation test was originally developed by R. A. Fisher[34] as a
statistical significance test, although there were no computers in his days to automate
such a laborious method. Cross-validation and to some extent bootstrapping was orig-
inally developed with model verification purposes.[52] The emergence of relatively
inexpensive fast computers and the development of new sophisticated algorithms, have
made resampling techniques practical for a wide range of problems.
A permutation test involves the random shuffling of observed data labels to determine
how unusual an observed outcome is.[3] The basic idea of a permutation test, is easily
demonstrated using data with two labels A and B whose sample means are µ¯A and µ¯B.
Suppose that we want to test, at some significance level, whether the data come from
the same distribution. If random relabeling of the data doesn’t change the means µ¯A
and µ¯B, we can infer that the labelling is of no consequence and hence the data comes
from the same distribution. Algorithmically the permutation test proceeds as follows:
1. Record the statistic of interest for the observed data, eg. T- or F-test statistic.
2. Combine the observations from all the samples.
3. Shuffle them and relabel them in samples of the same sizes as the original sam-
ples.
4. Record the statistic of interest, eg. T- or F-test statistic.
5. Repeat 4-5 many many times.
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6. Determine how often the resampled statistic of interest is as extreme as the ob-
served value of the statistic. The p-value is determined as
p=
number of tests greater than or equal observed value+1
number of tests less than observed value+1
(5.11)
The above procedure is a Monte Carlo permutation test, also called a sampled or ap-
proximate permutation test. A permutation test in which all possible shufflings are sys-
tematically used is an exhaustive permutation test. A permutation test is thus simple,
albeit time consuming. Monte Carlo permutation tests are asymptotically equivalent to
an exhaustive permutation test, and are used when there are too many possible order-
ings of the data to allow complete enumeration. The number of Monte Carlo samples
needed depends on the need for accuracy of the test, and depends on both the observed
p-value and number of samples.[52]
An important assumption behind permutation testing is that the observations are ex-
changeable under the null hypothesis.[21] A notable exception to this is functional MRI
data, which have intrinsic temporal correlations. If the labels are exchangeable under
the null hypothesis, then the resulting exhaustive permutation tests yield exact signifi-
cance levels.[35]
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CHAPTER 6
Traumatic brain injury (TBI)
The subject of the first paper [102] is a longitudinal study of patients who sustained
severe TBI, with a control group of healthy subjects for comparison (see appendix A
for full article). Additional findings relating patterns of regional atrophy to clinical
outcome in the cohort of patients is the subject of [106]. For a complete account of the
clinical implications of the findings for the entire study see [101].
6.1 Symptoms
Severe TBI comprises a number of different injuries to the brain due to an external me-
chanical force to the craniofacial region. Severe TBI is often associated with focal brain
lesions directly under the area of impact (in coup), as well as on the side opposite the
impact (contre coup). Such focal lesions involve the superficial gray matter, occasion-
ally with involvement of the underlying white matter, and are likely to be haemorrhagic.
Traumatic axonal injuries (TAI) are another lesion type, which are diffuse or micro-
scopic multi-focal lesions in white matter induced by sudden acceleration-deceleration
and/or rotational forces, causing shearing of the axons. TAI is the most important cause
of persistent vegetative state or death following TBI, and is also associated with long-
term cognitive deficits, such as memory deficits, information processing and executive
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functions. Secondary lesions types also occur, which are hypoxic-ischemic, due to
compromised oxygen supply and/or compromised global perfusion. Secondary lesions
are often avoidable if treated in due time.
6.2 Structural brain changes and TBI
Neuropathologists have long observed that the brains of patients with severe TBI months
or years before death usually show conspicuous atrophy upon macroscopic examina-
tion. This is in accordance with common observations on repeated CT or MRI during
rehabilitation, that the brain undergoes widespread atrophy concurrently with the clin-
ical improvement. The underlying mechanisms for this atrophy, as well as the clinical
implications for recovery, are poorly understood. Atrophy following severe TBI is not
homogenously distributed, and knowledge of any regional distribution of late atrophy
could potentially indicate the mechanism(s) accounting for the progressive volume loss.
With the continuous rapid development of computing power, the application of increas-
ingly sophisticated software for morphometric image analysis is made possible.[64]
6.3 Image processing
Conventional 3D high-resolution T1-weighted images was acquired at two time points
at which the patients also were evaluated clinically. Patients were scanned ∼ 8 weeks
and ∼ 12 months post-injury, and control subjects were scanned interleaved with pa-
tients. For 24 patients and 14 control subjects, sufficient-quality images were avail-
able at both time points. The images were processed to quantify both global volume
changes, as well as regional volume changes. The data processing paths are schema-
tized in figure 6.1, with 3 paths producing different measures of MRI morphometry.
As a rough estimate of the volume loss occurring before the first scan time point, pa-
tients were compared cross-sectionally to controls on global volume measures, using
SIENAX. Normalized brain parenchymal volume (BPV) was on average 8.4% smaller in
the patients than in the controls (mean ± SD: 1506 ml ± 85 ml and 1645 ml ± 85 ml,
respectively). Visual inspections of segmentation showed misclassifications of white
matter as gray matter in haemorrhagic areas, however this does not influence the BPV.
For quantitative evaluation of macrostructural changes over time, recent techniques
suited for longitudinal studies SIENA and Tensor Based Morphometry were chosen.
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Figure 6.1: Overview of image processing for TBI morphometry. Subsequent statistical
analyses are described in [102]. T1-W = T1-weighted; AC-PC = anterior commissure -
posterior commissure; MNI = Montreal Neurological Institute; GM = gray matter; WM
= white matter.
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Figure 6.2: Individual TBM result images (one slice per subject) for the 24 patients and
14 controls. Normalized and smoothed log Jacobian determinant maps overlaid onto
normalized T1-weighted images (scan 2). Longitudinal volume reduction is coded with
hot colours, volume expansion with cold colours.
6.4 Results 39
Figure 6.3: Regions of significant volume changes in TBI patients between ∼ 8 weeks
and ∼ 12 months post-injury, as compared to controls, thresholded at false discovery
rate (FDR) 0.05 (clusters of < 33.5 voxels rejected). Longitudinal volume reduction is
coded with hot colours, volume expansion with cold colours. Results are overlaid onto
the Montreal Neurological Institute (MNI) standard template.
These methods are thought to be more robust than traditional morphometric approaches
for the analysis of structurally highly heterogeneous brains. During the scan interval,
patients exhibited continued atrophy with percent brain volume change (%BVC), de-
rived from SIENA, ranging between -0.6% and -9.4% (mean -4.0%, median -2.9%). In
controls %BVC ranged between -0.9% and +0.3% (mean -0.18%, median -0.13%).[110,
111]
6.4 Results
As seen in figure 6.3, regional distribution of this late atrophy in patients (relative to
controls), investigated using TBM, revealed widespread symmetric volume loss in the
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Figure 6.4: Areas in which patients with unfavourable outcome (GOS-E = 1–4; n = 8)
exhibited more longitudinal volume change as compared to patients with favourable
outcome (GOS-E = 5–8; n = 16), thresholded at FDR p< 0.05, uncorrected (clusters of
< 33.5 voxels rejected). Longitudinal volume reduction is coded with hot colours, vol-
ume expansion with cold colours. Results are overlaid onto the MNI standard template.
brainstem and cerebellar peduncles, thalamus, putamen, internal and external capsules,
inferior and superior longitudinal fasciculus, corpus callosum and corona radiata, with
additional small clusters of volume loss mainly in the cerebellum and in the frontal
lobes. Significant volume expansion was found in the ventricles and scattered in the
subarachnoidal space (permutation test, FDR 0.05). Individual TBM result images for
all subjects (one axial slice only) are displayed in figure 6.2.
6.5 Additional findings
Additional analysis of the TBM results of patients was made in order to investigate
whether a different pattern of late atrophy would be found in patients with unfavourable
outcome in comparison with patients with favourable outcome. Limited by the small
number of subjects in each group (16 with favourable outcome and 8 with unfavourable
outcome) it was expected that, if any detectable differences existed, there might be
more extensive atrophy in the brainstem in patients with unfavourable outcome as com-
pared to patients with favourable outcome, reflecting the supposedly more frequent oc-
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currence of brainstem traumatic axonal injuries and extensive Wallerian degeneration
with unfavourable outcome.
Statistical analysis was performed similarly as for the main TBM analysis (permutation
test, same nuisance variables), however analysis was confied to the region that were
significant in the main TBM analysis (permutation test, FDR 0.05). The results are seen
in figure 6.4. Apart from clusters of volume expansion in the subarachnoidal CSF,
this shows a generally asymmetrical pattern of small clusters of volume loss scattered
mainly in deep white matter and brainstem. However, one bilateral cluster of volume
reduction in the brainstem was found at the level of pons and the middle cerebellar
peduncles, indicating more extensive volume loss over time in this area for patients
with unfavourable outcome as compared to patients with favourable outcome.
6.6 Discussion
As discussed in section 4.2, similar limitations apply to the voxel-wise morphometric
analyses performed in this study. The sensitivity to areas with high anatomical variabil-
ity between subjects, such as cortical gyri and sulci, is less than to areas exhibiting little
inter-subject variability[64, 117]. Combined with the frequent presence of focal lesions
in frontal and temporal cortices, possibly complicating registration, the relative sparing
of cortex observed in our group analysis in terms of volume loss over time could be a
false-negative result. However, the individual TBM results only revealed cortical atro-
phy in a minority of the patients, thus suggesting white matter atrophy generally being
more pronounced than cortical gray matter atrophy.
Most subjects in this patient population had visible focal lesions on conventional MRI.
Possible confounding of focal lesions on the pattern of longitudinal volume loss found
with TBM cannot be ruled out. In the cross-sectional TBM study [64], a subgroup
analysis was performed for the patients without focal lesions, showing a pattern of
volume loss comparable to that of the whole patient group. However, similar subgroup
analysis was not made in the present study because of the small number of patients
without focal lesions.
Certain limitations relate to the use of SIENAX and other segmentation algorithms for
estimation of volume loss in the patients prior to the first scan. Although the patients
and controls were fairly well matched with respect to demographic parameters, the
assumption that brain volume of the patients prior to injury was comparable to that of
the controls is a rough approximation. Further, the segmentation algorithm of SIENAX
tended to misclassify focal lesions as gray matter, which prevented us from studying
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gray and white matter separately. Since lesions were never misclassified as CSF, the
sum of gray and white matter volume estimates was considered as a relatively valid
estimate of parenchymal volume. However, in consideration of these limitations, the
SIENAX results should be regarded only as rough estimations of initial volume loss.
CHAPTER 7
Schizophrenia
The subject of the second and third paper [27, 28] was a morphological study of anti-
psychotic-naı¨ve first episode schizophrenia patients, with a control group of healthy
subjects for comparison(see appendices B and C for full articles). For a complete
account of the clinical implications of the findings for the entire study see [26].
7.1 Symptoms
Schizophrenia is a severe and heterogeneous mental illness affecting about 0.7 percent
of the population[76]. The illness is characterized by a disintegration of the process
of thinking, of contact with reality, and of emotional responsiveness[95, 119]. The
origin of schizophrenia is a complex interaction of both genetic liability and envi-
ronmental factors and the disorder is characterized by disturbances in brain biology
and function[62, 114, 115]. People with the schizophrenia illness experience differ-
ent symptoms, which are categorized into three broad categories: positive symptoms,
negative symptoms, and cognitive symptoms.[83]
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7.1.1 Positive symptoms
Positive symptoms are abnormal behavior patterns generally not seen in people without
schizophrenia, such as hallucinations, delusions, thought or movement disorders[115].
The most prominent positive symptoms are hallucinations affecting either of the per-
sons five senses; visual, auditory, olfactory, sensory or even taste[115]. Postive symp-
toms include
• Hallucinations are things a person sees, hears, smells, or feels that are obliv-
ious to others, with ”voices” being the most common type of hallucination in
schizophrenia.
• Delusions are false beliefs that often stand out as bizarre and are a persistent
part of the persons beliefs. Delusions include believes that people on television
are directing special messages to them, or that radio stations are broadcasting
their thoughts aloud to others. The person believes the delusions even after other
people disprove that the beliefs, and any logical explanation will strengthen their
false beliefs of conspiracy.
• Thought disorders are unusual or dysfunctional ways of thinking, making af-
fected patient talk in a garbled way that is hard to understand, or abruptly stop
speaking in the middle of a thought.
• Movement disorders appear as agitated body movements, or repetitive motions.
Positive symptoms can come and go, be severe and at other times hardly noticeable[115].
7.1.2 Negative symptoms
Negative symptoms are associated with disruptions of normal emotions and behavior
patterns. Such symptoms are harder to recognize as part of the schizophrenia disorder
as they are easily mistaken for other psychiatric illnessess such as depression or bipolar
disorder[119]. Negative symptoms include:
• ”Flat affect”, ie a person’s face does not move, or talks in a dull, monotonous
voice.
• Lack of pleasure
• Lack of ability to begin and sustain planned activities
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• Poverty of speech
People with negative symptoms need help with everyday tasks, from personal hygiene
to food preparation. This often makes people suffering from schizophrenia seem lazy
or unwilling to help themselves, but the problems are the negative symptoms caused by
the illness[76].
7.1.3 Cognitive symptoms
Cognitive symptoms can be subtle, much like negative symptoms. Cognitive symptoms
are thus as difficult to recognize as part of the disorder. Often, these symptoms are
detected only when other tests are performed. Cognitive symptoms include
• Poor ”executive functioning”, ie. the ability to understand information and use it
to make decisions.
• Trouble focusing or paying attention
• Problems with ”working memory”, ie. the ability to use information immediately
after learning it.
Cognitive symptoms often make it hard to lead a normal life and earn a living. Peo-
ple with schizophrenia are often aware of their cognitive dysfunction, causing great
emotional distress[76].
7.2 Structural brain changes in schizophrenia
The first MRI study of schizophrenia was conducted in 1984 [109] and despite negative
findings, possibly due to small sample size (9 subjects) and poor resolution, numer-
ous MRI studies have since confirmed early post-mortem findings[2]. MRI findings in
chronic schizophrenia patients include reductions in total brain volume and gray matter
volume reductions in severak sub-regions of the frontal, temporal (including amygdala-
hippocampal complex, parahippocampal gyrus and superior temporal gyrus), parietal
and occipital lobes, and in cerebellum. Subcortical abnormalities have been described
in striatum, cavum septi pellucidi, anterior cingulate and thalamus.[41, 100]
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The striatum, comprising the caudate nucleus, putamen, and nucleus accumbens, may
constitute a specific region with regard to the pathophysiology of schizophrenia. These
regions are involved in cognitive functions such as motivation and goal directed be-
haviour, and in sensorimotor coordination. Moreover, activation of the caudate nucleus
and nucleus accumbens has been linked to reward processes. The caudate nucleus has
been associated with language impairment and emotional processes such as romantic
love.[26, 44]
Other regions of the brain are affected as well. Hippocampus volume reductions are not
a characteristic of schizophrenia, but have been associated with numerous neuropsy-
chiatric disorders. Hippocampus plays a vital role in processes of memory formation
and stress and emotional regulation[40, 41]. Ventricular enlargement has been widely
reported in schizophrenia, however ventricular enlargement has also been associated
with various other neuropsychiatric disorders such as mild cognitive impairment and
Alzheimers disease, delirium, late-life depression, bipolar disorder and alcoholism[100].
7.3 Image processing
In the present longitudinal study conventional 3D high-resolution T1-weighted and
T2-weighted images were acquired at two time points at which the patients also were
evaluated clinically. Patients were scanned at baseline and ∼ 6 months followup, and
control subjects were scanned interleaved with patients.
The images were corrected for geometric distortions due to non-linearities in the scan-
ner gradient system (see section 2.1) and subsequently processed using the VBM5 tool-
box (see section 4.2). T2-weighted images were used to create brain masks to clean up
segmentations.
Baseline images were spatially normalized using the DARTEL toolbox(see section 3.4).
Using the final flow fields, the tissue maps were warped into average image space
(DARTEL space) with 1 mm3 interpolated (7th degree b-spline) isotropic voxels, and
the voxel intensities were modulated using the Jacobian determinants of the warp de-
formations. Subsequently, the corresponding native T1-weighted images were warped
into average image space without modulation, and an average T1-weighted image was
calculated usable for regions-of-interest (ROI) delineation to be used small volume cor-
rection and extracting volume estimates.
For each subject, all follow-up T1-weighted images in native space were warped to in-
dividual subjects baseline T1-weighted images using the high-dimensional toolbox(see
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section 3.5). The Jacobian determinant images of the resulting warp deformations were
transformed to the DARTEL space with the previously generated DARTEL warps using
logarithmic interpolation. Next, multiplying the corresponding baseline tissue maps
with the Jacobian determinant images generated tissue maps for the follow-up images
in DARTEL space.
7.4 Results of baseline study
Based on VBM analysis of 38 patients and 43 controls, volumes of hippocampus and
caudate nucleus were decreased in patients as was hypothesized a priori. Any ventric-
ular enlargement was absent, as well as global volume differences. The hippocampal
volume reductions appeared influenced by a history of abuse. Exploratory analyses
indicated reduced nucleus accumbens volumes in the patients.
After the baseline investigations the patients were treated with the second generation
antipsychotic compound, quetiapine for 6 months in flexible doses according to their
clinical need.
7.5 Results of followup study
Based on TBM analysis of 22 patients matched with 28 healthy control subjects, pa-
tients had significant volume loss in striatum and hippocampus, following six months
of quetiapine treatment. The striatal volume loss was most pronounced in low que-
tiapine doses and less apparent in high doses. Conversely, hippocampal volume loss
appeared more pronounced in high quetiapine doses than in low doses. Clinically,
higher baseline positive symptoms were associated with more striatal and hippocampal
volume loss over time.
7.6 Discussion
Global estimates of inter-cranial volume, parenchymal brain volume, gray or white
matter volumes or atrophy estimated using SIENAX and SIENA did not reveal any sig-
nificant volume differences between groups. The absence of brain parenchymal brain
volume (BPV) reduction in the patients is in contrast to results in [112] and may reflect
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that some of the patients included in this analysis had been exposed to first generation
anti-psychotics, which may attenuate global gray matter loss[73].
Our finding of reduced caudate nucleus volume agrees with studies reporting absolute
or significant caudate volume reductions in antipsychotic-naive schizophrenia patients.
Thus, our findings add to the evidence that the caudate nucleus is a key structure in
the pathophysiology of schizophrenia. The pathway to the observed volumetric reduc-
tions in the antipsychotic-naı¨ve state is not clear but may be attributable to decreased
metabolic rates in the basal ganglia. The magnitude of the caudate volume reductions
in this study of about 5% are in line with the average caudate reduction in found in the
literature.
MRI studies have previously associated striatal volume reductions with positive symp-
toms [25, 98], however the present study is the first to show that the severity of positive
symptoms in the antipsychotic state may predict progressive striatal volume loss. The
fact that no association between striatal volume and positive symptoms was observed
at baseline, could indicate that in the earliest phase of schizophrenia the structural con-
sequences of psychotic symptoms may occur with a delay in time.
Hippocampal activation has been associated with positive symptoms in at risk subjects
for schizophrenia [124] and we speculate that the positive correlation between hip-
pocampal volume loss and baseline positive symptoms could reflect a higher level of
stress accompanying a psychotic state [91].
Although we did not find ventricular enlargement over time a significant correlation
between ventricular increase and less negative symptom improvement was observed.
As such our data are consistent with the growing body of evidence which has associated
negative symptoms and poor prognosis with ventricular enlargement (for review, see
[56]).
The mechanisms underlying these progressive brain dynamics, specific antipsychotic
compounds and clinical symptoms warrant further clarification.
CHAPTER 8
Discussion and conclusions
Computational neuroanatomy is a widely applicable technique, which is reflected in
the diversity of neuroscientific questions addressed in the selected papers. The TBM
procedure uses serial high-resolution MRI scans for studying (disease-related) structural
anatomical changes over time. Specifically TBM is a highly automated image analysis
technique that delineates local tissue gain or loss at a great spatial resolution. The
applicability of TBM is clearly demonstrated in the papers presented in this thesis.
The first paper describes a study on the macrostructural brain changes during recovery
after traumatic brain injuries. Traumatic brain injuries exhibit neuroanatomical changes
that are obvious even to non-experts, however the diversity of the injuries as well as the
gross pathological changes make it difficult to quantify changes over time in patients.
Here TBM was utilized to characterize global and regional brain volume changes be-
tween two scan time points through a voxel-wise analysis. Despite remarkable clinical
improvement in most patients, they all exhibited brain volume loss during the scan in-
terval. Global volume change correlated with clinical injury severity, functional status
at both time points, as well as 1-year outcome. The areas which underwent the most
change were structures particularly susceptible to traumatic axonal injury such as copus
callosum and regions in deep white matter and consequent Wallerian degeneration.
The second and third paper describe a study of the neurodegenerative consequences
of schizophrenia and anti-psychotic drug treatment. Schizophrenia is associated with
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subtle changes in the brain, which are undetectable by a non-expert, and as such pro-
vides a different challenge than the previous study. In the baseline study, VBM analysis
combined with hypothesis driven regions of interest approach verified the presence of
a morphological fingerprint in a first-episode schizophrenia sample with no prior life-
time anti-psychotic exposure. The follow-up study focused on medication effects over
time and the results suggested differential dose-dependent effects on brain structure
after exposure to only one anti-psychotic compound. TBM results among other things
indicated that the severity of positive symptoms in first-episode schizophrenia patients
may to some extend predict regional brain volume changes. This implies that early de-
tection of symptoms of schizophrenia and relevant intervention may somewhat prevent
regional brain deterioration and in turn improve the prognosis of the patients.
The image registration methods and statistical models used in the present thesis facili-
tated the remarkable spatial specificity and sensitivity of the results featured in the three
selected papers. The neuroscientific questions addressed in each paper instigated dif-
ferent specialized image processing streams, built to characterize differences between
brains, while considering neuroanatomical variability among subjects. The design, de-
velopment and implementation of these complex image processing streams, required
intricate understanding of the employed image registration and statistical methods.
In addition to TBI and schizophrenia, VBM and TBM have been successfully employed
in numerous studies aimed to further our understanding of the brain in health and dis-
ease, including healthy aging and development during maturation and psychiatric dis-
orders, e.g. autism, depression, tracking degenerative disease progression, and moni-
toring drug treatment effect. Additionally, such studies generally investigate how mor-
phological characteristics are associated with for example specific cognitive measures,
IQ, and genetic polymorphisms. Besides VBM and TBM several other complementary
morphometric methods exist, such as cortical thickness measures and shape analysis
of sub-cortical structures. Neuroimaging studies have become increasingly success-
ful in combining multiple imaging modalities and computational methods to address
neuroscientific questions. Indeed, it is important to note that most techniques, be it
imaging modalities or computational methods, are complementary, emphasizing each
other’s qualities. Only in recent years have techniques, computational power and ex-
pertise consolidated and thereby reached the necessary level of sensitivity, reliability
and feasibility.
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Atrophy
Traumatic brain injury (TBI) results in neurodegenerative changes that progress for months, perhaps even
years post-injury. However, there is little information on the spatial distribution and the clinical signiﬁcance
of this late atrophy. In 24 patients who had sustained severe TBI we acquired 3D T1-weighted MRIs about
8 weeks and 12 months post-injury. For comparison, 14 healthy controls with similar distribution of age,
gender and education were scanned with a similar time interval. For each subject, longitudinal atrophy was
estimated using SIENA, and atrophy occurring before the ﬁrst scan time point using SIENAX. Regional
distribution of atrophy was evaluated using tensor-based morphometry (TBM). At the ﬁrst scan time point,
brain parenchymal volume was reduced by mean 8.4% in patients as compared to controls. During the scan
interval, patients exhibited continued atrophy with percent brain volume change (%BVC) ranging between
−0.6% and −9.4% (mean −4.0%). %BVC correlated signiﬁcantly with injury severity, functional status at both
scans, and with 1-year outcome. Moreover, %BVC improved prediction of long-term functional status over
and above what could be predicted using functional status at ∼8 weeks. In patients as compared to controls,
TBM (permutation test, FDR 0.05) revealed a large coherent cluster of signiﬁcant atrophy in the brain stem
and cerebellar peduncles extending bilaterally through the thalamus, internal and external capsules,
putamen, inferior and superior longitudinal fasciculus, corpus callosum and corona radiata. This indicates
that the long-term atrophy is attributable to consequences of traumatic axonal injury. Despite progressive
atrophy, remarkable clinical improvement occurred in most patients.
© 2008 Elsevier Inc. All rights reserved.
Introduction
Traumatic brain injury (TBI) affects about 235 per 100,000
individuals each year in Europe (Tagliaferri et al., 2006) and is a
major cause of death and severe morbidity worldwide. In survivors of
severe TBI, long-term impairment of consciousness is usually
attributable to traumatic axonal injury (TAI, also known as diffuse
axonal injury). TAI results from rotational acceleration-deceleration
causing shear strain deformation and subsequent disconnection of
axons. It is characterized by microscopic lesions scattered throughout
the white matter in particular, with certain regions being character-
istically involved, namely the dorsolateral rostral brain stem, the
corpus callosum and the subcortical parasagittal white matter. Other
regions susceptible to TAI are the internal and external capsules, the
deep grey matter, the cerebellum, various tracts in the brain stem and
the cerebellar peduncles (Graham et al., 2002). It has been repeatedly
observed in animals (Smith et al., 1997; Bramlett and Dietrich, 2002;
Rodriguez-Paez et al., 2005) and in humans (Graham et al., 2002) that
TBI results in widespread brain atrophy that progresses over several
months and perhaps even years post-injury. While it is remarkable
that atrophy continues in the chronic phase of TBI, concurrently with
clinical recovery, the clinical signiﬁcance of this late atrophy remains
unclear. The progressive degeneration is thought to involve Wallerian
degeneration of the white matter tracts disrupted by TAI, but other
mechanisms such as apoptosis, inﬂammation, excitotoxicity, and
prolonged hypoperfusion may also play a role (Bramlett and Dietrich,
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2002; Rodriguez-Paez et al., 2005). Characterising the spatial
distribution of late atrophy might contribute to the understanding of
its pathogenesis.
Few longitudinal MRI studies have quantitatively examined
progressive atrophy following TBI and the correlation to clinical
parameters. In seven patients with mild to moderate TBI, scanned
twice at least 3 months (up to 2.5 years) apart, MacKenzie et al.
reported a longitudinal change in brain parenchymal volume of on
average −4.16% (relative to −1.49% in healthy controls) and found
greater volume loss in patients with initial loss of consciousness than
in those without loss of consciousness (MacKenzie et al., 2002).
However, in this study early and late atrophy were conﬂated since
the time from injury to the ﬁrst scan varied between 7 and 430 days.
Recently, Trivedi et al. (2007) published a study applying SIENA
(Smith et al., 2002) to evaluate global brain volume change between
approximately 79 and 409 days post-TBI in 37 patients with TBI
ranging from mild to severe. The authors found a change in brain
volume of mean −1.43% (relative to +0.1% in healthy controls), with
greater decline in brain volume being associated with longer
duration of post-injury coma. However, relation to outcome was
not reported.
Characterising quantitatively the regional distribution of late
atrophy following TBI is challenging, especially because focal lesions
often coexist with diffuse lesions, causing regional distortions in brain
shape and intensity inhomogeneities which complicate procedures
such as registration and tissue segmentation. Until recently, previous
studies on TBI have been based on regions-of-interest (for a review,
see Bigler, 2001) or on voxel-based morphometry (Gale et al., 2005;
Tomaiuolo et al., 2005; Salmond et al., 2005; Bendlin et al., in press).
However, recent advances in computational techniques for nonlinear
image registration have allowed for an unbiased and more precise
registration that does not necessarily rely on tissue segmentation,
thus overcoming some of the major limitations of traditional
volumetric approaches. One such approach is tensor-based morpho-
metry (TBM), which determines the deformation ﬁeld required to
warp the early image to match the late image within subject (or in
cross-sectional studies, the deformation ﬁeld required to warp the
image to a study-speciﬁc template). Regional volume change is
quantiﬁed by taking the Jacobian determinant at each voxel
(Ashburner et al., 2000). One cross-sectional TBM study on TBI was
very recently published (Kim et al., 2008). The population consisted of
29 patients with moderate to severe TBI, scanned once at least
3months (ranging between 4months and 27.5 years) following injury.
The authors found localized volume loss most prominently in the
thalamus, themidbrain, the corpus callosum, the cingulate cortex, and
the caudate. Signiﬁcant volume increase was found mainly in the
ventricles. However, as this studywas not based on serial scans, and as
the time from injury to MRI varied considerably between patients, no
conclusions could be drawn about the time course of the structural
changes.
In the present prospective longitudinal study, we examined the
morphological changes occurring between two time points, approxi-
mately 8 weeks and 12 months post-injury, in 24 patients with severe
TBI, comparing them to 14 healthy matched controls scanned with a
similar time interval. We used SIENA to provide an estimate of global
atrophy between scans, and TBM to investigate the regional distribu-
tion of late volume change. Additionally we used SIENAX (Smith et al.,
2002) to estimate global atrophy occurring before the ﬁrst scan time
point, in order to compare this with the late atrophy.We hypothesized
that the most pronounced late volume change would be found within
regions susceptible to TAI (listed at the beginning of this introduction)
as well as along the affected white matter tracts (as a consequence of
secondary Wallerian degeneration). Further, we expected that the
extent of global brain volume change from ﬁrst to second scan would
be larger in patients with longer duration of coma/post-traumatic
amnesia and with poorer functional status and outcome.
Materials and methods
Subjects
Twenty-six adult patients with severe TBI were evaluated for this
study. As two patients were subsequently excluded because of motion
artefacts in the MR images, the ﬁnal TBI group comprised 24 patients.
Fourteen healthy control subjects were selected to match the
patient group with respect to age, sex and education. Both patients
and controls had two MR scans with an interval of 345±42 days
(mean±SD). Group comparisons of age, sex, education and scan
interval are listed in Table 1.
Patients were recruited from the Brain Injury Unit at Copenhagen
University Hospital, Hvidovre, Denmark, to which they were
admitted for subacute rehabilitation. Patients were referred from
neuro-intensive units, and admitted for rehabilitation only if Glasgow
Coma Scale score (GCS; Teasdale and Jennett, 1974) was still
subnormal after cessation of sedation. Severe TBI was deﬁned as a
post-resuscitation GCS b8 measured within 24 h post-injury and
prior to the initiation of paralytics or sedatives. Patients were
excluded from the present study if they had any previous history of
TBI or other neurological disorder, if contraindications to MRI or to
sedation during MRI were present, or if the ﬁrst MRI could not be
performed within 12 weeks post-trauma for safety or practical
reasons. Controls had no history of signiﬁcant TBI or other
neurological disorder.
The study was approved by the local Scientiﬁc Ethics Committee
(KF 01-038/03), meeting criteria of the Helsinki Declaration. Informed
consent was obtained from the participants or, for patients with
impaired consciousness, from next of kin.
Clinical assessments
For all patients, clinical data were documented in medical ﬁles,
and ratings were performed by trained staff, neurologists, and
neuropsychologists. Cause of trauma was either motor vehicle
accident (n=16), fall (n=7) or assault (n=1). Accidents with any
direct involvement of a motor vehicle (including pedestrian or
bicyclist hit by car) were classiﬁed as motor vehicle accident.
Neurosurgery was deﬁned as surgery that involved craniotomy,
excluding insertion of ICP monitoring devices. The number of days
from TBI until GCS N8 was registered as a measure of coma duration,
and the Galveston Orientation and Amnesia Test (Levin et al., 1979)
was repeatedly applied to establish duration of post-traumatic
amnesia (PTA). Both were regarded as measures of injury severity.
The Functional Independence Measure (FIM; Granger et al., 1986)
was documented regularly, including at both scan time points (sum
score ranging from 18 indicating “total assist”, to 126 indicating
“complete independence”). Functional outcome at ∼12 months post-
TBI was evaluated using the 8-point Glasgow Outcome Scale
Extended (GOS-E; Wilson et al., 1998), ranging from 1=dead to
8=good recovery (upper). For dichotomized outcome, the commonly
used division into unfavourable outcome (GOS-E=1–4) and favour-
able outcome (GOS-E=5–8) was applied, distinguishing whether or
not patients were able to live independently.
Image acquisition
All patients and controls were scanned on the same 1.5 T MRI
scanner (Magnetom Vision; Siemens Medical Solutions, Erlangen,
Germany) using a standard circular-polarized head coil. During the
study period, MRI sessions for patients and controls were interleaved
in time, and nomajor upgrades were carried out on the scanner during
the study.
A 3D sagittal T1-weighted sequence (MPRAGE, TR/TE/TI=13.5/7/
100 ms, ﬂip angle 15°, isotropic 1 mm resolution) was acquired in all
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subjects at both scan time points. For patients, additional conventional
sequences included: axial T2-weighted images (spin-echo, TR/
TE=5400/99 ms, 27 contiguous, 5 mm thick slices, 0.5×0.5 mm in-
plane resolution), coronal T2⁎-weighted gradient-echo images (TR/
TE=544/15 ms, 34 contiguous, 5 mm thick slices, 0.9×0.9 mm in-
plane resolution), axial and sagittal FLAIR (TR/TE/TI=9000/110/
2500 ms, 34 contiguous, 5 mm thick slices, 0.9×0.9 mm in-plane
resolution). All the structural images were evaluated by a neuror-
adiologist (M.H.) for identiﬁcation and classiﬁcation of lesions.
All patients were referred for the ﬁrst MRI for clinical purposes.
The majority of patients (n=19) were sedated for this scan, since they
were unable to cooperate due to decreased level of consciousness or
cognitive impairment. Intravenously administered propofol was used
for sedation, and patients were monitored by anaesthesiology staff.
Oxygen supply and mechanical ventilation were provided when
necessary.
For the follow-up scan, subjects were repositioned as close as
possible to their position in the previous scan. For ethical reasons
patients were sedated only if a follow-up MRI was requested for
clinical purposes and patients were unable to cooperate for MRI.
While 4 patients were sedated for the follow-up MRI, 20 were fully
cooperative without sedation. Two additional non-sedated patients
were excluded from this study due to motion artefacts in the follow-
up images. All the remaining images were judged of good quality.
Image processing
Preprocessing: global volume changes
The 3D T1-weighted images were ﬁrst reoriented manually to the
anterior–posterior commissure (AC–PC) orientation, and resliced to
1 mm3 voxels. Intensity normalisation within and between scans was
performed using N3 and MRI Normalise from the MNI toolbox (www.
bic.mni.mcgill.ca).
We used SIENA, available in the FSL 3.3 toolbox (www.fmrib.ox.ac.
uk/fsl), to evaluate global brain volume change between the two scan
time points for each subject. Additionally we applied SIENAX (also
within FSL) for an estimation of brain parenchymal volume, normal-
ized for head size, at the ﬁrst scan time point. These methods have
been described in detail elsewhere (Smith et al., 2001; Smith et al.,
2002). In brief, SIENA starts by extracting brain and skull images from
the two-timepoint whole-head input data. The two brain images are
then aligned to each other (using the skull images to constrain the
registration scaling); both brain images are resampled into the space
halfway between the two. (This intermediate result was later entered
into the TBM analysis, see below). Then segmentation is carried out in
order to ﬁnd brain/non-brain edge points. Perpendicular edge
displacement, between the two time points, is estimated at these
edge points, and the mean edge displacement is converted into a
global estimate of percentage brain volume change (%BVC) from ﬁrst
to second scan. Measurement error of %BVC is reported to be
approximately±0.20% (Smith et al., 2002).
In SIENAX, brain and skull images are extracted, and the brain
image is afﬁne-registered to an MNI standard template (using the
skull image to determine registration scaling, to be used as a
normalisation for head size). Next, segmentation with partial volume
estimation is carried out in order to calculate the total volume of brain
tissue: normalised brain parenchymal volume (BPV).
Preprocessing: regional volume changes
We used TBM to evaluate the regional distribution of brain volume
change between the two scan time points. Following the intensity
Table 1
Group comparisons of demographics and scan interval
Patients (n=24) Controls (n=14) Group
differences
Age, at scan 1 (years) [mean (SD)] 33.2 (13.5) 31.2 (8.1) PN0.5a
Sex: M/F 18/6 9/5 PN0.7b
Education (years) [mean (SD)] 13.3 (3.1) 13.7 (2.7) PN0.6a
Scan interval (days) [mean (SD)] 343 (47) 348 (30) PN0.6b
a Independent-samples t-test.
b Fishers Exact test.
Table 2
Clinical characteristics and global brain volume results for the 24 patients
Patient no. Age at
scan1 (years)
Sex Cause of
trauma
Neurosurgery Duration of
coma (days)
Duration of
PTA (days)
TBI to
scan1 (days)
TAI
gradea
Focal
lesionsb
FIM at
scan1
FIM at
scan2
GOS-E at
∼1 year
BPV at
scan1
%BVC
1 23 F Fall − NFU NFU 58 2 − 18 18 2 1406 −9.42
2 21 F MVA + 12 39 64 2 + 79 117 4 1536 −5.29
3 34 M MVA − 126 NFU 81 3 − 18 30 3 1471 −8.80
4 40 F Fall + 9 NFU 64 2 + 18 20 3 1263 −7.02
5 40 M Assault − 4 88 50 0 − 87 122 6 1405 −1.16
6 60 M Fall + 21 NFU 46 2 + 34 35 3 1543 −7.21
7 28 M MVA − 24 66 69 3 − 122 125 8 1595 −4.08
8 54 M Fall − 14 119 45 2 + 60 125 5 1429 −1.80
9 23 M MVA + 18 47 81 2 + 117 124 6 1584 −2.56
10 24 M MVA − 1 39 36 1 − 93 125 5 1549 −0.62
11 65 M Fall − 3 39 42 1 + 116 120 6 1449 −2.60
12 31 M MVA + 7 48 40 2 + 38 102 5 1609 −6.28
13 37 M MVA + 14 40 69 1 + 117 122 7 1535 −2.74
14 22 M MVA − 7 31 55 2 − 120 125 7 1587 −1.78
15 19 M MVA − 2 23 37 1 − 113 124 7 1673 −1.28
16 41 F MVA + 10 65 41 2 + 55 113 5 1537 −3.73
17 26 M MVA − 22 65 77 1 + 106 124 6 1500 −1.87
18 22 M MVA − 9 178 79 2 − 18 103 4 1543 −2.45
19 23 M MVA − 11 107 55 3 + 23 111 4 1515 −5.58
20 18 F MVA − 15 66 62 3 + 24 105 4 1443 −2.69
21 40 M Fall + 10 84 48 2 + 100 117 5 1484 −1.63
22 53 M Fall + 5 171 39 3 + 18 111 5 1443 −6.80
23 27 M MVA − 10 77 47 2 − 49 113 5 1498 −2.98
24 26 F MVA − 4 58 29 2 − 59 126 8 1557 −4.75
MVA =motor vehicle accident; NFU = exceeds ∼1 year follow-up; PTA = post-traumatic amnesia; FIM = functional independence measure; GOS-E = Glasgow outcome scale, extended;
BPV = brain parenchymal volume; %BVC = percent brain volume change. See text for details.
a According to location of microhaemorrhages on T2⁎-W images (0=none, 1=subcortical only, 2=callosal, 3=brainstem).
b Parenchymal lesions excluding TAI (mainly contusions).
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normalisation and initial registration steps from SIENA, described
above, we then applied the high dimensional warping available in the
SPM2 ‘Deformation toolbox’ (www.ﬁl.ion.ucl.ac.uk/spm) to these
images. This TBM analysis estimates the deformation ﬁeld that
would warp the early T1 image to match the late T1 image within
each subject (Ashburner et al., 2000). From this deformation ﬁeld the
amount of regional expansion or contraction is extracted by taking the
Jacobian determinant at each point, thus generating a Jacobian
determinant map in alignment with the late image. Following
logarithmic transformation of the Jacobian determinant values
(Leow et al., 2007) regional contraction corresponded to positive
values and regional expansion to negative values. The non-skull-
stripped follow-up T1 images were then normalized in SPM2 to the
MNI standard space, and this transformation was applied to the log-
transformed Jacobian determinant maps. Finally, these images were
smoothed with an 8 mm Gaussian kernel.
Statistical analysis: global volume changes
The outputs from SIENA and SIENAX, %BVC and BPV respectively,
were analysed group-wise using the non-parametric Mann Whitney
U-test. Correlation analyses with clinical and conventional imaging
variables were performed using the Spearman's rho. Prediction of
functional status at follow-up by BPV and FIM at the ﬁrst scan and %
BVC was assessed using linear regression.
Statistical analysis: regional volume changes
For statistical analysis of TBM results, we used a permutation test
(Randomise, available in FSL). Unlike the general linear model,
permutation tests do not rely on the assumption that data are
normally distributed (Nichols and Holmes, 2001). To compare patients
and controls, a design matrix was constructed that included the
nuisance variables age, sex, education and scan interval. Calculations
were performed voxel-wise with 10,000 permutations, and a whole-
brain correction for multiple comparisons was applied using a false
discovery rate (FDR) of 0.05. Clusters with a radius of b2 mm (volume
b33.5 mm3) were rejected for display purposes. Anatomy atlas tools
available in FSL were used to help identify anatomical regions.
Results
Global volume changes
Already at the ﬁrst scan time point ∼8 weeks post-trauma,
normalized BPV, derived from SIENAX, was 8.4% lower in patients
Fig. 1. Regions of signiﬁcant volume changes in TBI patients between ∼8 weeks and ∼12 months post-injury, as compared to controls, thresholded at false discovery rate (FDR) 0.05
(clusters of b33.5 voxels rejected). Longitudinal volume reduction is coded red/yellow, volume expansion is coded blue. Results are overlaid onto the MNI standard template.
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than controls (mean±SD: 1506 ml±85 ml vs. 1645 ml±85 ml,
Pb0.0001, Mann–Whitney U-test).
During the ∼11 months scan interval %BVC, derived from SIENA,
ranged between −0.6% and −9.4% (mean −4.0%, median −2.9%) in
patients, compared to between −0.9% and +0.3% (mean −0.18%,
median −0.13%) in controls (patients vs. controls: Pb0.000001, Mann–
Whitney U-test).
For each patient, Table 2 lists BPV and %BVC together with selected
demographic, clinical and conventional imaging variables. Therewas a
signiﬁcant correlation between BPV and %BVC when all subjects were
considered (r=0.57, Pb0.001, Spearman's rho); however this correla-
tion was not signiﬁcant for either patients or controls separately. No
signiﬁcant correlations were found between %BVC and scan interval,
age or gender. All but one patient had microhaemorrhages on T2⁎-
weighted images, indicating TAI. Graded according to location
(Graham et al., 2002), TAI grade correlated with %BVC (r=−0.59,
Pb0.01, Spearman's rho), but not with BPV.
To check for the robustness of SIENAX for these traumatized brains,
we also applied SIENAX on the follow-up scans, again comparing to
controls, and calculated the differences (in %) between BPV at the ﬁrst
and second scan (data not shown). These values were roughly
comparable to the %BVC derived from SIENA, indicating that
the estimates from SIENAX were reliable, at least as rough estimates
of BPV.
Regional volume changes
TBM, with whole-brain correction for multiple comparisons,
identiﬁed regions with signiﬁcant volume loss or volume expansion
over time in patients as compared to controls. Fig. 1 shows the
differences between patients and controls using an FDR of 0.05. At this
threshold, a large coherent cluster of volume loss extended from the
brain stem and cerebellar peduncles and bilaterally through the
thalamus, internal capsule, external capsule, putamen, inferior and
superior longitudinal fasciculus, corpus callosum (genu, body and
splenium) and corona radiata. Small clusters of signiﬁcant volume loss
were also found, mainly in the cerebellum and in the frontal lobes.
Signiﬁcant longitudinal volume expansion in patients compared to
controls was found in the ventricles and scattered in the subarach-
noidal space (with a large cluster at the fundus of the intraparietal
sulcus). In general the pattern of volume loss as well as volume
expansionwas relatively symmetric. The statistical strength of volume
loss, reaching its maximum in the tectum mesencephali (Z=6.86),
exceeded that of volume expansion (maximum Z=5.07). Details of
signiﬁcant volume loss are found in Table 3.
Correlation with clinical variables
Injury severity
BPV at the ﬁrst scan correlated signiﬁcantly with duration of PTA
(r=−0.59, Pb0.01, Spearman's rho), however not with duration of
coma. Both duration of coma and PTA correlated signiﬁcantly with %
BVC between the two scan time points (r=−0.45, Pb0.05 and r=−0.53,
Pb0.01, respectively, Spearman's rho).
Functional status and outcome
BPV at the ﬁrst scan correlated signiﬁcantly with concomitantly
evaluated FIM (r=0.46, Pb0.05, Spearman's rho). Also %BVC between
the two scan time points was signiﬁcantly correlated with FIM
evaluated both at the ﬁrst and at the second scan time point (r=0.62,
P=0.001 and r=0.68, Pb0.001 respectively, Spearman's rho).
Table 3
Clusters of signiﬁcant volume loss in patients compared to controls at false discovery rate (FDR) 0.05
Anatomical region Tissue
type
Side MNI coordinates of voxel of
maximum signiﬁcance
PeakZ Cluster size
(voxels)
x y z
1 Large coherent cluster in the brain stem and
cerebellar peduncles, extending bilaterally through
internal capsule, thalamus, putamen, external capsule,
inferior and superior longitudinal fasciculus, corpus callosum,
corona radiata
WM+GM L/R −1 −31 −16 6.86 129013
2 Cerebellum GM L −8 −50 −54 4.06 963
3 Frontal orbital cortex GM L −29 18 −18 3.54 736
4 Cerebellum GM R 10 −62 −52 3.74 508
5 Frontal orbital cortex GM R 9 20 −21 3.04 301
6 Cerebellum GM R 25 −53 −23 3.05 212
7 Frontal lobe, subcortical WM WM L −43 10 18 3.13 178
8 Frontal lobe, cortex/subcortical WM WM+GM L −42 29 2 3.77 148
9 Middle temporal gyrus GM L −60 −56 10 3.40 122
10 Superior corona radiata WM R 23 8 38 2.72 110
11 Lateral occipital cortex GM L −50 −77 13 3.06 61
Coordinates of each cluster maximum are reported. Cluster maximum for cluster 1 corresponds to tectum mesencephali.
GM = grey matter; WM = white matter; L = left; R = right.
Fig. 2. Box and whiskers plot of %BVC in patients with favourable (n=16) and
unfavourable (n=8) outcome (Pb0.01, Mann–Whitney U-test). Control values (n=14)
are displayed for comparison. %BVC = percent brain volume change.
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With respect to 1-year outcome, BPV at the ﬁrst scan did not differ
signiﬁcantly between favourable and unfavourable outcome groups
(Mann–Whitney U-test). However, BPV correlated signiﬁcantly with
the full scale GOS-E (r=0.48, Pb0.05). Late volume change (%BVC
between the two scan time points) was signiﬁcantly different between
outcome groups (Fig. 2; Pb0.01, Mann–Whitney U-test) and also
correlated signiﬁcantly with the full scale GOS-E (r=0.55, Pb0.01).
In a linear regression model with FIM at the follow-up scan as the
dependent variable, FIM at the initial scan signiﬁcantly predicted late
FIM, as one would expect (Pb0.001). Adding BPV at the ﬁrst scan did
not improve themodel. However, adding %BVC to themodel improved
prediction of late FIM (increment F=4.7 and parameter estimate
Pb0.001 for %BVC), with pronounced late atrophy predicting lower
FIM at follow-up, and vice versa.
Discussion
We studied late atrophy occurring between ∼8 weeks and
∼12 months following severe TBI, using TBM to evaluate the regional
distribution of volume change and SIENA to estimate individual global
atrophy. Additionally, SIENAX was used to estimate global atrophy
occurring prior to the ﬁrst time point. In patients, as compared to
controls, signiﬁcant atrophy during the scan interval was found in: a
large coherent cluster in the brain stem and cerebellar peduncles
extending bilaterally through the thalamus, internal capsule, external
capsule, putamen, inferior and superior longitudinal fasciculus, corpus
callosum and corona radiata; and in smaller clusters mainly in the
cerebellum and the frontal lobe. At∼8weeks post-injury brain volume
was already reduced bymean 8.4% in patients as compared to controls,
but an additional mean 4.0% (median 2.9%) volume loss occurred in
patients during the scan interval. The magnitude of this late volume
loss was signiﬁcantly correlatedwith injury severity (duration of coma
and PTA), with FIM at both scan time points, and with 1-year GOS-E.
Global volume changes
We found a highly signiﬁcant decline in brain volume during the
late subacute and chronic phases of TBI. This is in agreement with the
recent study by Trivedi et al. also using SIENA (Trivedi et al., 2007).
While our patient population represented very severely injured
survivors of TBI (Engberg et al., 2006), Trivedi studied a population
of mixed injury severity ranging frommild to severe TBI. This probably
explains whywe found a greater decline in brain volume (mean −4.0%,
median −2.9%) compared to their study (mean −1.43%). However, part
of this difference may also be due to the fact that the time from TBI to
the ﬁrst scan was slightly shorter in our study (55 days, range=29–
81 days compared to 79 days, range=39–109 days).
All but one patient in the present study had microhaemorrhages
on conventional T2⁎-weighted images, indicating the presence of TAI.
In accordance with the view that general atrophy post-TBI is mainly
caused by TAI, we found that TAI grade, as evaluated on T2⁎-weighted
images, correlated with %BVC. However, a similar correlation could
not be found for initial atrophy estimated by BPV.
To relate longitudinal decline in brain volume to the early atrophy
occurring between the time of injury and the ﬁrst scan time point (the
ﬁrst ∼8 weeks post-injury), we used SIENAX, comparing brain volume
in patients at the ﬁrst scan time point to that of the controls. With
SIENAX we found that BPV in patients at the ﬁrst scan time point was
on average 8.4% smaller than BPV in controls. While this should be
regarded as a fairly rough estimate (see subsection Limitations), it
clearly indicates that the rate of decline in brain volume is much
higher in the acute/early subacute phase post-trauma than at later
stages. Obviously our study does not allow further conclusions to be
made about the time course of atrophy following TBI, as we cannot
know whether the late atrophy occurred gradually during the whole
scan interval, or whether the degenerative process ended already after
a few months. However, animal studies suggest a gradual volume
decrease up to at least 1 year post-trauma (Rodriguez-Paez et al.,
2005). Future human studies withmultiple scan time points should be
conducted to better characterize the time course of the progressive
atrophy following TBI.
Regional volume changes
The pattern of late atrophy observed in patients as compared to
controls corresponds well to those regions known from neuropatho-
logical and biomechanical studies to be susceptible to TAI or to
consequences of TAI (Graham et al., 2002; Maxwell et al., 1997). The
continuous involvement of the corticospinal tract from the corona
radiata through the posterior limb of the internal capsule, crus cerebri
and pons is likely to represent Wallerian degeneration secondary to
TAI. These results suggest that the progressive atrophic process
following TBI is a direct consequence of TAI. The highest level of
signiﬁcancewas found for the tectummesencephali, which is one area
particularly susceptible to TAI.
The results of the present study are mainly in agreement with the
ﬁndings of the single available TBM study on TBI (Kim et al., 2008).
When comparing these two studies, one should bear in mind that
while we investigated the regional distribution of late atrophy only,
the study by Kim et al. was not longitudinal and therefore did not
distinguish between early and late atrophy. In both studies, the
statistical strength of volume loss was generally higher than that of
volume expansion. As concluded by Kim et al. this suggests that using
ventricular enlargement to indirectly measure atrophy is not the most
sensitive measure. Like in the study by Kim et al. we found signiﬁcant
volume loss (at FDR 0.05) in the brainstem, thalamus, corpus callosum,
putamen and cerebellum. However, the volume loss was more
widespread in our study and included the entire corticospinal tract
from corona radiata to pons as one coherent cluster. Additionally we
found signiﬁcant volume loss in the external capsule, inferior and
superior longitudinal fasciculus and in the cerebellar peduncles.
Unlike Kim et al. we did not ﬁnd volume loss in the caudate. While in
both studies signiﬁcant volume expansionwas found in CSF, Kim et al.
also found apparent volume expansion in some white matter areas
including the internal capsule, which they interpreted as secondary to
heavy atrophy of surrounding areas.
Some of the discrepancies between the present study and the
study by Kim et al. are likely to be due to differences in injury severity,
as Kim et al. included patients with bothmoderate and severe TBI. It is
possible that there are also some differences in the regional
distribution of the atrophy occurring in the acute/early subacute
phase compared to the late atrophy in the late subacute/chronic
phase. One should also bear in mind the somewhat random nature of
the injuries in the individual TBI patients, which inadvertently is
another source of variability between studies. Finally, discrepancies
may also be related to methodological differences in the two studies.
Importantly, in the cross-sectional study by Kim et al., every brainwas
warped to a population-speciﬁc template based on both controls and
patients, while in our longitudinal study warping was performed
within subject.
In a very recent longitudinal study, Bendlin and co-workers
(Bendlin et al., in press) measured regional volume changes in
patients with moderate TBI using voxel-based morphometry (VBM).
Their study design is somewhat similar to ours, but differs in some key
elements. Firstly, there is a difference in injury severity of the TBI
patients. Secondly, as opposed to VBM, TBM is based on intra-subject
volume change. Thirdly, VBM relies on segmented white matter and
grey matter maps, whereas our TBM analysis has the advantage of not
relying on tissue segmentation (in our dataset tissue segmentation
tended to misclassify focal lesions, see subsection Limitations).
Despite these differences, our results are largely in agreement with
the ﬁndings of Bendlin et al. who reported longitudinal volume losses
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in corona radiata, corpus callosum, internal and external capsules,
superior and inferior longitudinal fascicules, cingulum, inferior fronto-
occipital fasciculus, corticospinal tract, cerebellar peduncles, thala-
mus, and pallidum, as well as small areas with volume loss in the
cerebellar white matter, right post-central and precentral gyri,
supplementary motor area, and putamen.
Clinical signiﬁcance of progressive atrophy
One of the advantages of the prospective longitudinal design used
in this study is that it allowed us not only to scan the patients with a
uniform time interval, but also to collect clinical data at predeﬁned
time points, including outcome evaluation about 1 year post-injury.
We found several correlations between clinical variables and the
degree of late global atrophy. In agreement with the study by Trivedi
et al., we found a signiﬁcant correlation between duration of coma and
%BVC, although duration of coma was deﬁned slightly differently in
the two studies. Another indicator of injury severity, duration of PTA,
also correlated signiﬁcantly with %BVC in our study. These ﬁndings are
not surprising given that the extent of TAI is likely to be a major
determinant of %BVC as well as of the severity of impairment of
consciousness reﬂected by duration of coma or PTA.
Furthermore, we found signiﬁcant correlations between %BVC and
functional status (as evaluated by FIM) at both scan time points, and
between %BVC and 1-year GOS-E. These ﬁndings, however, do not
necessarily imply that late volume loss per se is a determinant of
functional status and outcome. It might be that the extent of TAI is the
major determinant of both %BVC and clinical function including long-
term clinical outcome. The consequences of TAI may involve cellular
processes other than atrophy, which also might account for some of
the clinical consequences following TAI.
Using linear regression, we determined which parameters pre-
dicted functional status at the follow-up scan.We found that inclusion
of %BVC dramatically improved upon the predictive performance
offered by the∼8week FIM values alone. Thus, a higher rate of volume
loss during the scan interval was associated with poorer functional
status at follow-up, controlling for the degree of functional impair-
ment present at the ﬁrst scan time point. It should be noted, however,
that the four most severely injured patients (patient no. 1, 3, 4 and 6 in
Table 2, who all had PTA N1 year) stood out from the rest, causing the
correlation between %BVC and FIM at ∼12 months to be driven mainly
by these subjects. Larger studies are clearly needed to conﬁrm the
observed relationship between atrophy and functional impairment.
For the majority of patients, decline in brain volume occurred
concurrently with remarkable clinical improvement, as for example
reﬂected in the median FIM-value which increased from 60 (18–122)
at the time of the ﬁrst scan to 117 (18–126) at the second scan. This
apparent paradox indicates that some regenerative processes must
occur despite the macroscopic degeneration. From animal studies
evidence is accumulating that neuroplastic changes, such as axonal
sprouting and synaptic reorganization, accompany functional recov-
ery following TBI (reviewed e.g. by Levin 2003; Albensi and Janigro
2003, Dancause 2006) andmay even be enhanced by pharmacological
procedures (see e.g. Priestley 2007). In humans, using diffusion tensor
imaging, we recently found that diffusion abnormalities fol-
lowing severe TBI, supposedly reﬂecting disruption of axonal micro-
architecture, partly normalise during clinical recovery, particularly in
patients with good outcome (Sidaros et al., 2008). Metabolite
abnormalities, as measured by MR proton spectroscopy, also have
been found to recover over time to near normal levels in good
outcome patients (Holshouser et al., 2006; Signoretti et al., 2008).
Limitations
The use of SIENAX is based on the assumption that brain volume of
the patients prior to injury was comparable to that of the controls.
Since the groups werematchedwith respect to age, sex and education,
this may be a reasonable approximation. Even if it had been feasible to
acquire another MRI in the very acute phase following trauma,
oedema would have greatly confounded longitudinal volume
comparisons.
In principle, clearing of brain oedema between scans could be
responsible for an apparent loss of brain volume over time. However,
we found no radiological evidence of oedema at the ﬁrst MRI
(evaluated on T2-weighted and FLAIR images), consistent with the
experience that oedema resolution usually occurs within the ﬁrst four
weeks post-injury, i.e. before the ﬁrst scan time point of this study.
Furthermore, the fact that BPV was found to be substantially lower in
patients than controls at the ﬁrst scan time point, strongly argues that
oedema had resolved at that point and thus did not mediate the
observed longitudinal decline in brain volume.
Grey matter/white matter segmentation tended to misclassify
focal lesions as grey matter, regardless of original tissue type. This
prevented us from studying grey and white matter atrophy separately.
However, lesioned tissue was never misclassiﬁed as CSF, and the sum
of grey matter and white matter volume estimates, derived from
SIENAX, were therefore regarded as valid estimates of BPV.
One limitation related to voxel-wisemorphometric approaches such
as TBM is that the sensitivity to areas with high anatomical variability
between subjects, such as cortical gyri and sulci, is less than to areas
exhibiting little inter-subject variability. In a TBI population, the correct
warping of cortical areas is even further complicated by the occurrence
of focal lesions,which are often cortical in location. Therefore,we cannot
exclude the possibility that the observed relative sparing of cortical
areas, in terms of late atrophy, could be a false-negative result. On the
other hand,we did not expect cortical atrophy to be a prominent feature
in comparisonwithwhitematter atrophy, because local cortical atrophy
due to focal lesionswould vary in location betweenpatients and thus be
unlikely to emerge as signiﬁcant in a voxel-wise group analysis. The
possibility of more widespread cortical thinning, e.g. secondary to TAI
with retrograde degeneration, would probably be below the limit of
detection by TBM. Future studies, using for example cortical thickness
mapping, might elucidate a possible cortical involvement in the
degenerative process following TBI.
Finally, another limitation of our study is that we did not acquire
MRI at more than two time points. Future studies using multiple data
acquisitions at shorter time intervals would allow for a more detailed
description of the time course of atrophy following TBI.
Conclusions
In this prospective longitudinal study of late volume changes
following severe TBI we have demonstrated that themost pronounced
atrophy is found in regions susceptible to TAI or to consequences of
TAI, suggesting that TAI is a major factor responsible for late
degeneration. We have further shown associations between the
extent of global atrophy and clinical parameters, including duration
of coma and PTA, functional status and 1-year outcome. Interestingly,
in most patients these long-term degenerative changes occurred
concurrently with functional improvement, suggesting that macro-
scopic tissue loss is less important than supposedly microscopic
neuroplastic processes in determining clinical function.
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Background: Enlarged ventricles and reduced hippocampal volume are consistently found in patients with first-episode schizophrenia.
Studies investigating brain structure in antipsychotic-naive patients have generally focused on the striatum. In this study, we examined
whether ventricular enlargement and hippocampal and caudate volume reductions are morphological traits of antipsychotic-naive first-
episode schizophrenia. Methods: We obtained high-resolution 3-dimensional T1-weighted magnetic resonance imaging scans for 
38 antipsychotic-naive first-episode schizophrenia patients and 43 matched healthy controls by use of a 3-T scanner. We warped the brain
images to each other by use of a high-dimensional intersubject registration algorithm. We performed voxel-wise group comparisons with
permutation tests. We performed small volume correction for the hippocampus, caudate and ventricles by use of a false discovery rate
correction (p < 0.05) to control for multiple comparisons. We derived and analyzed estimates of brain structure volumes. We grouped pa-
tients as those with (n = 9) or without (n = 29) any lifetime substance abuse to examine the possible effects of substance abuse. Results:
We found that hippocampal and caudate volumes were decreased in patients with first-episode schizophrenia. We found no ventricular en-
largement, differences in global volume or significant associations between tissue volume and duration of untreated illness or psycho -
pathology. The hippocampal volume reductions appeared to be influenced by a history of substance abuse. Exploratory analyses indi-
cated reduced volume of the nucleus accumbens in patients with first-episode schizophrenia. Limitations: This study was not a priori
designed to test for differences between schizophrenia patients with or without lifetime substance abuse, and this subgroup was small.
Conclusion: Reductions in hippocampal and caudate volume may constitute morphological traits in antipsychotic-naive first-episode
schizophrenia patients. However, the clinical implications of these findings are unclear. Moreover, past substance abuse may accentuate
hippocampal volume reduction. Magnetic resonance imaging studies addressing the potential effects of substance abuse in antipsychotic-
naive first-episode schizophrenia patients are warranted.
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Introduction
Magnetic resonance imaging (MRI) studies have demon-
strated the presence of structural brain abnormalities in mul-
tiple brain regions in chronic schizophrenia patients com-
pared with healthy controls.1 Although, volume changes
have also been observed in various brain regions in first-
episode schizophrenia patients,2 only hippocampal volume
reduction and ventricular enlargement are consistently pres -
ent, as shown in 2 recent meta-analyses.3,4 Inconsistencies
among studies are probably because of differences in meth-
ods, samples sizes and sample composition (e.g., studies vary
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in the inclusion criteria regarding previous exposure to anti -
psychotic medications and substance abuse or dependence).
Numerous studies point toward hippocampal involvement
in schizophrenia (for reviews see5,6). Volumetric reductions in
hippocampus, however, are not pathognomonic for schizo-
phrenia, but they have been associated with numerous
neuro psychiatric disorders, including substance abuse.7
Moreover, typical and atypical antipsychotics may affect hip-
pocampal volumes differently.8 In antipsychotic-naive pa-
tients, significant hippocampal reductions have been reported,9
although not consistently.10 The clinical implications of hip-
pocampal involvement in antipsychotic-naive schizophrenia
patients are unclear. However, hippocampal reductions may
be associated with illness duration and psycho pathology.11
Ventricular enlargement is also not specific for schizophre-
nia.12 Nevertheless, recent studies suggest that ventricular en-
largement may progress during the course of the disease and
may be related to outcome13 or antipsychotic treatment.14
Studies investigating minimally medicated and antipsychotic-
naive schizophrenia patients have often focused on the stria-
tum, which consists of the caudate nucleus, putamen and 
nucleus accumbens.15 Striatal volume reductions are not con-
sistently found in medicated first-episode patients, likely be-
cause antipsychotic treatment in itself can induce alterations
in the striatum (for review see16). Nevertheless, a recent meta-
analysis of voxel-based structural MRI studies in first-
episode patients found the presence of caudate nucleus re-
ductions as compared with chronic schizophrenia patients.2
Moreover, nonpsychotic children of psychotic individuals
have been shown to have smaller caudate nuclei.17 Absolute
volume reductions in the putamen and nucleus accum-
bens15,18,19 have also been observed, although significant
changes have only been observed in the putamen.18 Signifi-
cantly increased putamen volumes have also been reported.9
Although the clinical implications of structural striatal
changes in schizophrenia are unresolved, caudate volume
changes have been associated with illness duration and posi-
tive symptoms.20 Also, a positive correlation was found be-
tween putamen surface contractions and affective flattening.18
Structural changes already observed in antipsychotic-naive
schizophrenia patients are likely not because of hospitaliza-
tion, chronicity or antipsychotic treatment. However, schizo-
phrenia patients commonly have a past or present history of
substance abuse or dependence. Both alcoholism21,22 and
cannabis abuse23,24 have been associated with grey matter
changes in frontal, temporal and subcortical regions as well
as ventricular changes. Some studies have dealt with this 
issue by excluding patients with comorbid substance abuse
or dependence.25–27 However, the criteria used are not uniform
among studies and encompass exclusion because of sub-
stance dependence20, “significant abuse”19 or abuse within a 
6-month period,28 as well as no mention of abuse.9,10,29
The primary aim of our study was to investigate whether
the presence of hippocampal reduction, ventricular enlarge-
ment and caudate reduction is a morphologic trait in first-
episode antipsychotic-naive schizophrenia patients compared
with matched healthy controls. Regional voxel-wise and 
volumetric analyses were performed after high-dimensional
intersubject warping of all patients’ brains.30 Region-of-interest
(ROI) masks of the hippocampus, ventricles and caudate
were created to test our a priori hypotheses. Moreover, asso-
ciations with clinical measures were explored. Finally, we
tested for possible effects of any lifetime substance abuse.
Methods
The study was conducted in accordance with the declaration
of Helsinki II and approved by the ethics committee of the
Capital Region (H-KF-01–78/97). After complete description
of the study to the participants, written informed consent
was obtained.
Participants
Initially, 43 patients and 43 healthy controls, matched for age,
sex and parental socio-economic status, underwent MRI
scans. Patients were recruited as part of a first-episode
schizo phrenia study conducted in the Capital Region 
of Copen hagen, Denmark (Psychiatric Centres Amager,
Ballerup, Bispebjerg, Gentofte, Glostrup and Rigshospitalet).
We included patients aged 18–45 years with a diagnosis of
schizophrenia, no prior exposure to antipsychotic medication
and no medical or neurologic comorbidity. The DSM-IV di-
agnoses were based on the Schedules for Clinical Assessment
in Neuropsychiatry (SCAN), version 2.1.31 We also included
patients who used benzodiazepines (to reduce agitation and
anxiety). Use of antidepressants was recorded. Patients with
any lifetime substance abuse are denoted Ptab, patients with
no lifetime substance abuse diagnosis are denoted Ptnon-ab and
the total patient sample is denoted Ptall.
The controls were recruited from the community and had
no prior or present psychiatric disorder, had never used
psycho tropic medication and had no first-degree relatives
with a psychiatric disorder, as determined by SCAN inter-
views. Both patients and controls had normal physical and
neurologic examinations, no history of major head injury (loss
of consciousness), no mental retardation, no contraindications
on MRI or any nonpsychiatric disorder. We assessed handed-
ness by use of the Edinburgh Inventory.32 A neuroradiologist
(A.L.) examined the MRI scans, which were free of pathology.
We excluded controls with substance abuse or dependence. 
Clinical measures
Trained raters assessed psychopathology with the Positive
and Negative Syndrome Scale (PANSS),33 and the interviews
were recorded on DVDs for validation purposes. In a ran-
dom subset of 10 PANSS recordings, an intraclass correlation
of 0.92 in a 2-way mixed effect model was achieved.
We defined the duration of untreated illness as the time be-
tween the first unspecific symptoms related to psychosis to
the date of the MRI scan. Symptoms had to be associated
with a decline in a previous stable level of function. We col-
lected data about the duration of untreated illness with the
best-estimate approach25 with information from the SCAN in-
terview, clinical records and relatives, if possible.
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Image acquisition
We acquired high-resolution 3-dimensional (3-D) T1-weighted,
sagittal, magnetization-prepared rapid-gradient echo
(MPRAGE) scans of each patient’s whole head (echo time
3.93 ms, repetition time 1540 ms, inversion time 800 ms, flip
angle 9°, field of view 256 mm, matrix 256 × 256, 1 × 1 × 1 mm
voxels, 192 slices) and 2-dimensional (2-D) T2-weighted, axial,
turbo spin echo (TSE) scans of the whole brain (echo time one
17 ms, echo time two 100 ms, repetition time 9000 ms, flip 
angle 150°, field of view 220 mm, matrix 256 × 256, GRAPPA
acceleration factor 2, 30 reference lines, 0.9 × 0.9 × 3 mm voxels,
50 slices). We used a Siemens Magnetom Trio 3-T scanner with
an 8-channel head coil (Invivo Corporation).
Image processing
We corrected the images for spatial distortions owing to 
nonlinearity in the gradient system of the scanner34 and
processed the images using the VBM5 toolbox (http://dbm
.neuro .uni-jena.de/vbm/vbm5-for spm5/) in SPM5 (Well-
come Department of Cognitive Neurology, University Col-
lege London, UK), which includes a unified segmentation al-
gorithm,35 and a hidden Markov random field method.36 We
used the T2-weighted images to automatically create brain
masks in native space. We derived brain masked grey and
white and cerebral spinal fluid tissue maps in native space
from the T1 images. We used these masks, together with the
affine part of the spatial transformation from native to Mon-
treal Neurological Institute (MNI) space, in Diffeomorphic
Anatomical Registration Through Exponentiated Lie 
Algebra (DARTEL)30 using default settings, allowing for
high-dimensional intersubject registration. Recently, it has
been shown that DARTEL can successfully register the hip-
pocampus across patients.37 Using the final flow fields that
parameterize the deformations, brain masked grey matter,
white matter and cerebral spinal fluid images were warped
into average image space (DARTEL space) and modulated
with the Jacobian determinant of the applied deformation
fields to correct for local volume changes following the high
dimensional intersubject warping. We used voxel-wise analy-
ses to test for differences in regional tissue volume. We
smoothed these tissue images with an 8-mm full-width at
half-maximum Gaussian kernel. We visually checked the
quality of the images generated at each processing stage. 
Regions of interest
We created the following ROI masks on the average of DARTEL
warped MPRAGE images for all participants. The delineation
landmarks were as follows: hippocampus,38 ventricles, lateral
and third ventricle,39 caudate nucleus, nucleus accumbens
and putamen.15
Volumetric brain measures
We acquired intracranial volume estimates by integrating
and adding image intensity values of modulated and
warped grey matter, white matter and cerebral spinal fluid
images. Total brain volume was acquired by integrating and
adding grey matter and white matter image intensity values.
Total ROI volumes were acquired to investigate whether 
local voxel-wise differences were reflected in whole ROI vol-
ume differences, and to generate percent difference esti-
mates. We derived hippocampal, caudate and accumbens
volume estimates by integrating image intensity values of
modulated and warped grey matter images within the hip-
pocampus, caudate and accumbens masks, respectively. We
derived ventricle estimates by integrating image intensity
values of modulated and warped cerebral spinal fluid im-
ages within the ventricle masks. Because the grey matter tis-
sue of the putamen was only partially classified, we derived
putamen volume estimates by integrating intensity values of
modulated and warped binary image volumes within the
putamen mask.
Statistical analyses
We used the Statistical Package for the Social Sciences (SPSS)
to analyze demographic and volumetric data. We tested the
distribution of all continuous data for normality with the
Shapiro–Wilk test. Age, duration of untreated illness, cere-
bral spinal fluid and ventricle volumes were not normally
distributed. Logarithmic transformation only normalized the
distribution of duration of untreated illness. We tested age,
cerebral spinal fluid and ventricle volumes nonparametri-
cally with the Mann–Whitney U test. We tested handedness
and sex differences with the Fisher exact test and socio-
economic status with the Pearson χ2 test. Because the Ptab
group only consisted of 9 patients, the Mann–Whitney U test
was used to compare clinical data (PANSS scores and dura-
tion of untreated illness) between the 2 subgroups. We identi-
fied potential outliers with the Grubb outlier test.40
We used analysis of covariance to compare Ptall and con-
trols for volumetric estimates of intracranial volume, total
brain volume, grey matter and white matter. We entered age,
sex and intracranial volume as covariates. Intracranial 
volume was only corrected for age and sex. We used the
Mann–Whitney U test to test for group differences in cerebral
spinal fluid volume after the effects of age, sex and intracra-
nial volume had been regressed out. We used the latter ap-
proach to test differences for in intracranial volume, total
brain volume, grey matter, white matter and cerebral spinal
fluid volumes between Ptnon-ab and Ptab.
In the voxel-wise analyses of group differences, age, sex and
intracranial volume were covariates. We first tested for differ-
ences between Ptall and controls. Subsequently, planned com-
parisons tested for differences between Ptnon-ab and controls, Ptab
and controls, and Ptnon-ab and Ptab. We estimated general linear
models nonparametrically using Randomize, version 2.1, part of
the FSL library of tools (www.fmrib.ox.ac.uk /fsl/randomise/
index.html) with 10 000 permutations. We used small volume
correction, applying ROI masks, to test our a priori hypotheses
of hippocampal reduction, ventricle enlargement and caudate
reduction. A false discovery rate threshold of 0.05 was used to
correct for multiple comparisons. The clinical data (positive,
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negative and total PANSS scores, and duration of untreated ill-
ness) were used as covariates in separate analyses.
We analyzed group differences in total hippocampal, ven-
tricles, caudate, accumbens and putamen volume estimates
with SPSS using a repeated-measures analysis of variance
with group (Ptall and control or Ptnon-ab and control) as the 
between-subjects factors, and hemisphere (left and right) as
the within-subjects variable. Age, sex and intracranial vol-
ume were covariates. We tested for volumetric differences of
ROIs between Ptab and controls and Ptnon-ab and Ptab by use of
the Mann–Whitney U test, after regressing out age, sex and
intracranial volume effects. We calculated the percentage ROI
volume differences between groups using corrected volumes
adjusted for age, sex and intracranial volume.
All tests were 2-tailed, and the significance level was set to
p < 0.05.
Results
Demographic characteristics
Of the 43 patients with first-episode schizophrenia, we ex-
cluded 5 patients from further analyses (3 whose diagnoses
were adjusted to schizotypal personality disorder and 2 with
artifacts on their MRI scans). Of the 38 patients included, 9
ful filled the DSM-IV criteria for lifetime substance abuse.
Three of the 9 patients had no history of abuse for the past
year, and 5 patients had no abuse for the past month. Diag-
noses were based on excessive intake of alcohol (n = 3),
cannabis (n = 2), alcohol and cannabis (n = 3) and central
stimulants (n = 1). One patient had smoked cannabis on a
few occasions in the month before the MRI scan. All partici-
pants had a negative urine screening result for substance in-
take. In total, there were 9 patients with any lifetime sub-
stance abuse side-diagnosis (Ptab), 29 patients with no lifetime
substance abuse diagnosis (Ptnon-ab). Demographic and clinical
characteristics are shown in Table 1.
There were no differences between Ptall and control groups
for age (Z = –0.51, p = 0.61), sex (Fisher exact test, p > 0.99),
handedness (Fisher exact test, p > 0.99) and parental socio-
economic status (χ22 = 1.85, p = 0.40). Likewise, the 2 patient
subgroups, Ptab and Ptnon-ab, did not differ in age, sex, handed-
ness or parental socio-economic status (p > 0.21). Compared
with Ptnon-ab, the Ptab group had more benzodiazepines pre-
scribed in the investigation period (Fisher exact test, p = 0.02)
and a tendency toward higher PANSS positive scores (Z =
–1.84, p = 0.07). There was no difference in antidepressant ex-
posure between the 2 patient groups (lifetime exposure:
Fisher exact test, p = 0.66; current treatment: Fisher exact test,
p = 0.13), and there was no difference between PANSS nega-
tive, PANSS total or duration of untreated illness (p > 0.76).
Global brain volumes
There were no volumetric differences in intracranial volume,
total brain volume, grey matter, white matter or cerebral
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Table 1: Demographic characteristics, clinical data and global brain volumes for antipsychotic-naive first-episode schizophrenia patients and
healthy controls
Group; mean (SD)*
Characteristic Ptab,† n = 9 Ptnon-ab, n = 29 All patients, n = 38 Healthy controls, n = 43
Age, yr, mean (SD) [range] 28.0 (4.4) [20–35] 25.7 (5.6) [18–37] 26.2 (5.4) [18–37] 26.9 (5.7) [18–38]
Sex, male:female 6:3 20:9 26:12 30:13
Handedness, right:left, no. of patients 9:0 36:3 35:3 39:4
Parental socio-economic status,
high/moderate/low, no. of patients 3/4/2 18/10/1 21/14/3 30/11/2
Benzodiazepine prescription,‡ no. of patients 8 12 20 —
Antidepressant use, lifetime, § no. of patients 3 6 9 —
Antidepressant use, current,¶ no. of patients 3 3 6 —
Positive and Negative Syndrome Scale33 score
Positive 21.6 (4.6) 18.5 (3.8) 19.2 (4.2) —
Negative 21.8 (6.0) 21.8 (7.1) 21.8 (6.8) —
Total 81.9 (16.5) 79.5 (14.9) 80.1 (15.1) —
Duration of untreated illness, wk 188.0 (193.3) 174.5 (229.4) 178.0 (219.0) —
Absolute, uncorrected volume, cm3
Intracranial 1619.7 (188.3) 1517.9 (159.9) 1542.0 (170.1) 1552.6 (124.3)
Total brain 1320.4 (155.9) 1242.1 (139.5) 1260.7 (145.3) 1271.4 (109.1)
Total grey matter 792.7 (85.3) 760.7 (79.8) 768.3 (81.1) 777.0 (64.0)
Total white matter 527.6 (74.7) 481.4 (64.9) 492.4 (69.3) 494.3 (50.9)
Cerebrospinal fluid 299.4 (53.8) 275.7 (36.3) 281.3 (41.6) 281.2 (45.9)
Ptab = patients with any lifetime DSM-IV substance abuse diagnosis; Ptnon-ab = patients with no lifetime substance abuse diagnosis; SD = standard deviation.
*Unless otherwise indicated.
†The Ptab group comprised those with alcohol abuse, in sustained full remission (n = 2); alcohol abuse, on agonist therapy (n = 1); cannabis abuse, in a controlled environment, (n = 1);
other abuse, sustained full remission (n = 1); other abuse, moderate (n = 1); other abuse, in a controlled environment (n = 2); other abuse, early partial remission (n = 1). Diagnoses were
based on excessive intake of alcohol (n = 3), cannabis (n = 2), alcohol and cannabis (n = 3) and central stimulants (n = 1).
‡Number of patients with any prescription of benzodiazepines in the investigation period.
§Antidepressants lifetime: selective serotonin reuptake inhibitors (n = 7), noradrenergic and specific serotonergic antidepressant (n = 1), unknown antidepressant (n = 1).
¶Antidepressants, current: selective serotonin reuptake inhibitors (n = 5), noradrenergic and specific serotonergic antidepressant (n = 1).
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spinal fluid between the Ptall and control groups (p > 0.23) or
between the 2 patient subgroups (p > 0.14) (Table 1).
Regional brain analyses
Results for the voxel-wise analyses are shown in Table 2. Ab-
solute, uncorrected volume estimates for ROIs are presented
in Table 3.
Hippocampus
The voxel-wise analyses revealed significant bilateral reduc-
tions in hippocampal grey matter in the Ptall group as com-
pared with the control group. This difference was accounted
for by Ptab rather than by Ptnon-ab (Fig. 1). Direct comparison of
the 2 patient groups showed significantly reduced hippocam-
pal grey matter in the Ptab group.
The results of the volumetric analyses paralleled those of the
voxel-wise analysis. The significant main effect of group, Ptall ×
control (F1,76 = 4.26, p = 0.042), was accounted for by Ptab (Ptab ×
control; Z = –3.28, p = 0.001), rather than by Ptnon-ab (Ptnon-ab × con-
trol; F1,67 = 0.63, p = 0.43). Moreover, those in the Ptab group had
significantly smaller hippocampus volumes than those in the
Ptnon-ab group (Z = –2.73, p = 0.006). The comparison of Ptall and
control did not reveal a hemisphere × group interaction (F1,76 =
2.61, p = 0.11) or hemisphere effect (F1,76 = 0.31, p = 0.58). The
group differences represented corrected hippocampal volume
reductions of 2.4% between Ptall and control, 6.5% between Ptab
and control, and 0.1% between Ptnon-ab and control (Fig. 2).
Ventricles
Neither the voxel-wise nor the volumetric analyses revealed
ventricle differences between any of the groups (p > 0.38 in
the volumetric analyses). Grubbs test detected one outlier in
the control group. Visual inspection of this participant’s MRI
scan indicated no pathology or artifact. Exclusion of this out-
lier did not change the results. The results of exploratory
analyses of group differences for the third and the lateral
ventricle volumes separately were not significant.
Caudate nucleus
The voxel-wise analyses revealed significantly reduced cau-
date grey matter bilaterally in the Ptall group compared with
in the control group. This difference was primarily because of
Ptnon-ab rather than Ptab (Fig. 3) However, the 2 patient groups
did not significantly differ from each other.
The analyses of caudate nucleus volume paralleled the
Table 2: Results of the voxel-wise analyses for antipsychotic-naive first-episode schizophrenia patients and
healthy controls
MNI coordinates
Mask Contrast* Side Z score p value† x y z
Cluster size,
mm3
Hippocampus Pt
all < HC Left 3.65 0.004‡ –26 –12 –28 987
Right 3.99 0.004‡ 25 –17 –25 2270
Pt
ab < HC Left 3.99 0.002‡ –26 –13 –28 1930
Right 3.39 0.002‡ 22 –14 –27 2760
Pt
non-ab < HC Right 2.74 0.35 30 –17 –22 —
Pt
ab < Ptnon-ab Left 3.43 0.031‡ –24 –15 –26 1320
Right 2.79 0.033‡ 24 –10 –20 572
Ventricles Pt
all > HC Left 2.71 0.87 –28 –68 6 —
Pt
ab > HC Left 2.11 0.98 –28 –68 6 —
Pt
non-ab > HC Left 3.45 0.34 –34 –51 1 —
Pt
ab > Ptnon-ab Left 2.10 0.91 –15 4 25 —
Caudate nucleus Pt
all < HC Left 3.10 0.030‡ –14 17 2 2950
Right 2.59 0.033‡ 10 17 –5 2700
Pt
ab < HC Left 2.58 0.17 –10 20 –1 —
Pt
non-ab < HC Left 3.11 0.023‡ –15 –5 –25 3460
Right 2.86 0.023‡ 12 3 18 3060
Ptab < Ptnon-ab Left 0.93 0.93 –21 21 0 —
Nucleus accumbens Pt
all < HC Left 2.90 0.08 –12 14 –6 —
Pt
ab < HC Left 1.81 0.40 –13 14 –6 —
Pt
non-ab < HC Left 3.16 0.018‡ –10 16 –7 375
Right 2.75 0.018‡ 10 14 6 168
Pt
ab < Ptnon-ab Right 0.72 0.89 14 16 –11 —
Putamen Pt
all < HC Left 2.62 0.16 –24 6 –11 —
Pt
ab < HC Right 3.08 0.099 33 3 0 —
Pt
non-ab < HC Left 2.56 0.76 –14 8 –10 —
Ptab < Ptnon-ab Right 2.94 0.13 33 1 –1 —
HC = healthy controls; MNI = Montreal Neurological Institute; Ptab = patients with any lifetime DSM-IV substance abuse diagnosis;
Ptall = all patients; Ptnon-ab = patients with no lifetime substance abuse diagnosis.
*All significant contrasts are displayed. For nonsignificant contrasts, only the voxel with the lowest p value is displayed.
†p values are false discovery rate (FDR)–corrected (p < 0.05).
‡Significant after FDR correction.
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voxel-wise results. There was a significant main effect of
group, Ptall × control (F1,76 = 8.94, p = 0.004). This group differ-
ence was primarily accounted for by Ptnon-ab (Ptnon-ab × control;
F1,67 = 6.88, p = 0.01), although there was a tendency toward
caudate volume reduction in Ptab (Ptab × control; Z = –1.90,
p = 0.06). There was no volumetric difference between the
2 patient groups (Z = –0.17, p = 0.99). There was no hemi-
sphere × group interaction when comparing the Ptall and con-
trol groups (F1,76 = 0.62, p = 0.44) or hemisphere effect
(F1,76 = 3.24, p = 0.076). The group differences represented cor-
rected caudate volume reductions of 5.1% between Ptall and
control, 5.1% between Ptnon-ab and control, and 5.0% between
Ptab and control (Fig. 4).
Nucleus accumbens and putamen
Exploratory voxel-wise analyses of the nucleus accumbens
revealed a tendency for reduced grey matter in the Ptall group
compared with the control group. This tendency appeared to
be driven by Ptnon-ab, rather than by Ptab. However, the 2 pa-
tient groups did not significantly differ from each other.
Analyses of nucleus accumbens volume showed a significant
main effect of group (Ptall × control; F1,76 = 6.82, p = 0.011). This
group difference seemed to be accounted for by Ptnon-ab (Ptnon-ab ×
control; F1,67 = 7.58, p = 0.008), rather than by Ptab (Ptab × con-
trol; Z = –0.88, p = 0.38).
Voxel-wise exploratory analyses of the putamen did not re-
veal any differences between Ptall and control, Ptnon-ab and con-
trol or Ptab and control. Exploratory analyses of putamen vol-
ume did not reveal any group main effects (Ptall × control:
F1,76 = 0.42, p = 0.52; Ptnon-ab × control: F1,67 = 0.044, p = 0.83; Ptab ×
control: Z = –1.27, p = 0.20). When comparing the hemisphere
× group interactions for the Ptall and control groups (F1,67 =
1.25, p = 0.27 and F1,67 = 0.001, p = 0.97 for the accumbens and
putamen, respectively). Hemisphere effects (F1,67 = 0.18, 
p = 0.73 and F1,67 = 0.012, p = 0.33 for the accumbens and puta-
men, respectively) were absent.
Whole brain
Exploratory voxel-wise whole brain analyses did not reveal
any group differences in regional grey matter, white matter
or cerebral spinal fluid volumes.
Clinical measures
Neither the voxel-wise nor the volumetric analyses revealed
significant associations between PANSS scores or duration
of untreated illness and hippocampal, ventricle or striatal
structure volumes. However, we observed a weak tendency
of longer duration of untreated illness to be associated with
reduced hippocampal volume in the Ptall group (F1,32 = 2.55,
p = 0.13). Associations with other brain regions, as examined
with exploratory whole brain voxel-wise analyses, were ab-
sent. There were no significant associations between clinical
measures and global brain measures (intracranial volume,
total brain volume, grey matter, white matter or cerebral
spinal fluid).
Discussion
As we had hypothesized, this study revealed significant hip-
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Table 3: Absolute, uncorrected volume estimates for regions of interest for antipsychotic-naive first-episode
schizophrenia patients and healthy controls
Group; absolute, uncorrected brain volume, mm3, mean (SD)
Brain region Ptab, n = 9 Ptnon-ab, n = 29 All patients, n = 38 Healthy controls, n = 43
Hippocampus
Left 4235 (396) 4330 (390) 4307 (388) 4458 (387)
Right 4205 (424) 4260 (379) 4247 (385) 4331 (370)
Total 8440 (809) 8590 (756) 8554 (760) 8789 (717)
Ventricles
Left 8063 (3755) 7008 (2890) 7258 (3094) 7372 (4226)
Right 7173 (2030) 6812 (3635) 6898 (3301) 7078 (4149)
Third 488 (184) 397 (140) 418 (154) 432 (147)
Total 15 725 (5508) 14217 (6267) 14574 (6058) 14882 (8112)
Caudate nucleus
Left 3531 (370) 3374 (428) 3411 (416) 3598 (354)
Right 3611 (333) 3454 (410) 3491 (395) 3690 (368)
Total 7142 (698) 6828 (833) 6902 (805) 7288 (718)
Nucleus accumbens
Left 358 (52) 337 (42) 342 (45) 356 (40)
Right 381 (50) 359 (38) 364 (42) 383 (39)
Total 739 (100) 697 (78) 707 (84) 739 (76)
Putamen
Left 4117 (536) 4165 (492) 4153 (496) 4200 (376)
Right 4408 (522) 4388 (479) 4393 (482) 4444 (390)
Total 8525 (1055) 8553 (967) 8546 (974) 8643 (759)
Pt
ab = patients with any lifetime DSM-IV substance abuse diagnosis; Ptall = all patients; Ptnon-ab = patients with no lifetime substance abuse
diagnosis; SD = standard deviation.
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pocampal and caudate volume reductions in a relatively
large cohort of antipsychotic-naive first-episode schizophre-
nia patients compared with matched healthy controls. Ven-
tricular enlargement was absent. No differences in global vol-
umes were found, and no significant associations between
tissue volumes and psychopathology or duration of un-
treated illness were observed.
Our data support the growing body of evidence that indi-
cates that the hippocampal volume is significantly reduced at
the onset of schizophrenia.3,4,6 The observed corrected volume
reduction of 2.4% in the schizophrenia patients, Ptall, compared
with the control participants was somewhat smaller than the
8.2% reduction reported in a recent meta-analysis of data from
first-episode schizophrenia patients.4 However, the patients in
the present study had never taken antipsychotics, whereas
most of the studies included in the meta-analysis included
medicated patients.4 It has been suggested that previous expo-
sure to first-generation antipsychotics may not protect against
progressive reductions in hippocampal volume reduction.8
Moreover, the meta-analysis also included studies that did not
account for substance abuse or dependence. Interestingly, the
hippocampal volume reduction in our study appeared most
pronounced in patients with a lifetime substance abuse diag-
nosis (Ptab), accounting for a corrected volume reduction of
6.5% as compared with controls, whereas the reduction among
patients without a history of abuse (Ptnon-ab) was only 0.1%.
However, this study was not a priori designed to test for po-
tential effects of substance abuse; thus, interpreting the results
about the effects of abuse must be done cautiously.
Indeed, the absolute, uncorrected volumes (Table 3) sug-
gest that both patient groups might have reduced hippocam-
pal volumes compared with controls. Our findings of higher
PANSS positive scores and more frequent prescriptions of
benzodiazepines among the Ptab patients suggests that stress
could also have influenced hippocampal volumes.7 To our
knowledge, no studies have associated benzodiazepine use
with volumetric brain changes in schizophrenia. Finally, gen -
etic variants prevalent in the normal population may con-
tribute to morphologic variations in schizophrenia;41 hence,
the differences between the small patient subgroups ob-
served in this study could reflect random genetic profiles
rather than past substance abuse.
Our finding of reduced caudate nucleus volume agrees
with studies reporting absolute15 or significant9,25,26,29,42,43 cau-
date reductions in antipsychotic-naive schizophrenia pa-
tients. Thus, our findings add to the evidence that the cau-
date nucleus is a key structure in the pathophysiology of
schizophrenia.44 The pathway to the observed volumetric re-
ductions in the antipsychotic-naive state is not clear but may
be attributable to decreased metabolic rates in the basal gan-
glia.45 The magnitude of the caudate volume reductions in
Fig. 1: Voxel-wise hippocampal grey matter volume reductions in
first-episode schizophrenia patients for the right (right, mirrored)
and left hemispheres (left). Voxel-wise nonparametric statistic re-
sults showing areas were all schizophrenia patients had smaller
hippocampal grey matter volumes than healthy controls (yellow),
areas where patients with any lifetime substance abuse had smaller
volumes than healthy controls (red), and the overlap of the 2 con-
trasts (orange). Displayed voxels survived a false discovery rate–
corrected (p < 0.05) small volume correction restricted to the hip-
pocampus. Results are projected on sagittal slices of the average
of all DARTEL-warped magnetization-prepared rapid-gradient echo
images. From top to bottom, the images are 18, 23 and 28 mm, 
respectively, from the midsagittal plane.
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Fig. 2: Boxplot of hippocampal volumes in schizophrenia patients
with any lifetime substance abuse (Ptab), patients with no lifetime sub-
stance abuse (Ptnon-ab) and matched healthy controls. Volumes are
corrected for age, sex and intracranial volume. In the box-and-
whisker plot, the central box represents the values from the lower to
upper quartile. The transverse line in the box represents the me-
dian corrected volume. The vertical line extends from the minimum
to the maximum value, excluding outside values. Outside values
are defined as values smaller or larger than the lower quartile mi-
nus 1.5 times the interquartile range and are displayed as separate
points (? ). No outliers were identified.
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this study of about 5% are in line with the average caudate
reduction in the study by Glenthoj and colleagues.15 In the
present study, caudate volume reductions were significant in
the Ptnon-ab group and were also apparent in Ptab, suggesting
only a modest, if any, effect of abuse on caudate volumes.
Ventricular enlargement has consistently been observed in
first-episode schizophrenia3,4 and has also been reported in
antipsychotic-naive patients.39,43 Nevertheless, ventricular en-
largement was absent in the present cohort, and, as such, our
data suggest that ventricular enlargement may not occur 
until a later stage of the disease13 or may be related to anti -
psychotic medication use.14
In our voxel-wise analyses, the nucleus accumbens volume
appeared reduced at a trend-level in the Ptall group as com-
pared with the control group. However, in the volumetric
analyses, this reduction was significant. Volume reductions
in the nucleus accumbens have previously been found in 
antipsychotic-naive schizophrenia patients,15,18,19 but, to the
best of our knowledge, significant accumbens volume reduc-
tions have not been reported. Still, limited conclusions can be
drawn from our finding because it emerged from exploratory
analyses. Moreover, the accumbens reductions were only
partially supported by the voxel-wise analysis. In agreement
with most15,18,25,27,46 but not all19,26 reports on the putamen, we
also observed decreased absolute, uncorrected putamen vol-
umes in patients; however, this was not significant when cor-
rected for age, sex and intracranial volume. Only 1 study re-
ported putamen volumes to be significantly reduced,18
rendering the issue of structural changes in the putamen in
antipsychotic-naive schizophrenia patients unresolved.
We observed no significant differences in corrected global
brain volumes (intracranial volume, total brain volume, grey
matter, white matter and cerebral spinal fluid) in the patients
as compared with the controls. The absence of total brain vol-
ume reduction in the patients is in contrast to the findings by
Steen and colleagues4 and could reflect that some of the pa-
tients included in the meta-analysis had been exposed to
first-generation antipsychotics, which may attenuate global
grey matter loss.47
It is unclear whether reductions in the hippocampus and
caudate nucleus in antipsychotic-naive schizophrenia are as-
sociated with psychopathology and illness duration. Al-
though not significant, our observation of a weak association
between longer duration of untreated illness and reduced
hippocampal volume is in line with those of Matsumoto and
colleagues,11 suggesting that hippocampal changes may occur
during the transition to psychosis.48 Associations between
structural abnormalities and clinical variables presumably re-
flect underlying pathophysiologic disturbances in neuro-
transmission, metabolism and genetic variance, and different
mechanisms may underlie positive and negative symptoms.49
Studies investigating the relations between volumetric mea-
sures and clinical variables have yielded inconsistent results
likely attributable to differences in clinical samples, image ac-
quisition and processing and anatomic delineation protocols.
We found no altered asymmetry between patients and
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Fig. 4: Boxplot of caudate nucleus volumes in schizophrenia pa-
tients with any lifetime substance abuse (Ptab), patients with no life-
time substance abuse (Ptnon-ab) and matched healthy controls. Vol-
umes are corrected for age, sex and intracranial volume. See
Figure 2 for information about interpretation of the boxplot.
Fig. 3: Voxel-wise caudate grey matter volume reductions in pa-
tients with first-episode schizophrenia in the right (right, mirrored)
and left (left) hemispheres. Voxel-wise nonparametric statistic re-
sults showing areas were all patients had smaller caudate nucleus
grey matter volumes than healthy controls (yellow), areas where
patients with no lifetime substance abuse diagnosis had smaller
volumes than healthy controls (purple) and the overlap of the 2 con-
trasts (orange). Displayed voxels survived a false discovery rate–
corrected (p < 0.05) small volume correction restricted to the cau-
date nucleus. Results are projected on sagittal slices of the average
of all DARTEL warped magnetization-prepared rapid-gradient echo
images. From top to bottom, the images are 13, 18 and 23 mm, 
respectively, from the midsagittal plane. 
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controls, hence we have not replicated our previous finding
of altered asymmetry of the caudate nucleus in an indepen-
dent group of 19 antipsychotic-naive patients.15
Limitations
The present study is limited with respect to elucidating the
possible role of drug abuse on volumetric measures because
it was not a priori designed to test for differences between
patients with or without a lifetime substance abuse diagnosis.
Moreover, even though we have assessed all DSM-IV diag-
noses with a validated instrument (SCAN 2.1), we cannot ex-
clude the possibility that some of the patients in the Ptnon-ab
group may have had a past period of excessive drug use,
which we were not informed of. Additionally, because of the
small number of patients with abuse and the various types of
abuse, we cannot make causal inferences about the impact of
lifetime substance abuse on brain structure in first-episode
schizophrenia patients. Nevertheless, comorbid substance
abuse has previously been associated with morphologic
changes, including in the hippocampus.22,23
Another limitation was the unequal size of the patient sub-
groups. This was addressed by the use of nonparametric sta-
tistical analyses, which makes no assumptions about the dis-
tribution of the data. Notably, the volumetric analyses
confirmed the differences detected by the voxel-wise analy-
ses, hereby ruling out the possibility that the voxel-wise re-
sults were based on random local minima.
Conclusion
Our study indicates that reduced hippocampus and caudate
nucleus volumes may constitute morphologic traits in first-
episode antipsychotic-naive schizophrenia patients. How-
ever, the clinical implications of these findings are still un-
clear. Moreover, a history of substance abuse may accentuate
hippocampal volume reductions. Magnetic resonance imag-
ing studies explicitly addressing the potential effects of any
lifetime substance abuse in antipsychotic-naive first-episode
schizophrenia patients are warranted.
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Abstract
First-generation antipsychotics have been associated with striatal volume increases. The effects of second-
generation antipsychotics (SGAs) on the striatum are unclear. Moreover, SGAs may have neuroprotective
effects on the hippocampus. Dose-dependent volumetric effects of individual SGAs have scarcely been
investigated. Here we investigated structural brain changes in antipsychotic-naive, first-episode schizo-
phrenia patients after 6 months treatment with the SGA, quetiapine. We have recently reported on baseline
volume reductions in the caudate nucleus and hippocampus. Baseline and follow-up T1-weighted images
(3 T) from 22 patients and 28 matched healthy controls were analysed using tensor-based morphometry.
Non-parametric voxel-wise group comparisons were performed. Small volume correction was employed
for striatum, hippocampus and ventricles. Dose-dependent medication effects and associations with
psychopathology were assessed. Patients had significant bilateral striatal and hippocampal loss over the
6-month treatment period. When compared to controls the striatal volume loss was most pronounced with
low quetiapine doses and less apparent with high doses. Post-hoc analyses revealed that the striatal volume
loss was most pronounced in the caudate and putamen, but not in accumbens. Conversely, hippocampal
volume loss appeared more pronounced with high quetiapine doses than with low doses. Clinically, higher
baseline positive symptoms were associated with more striatal and hippocampal loss over time. Although
patients’ ventricles did not change significantly, ventricular increases correlated with less improvement of
negative symptoms. Progressive regional volume loss in quetiapine-treated, first-episode schizophrenia
patients may be dose-dependent and clinically relevant. The mechanisms underlying progressive brain
changes, specific antipsychotic compounds and clinical symptoms warrant further research.
Received 22 March 2010 ; Reviewed 15 May 2010 ; Revised 15 June 2010 ; Accepted 18 June 2010
Key words : Brain imaging (MRI), hippocampus, psychopathology, schizophrenia, second-generation
antipsychotic (SGA), striatum.
Introduction
Magnetic resonance imaging (MRI) studies have shown
widespread progressive brain alterations during the
course of schizophrenia. These brain changes seem
to occur most dramatically in the early stages of the
disease ; however, it is still unclear to what extend
specific regional changes are related to antipsychotic
medication and psychopathology (Arango et al. 2008;
Borgwardt et al. 2009; Hulshoff Pol & Kahn, 2008).
A growing body of evidence indicates that first-
generation antipsychotic (FGA) compounds may
induce striatal hypertrophy possibly linked to the
blockade of the dopamine D2 receptors and the
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induction of extrapyramidal side-effects (Lieberman
et al. 2008; Navari & Dazzan, 2009 ; Scherk & Falkai,
2006 ; Smieskova et al. 2009; Vita & De Peri, 2007).
Although second-generation antipsychotic (SGA)
compounds also target the D2 receptors, SGAs may not
cause volume increases (Chakos et al. 1994; Dazzan
et al. 2005; Smieskova et al. 2009) and they may even
decrease striatal volumes (Crespo-Facorro et al. 2008).
Notably, SGAs do not constitute a homogeneous
category (Leucht et al. 2009) and both preclinical
(Andersson et al. 2002; Lidow&Goldman-Rakic, 1997;
Tarazi et al. 2001) and clinical (Crespo-Facorro et al.
2008; Markianos et al. 2001) studies indicate differen-
tial effects depending on the specific SGA adminis-
tered, emphasizing the importance of investigating
individual antipsychotic compounds preferably in
antipsychotic-naive patients.
Among SGAs, both clozapine and quetiapine have
been shown to reverse volumetric increases caused by
FGAs in striatum (Scheepers et al. 2001; Stip et al.
2008). Interestingly, both compounds are charac-
terized by a low affinity and a loose binding (a fast
koff), for dopamine D2 receptors and a broad receptor
profile (Kapur & Seeman, 2001; Kessler et al. 2006).
However, clozapine is not recommended as a first
choice in first-episode schizophrenia patients (Kerwin,
2007). The biochemical mechanisms underlying the
antipsychotic effect of quetiapine are not fully under-
stood. Some have argued that the effect may be medi-
ated solely via a transiently high D2 occupancy (Kapur
et al. 2000; Tauscher-Wisniewski et al. 2002), while
others have proposed that a weak D2 antagonism in
combination with a potent 5-HT2A antagonism under-
lie the effect (Meltzer et al. 2003; Meltzer & Huang,
2008). Interestingly, in a positron emission tomo-
graphy (PET) study employing the 5-HT2A specific
radioligand fluorine 18-labelled altanserin in a subset
of the present cohort of first-episode schizophrenia
patients treated with quatiapine, higher 5-HT2A occu-
pancy was associated with a reduction in positive
symptoms. Moreover, the optimal clinical effect as-
sociated with 5-HT2A occupancy was obtained with
occupancies between 60% and 70%, corresponding to
moderate doses of 336–538 mg/d (Rasmussen et al.
2010). These observations could suggest that in doses
higher than y538 mg/d (70% 5-HT2A occupancy) the
antipsychotic effect of quetiapine may predominately
be mediated through dopaminergic blockade. Until
now, longitudinal studies investigating dose-depen-
dent effects of antipsychotic monotherapy on striatal
volumes are largely absent (for an exception see
Glenthoj et al. 2007). Hypothetically, dose-dependent
involvement of serotonergic and dopaminergic
systems, respectively, may induce differential striatal
alterations.
Investigations of the relationship between pro-
gressive striatal brain changes and symptom im-
provement have yielded inconsistent results. The
aforementioned caudate volume reduction associated
with clozapine treatment was significantly related
to positive and general symptom improvement
(Scheepers et al. 2001). In contrast, left-sided caudate
and putamen volume increases have been associated
with positive symptom improvement after 4 wk
treatment with either FGAs or SGAs (Taylor et al.
2005).
Administration of SGAs early in the course of
schizophrenia may protect against progressive global
grey-matter (GM) loss and ventricular enlargement
which in turn may improve symptoms and the
functional outcome (Hulshoff Pol & Kahn, 2008;
Lieberman et al. 2008). The hippocampus, in particu-
lar, is a plastic region which is highly susceptible
to neuropsychiatric stress (Geuze et al. 2005). Both
in chronic as well as in first-episode schizophrenia
patients hippocampal volume reductions have been
consistently found (Shenton et al. 2001; Steen et al.
2006; Vita et al. 2006). This has prompted the question
as to whether antipsychotic compounds, and in
particular SGAs, may protect against hippocampal
volume loss (Angelucci et al. 2000; Bai et al. 2003;
Halim et al. 2004). In preclinical studies quetiapine has
been shown to increase brain-derived neurotrophic
factor (BDNF) expression (Park et al. 2006; Xu et al.
2002), to reduce neurodegeneration induced by global
cerebral ischaemia (Bi et al. 2009; Yan et al. 2007), and
to reverse stress-induced suppression of neurogenesis
(Luo et al. 2005) in hippocampus.
The present study encompasses follow-up MRI
data on a cohort of antipsychotic-naive, first-episode
schizophrenia patients after 6 months treatment with
quetiapine. Twenty-two patients and 28 matched
healthy control subjects (HC) participated. At baseline
the patients (n=38) compared to HC (n=43) dis-
played a-priori hypothesized volume reductions in
the caudate nucleus and the hippocampus, albeit no
enlargement of the ventricles (Ebdrup et al. 2010).
In the current study, we used tensor-based morpho-
metry (TBM) to explore striatal volume changes after
y6 months of treatment. We explicitly tested if high
quetiapine doses were associated with relative striatal
volume increases compared to low doses. Moreover,
we investigated whether quetiapine had a preserving
effect on hippocampus and ventricle volumes. Finally,
associations between structural changes and psycho-
pathology were explored.
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Method
The study was conducted in accordance with the
Declaration of Helsinki II and approved by the Ethics
Committee of the Capital Region, Copenhagen (H-KF-
01-78/97). After complete description of the study to
the subjects, written informed consent was obtained.
Participants
Twenty-two patients and 28 HC participated in the
follow-up study. Demographic and clinical charac-
teristics are given in Table 1. All participants were
re-examined with MRI and psychopathology was re-
assessed with the Positive and Negative Syndrome
Scale (PANSS; Kay et al. 1987) by trained raters (intra-
class correlation=0.92). After the baseline examin-
ations, the patients were treated with quetiapine
according to their clinical need (mean=538; S.D.=
265 mg/d) in an intended treatment period of
6 months (mean=7.3, S.D.=1.0 months).
Baseline data on 38 patients and 43 age-, gender-
and parental socioeconomic status- (P-SES) matched
HC has been reported elsewhere (Ebdrup et al. 2010).
Briefly, patients were recruited from the Capital
Region of Copenhagen, Denmark. Inclusion criteria
were : a diagnosis of schizophrenia, no prior exposure
to antipsychotic medication, age between 18–45 yr,
and no medical or neurological comorbidity. DSM-IV
Table 1. Demographics, clinical data and global brain volumes
Time-point Loque (n=13) Hique (n=9) Ptall (n=22) HC (n=28)
Age (yr) B 26.2 (5.7) 27.8(5.1) 26.2 (5.4) 28.4 (6.0)
Gender (male/female) – 8/5 7/2 15/7 21/7
Handedness (right/left) – 13/0 8/1 21/1 26/2
P-SES (high/moderate/low) – 7/6/0 2/5/2 9/11/2 19/7/27
MR scan interval (months) – 7.3 (1.1) 7.2 (0.8) 7.3 (1.0) 7.7 (2.3)
Quetiapine (mean dose) F 352.3 (103.3) 807.2 (178.3) 538.4 (265.7) –
Benzodiazepines (yes/no)a L 7/6 9/0 16/6 –
F 0/13 3/6 3/19 –
Antidepressants (yes/no)b L 2/11 3/6 5/17 –
F 1/12 2/7 3/19 –
Weight (kg) B 73.9 (21.0) 76.4 (10.3) 74.9 (17.1) 75.8 (9.6)
F 80.2 (22.3) 86.3 (12.6) 82.7 (18.8) 76.7 (10.9)
Substance abuse (yes/no)c L 1/12 4/5 5/17 –
DUI (wk)d B 266.8 (296.1) 133.6 (174.5) 178 (219.0) –
PANSS positive score B 19.2 (3.0) 20.7 (5.3) 19.8 (4.0) –
F 14.5 (3.7) 15.2 (4.6) 14.8 (4.0) –
PANSS negative score B 21,9 (6.4) 21.1 (7.8) 21.6 (6.8) –
F 19.8 (4.9) 18.9 (5.4) 19.4 (5.0) –
PANSS total score B 80.5 (13.3) 79.8 (19.6) 80.2 (15.8) –
F 70.8 (17.1) 68.4 (20.0) 69.9 (17.8) –
Intracranial volume (ICV) B 1509.3 (142.7) 1612.2 (240.0) 1555.4 (190.4) 1576.5 (105.9)
Total brain volume (TBV) B 1226.1 (128.0) 1296.4 (128.0) 1254.9 (159.5) 1277.4 (100.8)
F 1228.2 (119.9) 1298.5 (179.3) 1257.0 (147.4) 1268.9 (94.5)
Total grey matter (GM) B 753.8 (73.3) 779.4 (113.1) 764.3 (90.1) 778.1 (63.1)
F 755.0 (69.1) 778.5 (101.8) 764.6 (82.6) 771.8 (57.6)
Total white matter (WM) B 472.2 (60.7) 517.1 (90.3) 490.6 (75.7) 499.3 (43.5)
F 473.2 (58.2) 520.1 (84.9) 492.3 (72.4) 497.1 (42.8)
Loque, Patients treated with quetiapine<538 mg/d; Hique, patients treated with quetiapinei538 mg/d; Ptall, all patients ;
HC, healthy control subjects ; B, Baseline ; F, Follow-up; L, Lifetime; P-SES, parental socioeconomic status ; PANSS, Positive
and Negative Syndrome Scale.
Volumes of ICV, TBV, GM, WM and CSF are in cm3 (S.D.).
a Number of patients having any prescription of benzodiazepines.
b Number of patients in antidepressant treatment. At follow-up the three patients were treated with : selective serotonin
re-uptake inhibitors (n=2) ; noradrenergic and specific serotonergic antidepressant (n=1).
c Number of patients with any lifetime diagnosis of substance abuse. None of the patients abused in the investigation period.
d DUI, Duration of untreated illness at baseline.
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diagnoses were based on the Schedules for Clinical
Assessment in Neuropsychiatry (SCAN) version 2.1
(Wing et al. 1990). Diagnoses were confirmed by
regular clinical contacts during the treatment period.
Benzodiazepines were allowed to reduce agitation and
anxiety. Use of antidepressants was registered. None
of the patients received anti-cholinergic medication.
Duration of untreated illness (DUI) was defined as the
time between the first unspecific symptoms related to
psychosis and the date of the MRI scan. Symptoms
had to be associated with a decline in a previous stable
level of functioning. DUI data were collected as a best-
estimate approach (Keshavan et al. 1998) with infor-
mation from the SCAN interview, clinical records and
relatives when possible. Of the 38 patients included
at baseline, nine fulfilled lifetime DSM-IV criteria for
substance abuse. At follow-up, 5/22 patients had a
lifetime history of substance abuse, but none abused in
the treatment period. Further, at follow-up all subjects
had a negative urine screening for substance intake.
Extrapyramidal side-effects (EPS) were evaluated with
The Extrapyramidal Symptom Rating Scale (ESRS;
Chouinard & Margolese, 2005).
HC were recruited from the community. Both
patients and HC had normal physical and neuro-
logical examinations and MRI scans were without
pathology.
Medication
As described in the Introduction, PET data from our
group have indicated that the antipsychotic effect of
quetiapine is associated with up to 70% 5-HT2A occu-
pancy corresponding toy538 mg/d (Rasmussen et al.
2010). We hypothesized that higher quetiapine doses
act primarily through D2 blockade. The mean quetia-
pine dose in this study was 538 mg/d and was suit-
able for testing if high doses would be associated with
relative striatal volume increases compared to low
doses. Accordingly, to test for medication effects the
patients were a-priori split into a high quetiapine
(Hique) (i538 mg) (n=9) and a low quetiapine (Loque)
(<538 mg) (n=13) group. Cumulative quetiapine
intake was also calculated (mean=111.8 g, S.D.=62.5),
but since this correlated strongly with the mean dose
(r=0.97) only data on the mean dose are presented
here.
Image acquisition and processing
Details of the MRI acquisition protocol and processing
of the images have been presented elsewhere (Ebdrup
et al. 2010). Briefly, high-resolution 3D T1-weighted,
sagittal, magnetization-prepared rapid gradient echo
(MPRAGE) scans and 2D T2-weighted, axial, turbo-
spin echo scans were acquired of the whole head at
two time-points on a Siemens Magnetom Trio 3 T MR
scanner (Siemens, Germany) with an eight-channel
head coil. Images were gradient un-warped (Jovicich
et al. 2006) and processed using the VBM5 toolbox
(http://dbm.neuro.uni-jena.de/vbm/vbm5-forspm5/)
in SPM5 (Wellcome Department of Cognitive Neur-
ology, University College London, UK). T2-weighted
images were used to create brain masks in native
space. Brain-masked GM and white-matter (WM)
tissue maps were used for high-dimensional inter-
subject registration by means of DARTEL (‘diffeomor-
phic anatomical registration through exponentiated lie
algebra’ ; Ashburner, 2007). The brain-masked GM,
WM, and CSF images were warped into average im-
age space (DARTEL space) and modulated with the
Jacobian determinant (JD) of the applied deformation
fields to correct for local volume changes following the
inter-subject warping.
To determine volumetric changes from baseline
to follow-up, follow-up bias-corrected and intensity-
normalized T1 images in average image space were
warped to their baseline counterparts using high-
dimensional intra-subject warping (Ashburner et al.
2000). To evaluate volume changes over time the re-
sulting intra-subject JD image was transformed with
the natural logarithm and warped into DARTEL
space. The volume of each tissue class at follow-up
was calculated by the following formula :
GMDARTEL*(1x exp [ log (JDintra!subject;, DARTEL)]):
The volume change from baseline to follow-up was
calculated by subtraction of baseline and follow-up
images.
Regions of interest (ROIs)
ROI masks were created using the average of
DARTEL-warped MPRAGE images of all subjects to
test our specific hypotheses (Ebdrup et al. 2010).
Used delineation landmarks are referenced: striatum
(comprised of masks of caudate nucleus, nucleus
accumbens, putamen) (Glenthoj et al. 2007), hippo-
campus (Baare et al. 2001), ventricles (comprised of
lateral and third ventricle) (Cahn et al. 2002).
Volumetric brain measures
Total brain volume (TBV) and intracranial volume
(ICV) were estimated by integrating and adding
image-intensity values of modulated and warped GM
and WM (TBV), and CSF (ICV) images. ROI volumes
were acquired to investigate whether local voxel-wise
4 B. H. Ebdrup et al.
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changes were reflected in whole ROI volume changes.
ROI volume estimates were derived by integrating
image intensity values of modulated and warped
images within the specific ROI (for details see Ebdrup
et al. 2010). Global and regional volume estimates are
given in Tables 1 and 3, respectively.
Statistical analyses
Statistical Package for the Social Sciences software
(SPSS Inc., USA) was used to analyse demographic
and volumetric data. The distribution of continuous
data was tested for normality with the Shapiro–Wilk
test. Age and volumetric changes in ROIs (caudate
nucleus, nucleus accumbens, putamen, hippocampus,
ventricles) were not normally distributed, thus group
comparisons were performed non-parametrically with
the Mann–Whitney U test. Handedness and gender
differences were tested with Fisher’s exact test and
socioeconomic status with Pearson’s x2 test. Potential
outliers were identified with Grubbs’ outlier test
(Grubbs, 1969). Differences in PANSS scores between
patient groups were tested with the Student’s t test.
In the voxel-wise analyses we tested how groups
differed on volumetric changes over time (base-
line – follow-up) and in volumes at follow-up. We first
tested for differences between all patients (Ptall) and
HC. Subsequently, we tested for medication effects
using the following contrasts : Hique vs. HC, Loque vs.
HC and Hique vs. Loque. TBV change served as a co-
variate. Since patients and HC did not differ regarding
age, gender and MR-scan interval analyses were
initially performed without these covariates. Post-hoc,
these variables were entered as covariates to assess
their possible effects. When contrasting Hique vs. Loque
groups, both TBV change and percentage weight
change were entered as covariates, because patients
significantly gained weight compared to HC. General
linear models were estimated non-parametrically
using randomize, part of FSL (http://www.fmrib.ox.
ac.uk/fsl/randomise/index.html), using 10 000 per-
mutations. Small volume correction, applying ROI
masks, was used to test a priori hypotheses. A false
discovery rate threshold of 0.05 was used to correct for
multiple comparisons.
The contrasts tested in volumetric analyses were
identical to those tested in the voxel-wise analyses.
Effects of TBV changes were regressed out. When
contrasting Hique vs. Loque groups, the ROI volumes
were corrected for both TBV change and percentage
weight change. Age, gender and MR-scan interval
were entered as covariates post-hoc. Moreover, TBV
and weight-corrected volumetric changes and the
corresponding follow-up ROI volumes were used
to test for linear effects (using Spearman’s rank
correlation coefficient) of medication and change
in psychopathology. Change in psychopathology
(baseline – follow-up) was calculated separately for
positive, negative and total PANSS scores. Regional
percentage volume change was calculated as ROI
volume change divided by total brain change.
To control for any lifetime substance abuse diag-
nosis (n=5), all analyses were also performed ex-
cluding these patients. All tests were two-tailed, and
the significance level was set to p<0.05.
Results
Attrition
Sixteen patients were not included at follow-up.
Reasons for attrition were : clinically inadequate effect
(n=2), intolerable side-effects (sedation, weight gain,
rise in liver enzymes) (n=4), pregnancy (n=2) or re-
fusal to participate at follow-up (n=5). Three patients
had stated that after the baseline examinations they
were not willing to undergo treatment with quetia-
pine. The 16 excluded patients had significantly
smaller baseline ventricles (Z=x2.10, p=0.044) com-
pared to the patients who participated at follow-up.
However, there were no baseline differences in
demographic measures (p values >0.38), PANSS
scores (p values >0.23), or in other volumetric brain
measures (p values>0.36).
Baseline
At baseline Hique patients had significantly higher
lifetime exposure to benzodiazepines than Loque
patients (Fisher’s exact test, p=0.046). There were no
other significant differences on baseline demographic,
clinical and volumetric measures between the patient
subgroups (Tables 1 and 3).
Follow-up
Demographics
The interval between baseline and follow-upMR scans
did not differ between any of the patient groups and
HC (Z=x0.51 p=0.61). Patients gained significantly
more weight than did HC (Z=x3.43 p=0.001). The
mean weight gain in patients was 7.8 kg (S.D.=8.4),
corresponding to 11.1% (S.D.=12.4). There was no as-
sociation between quetiapine dosage and percentage
weight gain (r=0.26, p=0.24). Hique patients tended
to use more benzodiazepines than Loque patients
(Fisher’s exact test, p=0.055). None of the patients
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developed EPS. Follow-up PANSS scores were miss-
ing for one patient.
Global brain volumes
No significant global brain tissue volume (TBV, GM,
WM) changes were observed between PtallrHC,
HiquerLoque, HiquerHC, and LoquerHC (p values
>0.15).
Striatum
The voxel-wise analyses revealed significant bilateral
volume loss in Ptall compared to HC in the caudate
nucleus and putamen (Table 2). The volumetric
analyses paralleled the voxel-wise results. The striatal
volume was significantly reduced over time in Ptall
compared to HC (Z=x2.21, p=0.027). In post-hoc
analyses of striatal subregions separately Ptall com-
pared to HC had significant caudate (Z=x2.62,
p=0.009), putamen (Z=x1.99, p=0.046), but not
accumbens (Z=x1.72, p=0.17) volume loss over time.
At follow-up Ptall had significantly smaller striatal
volumes than did HC (Z=x2.15, p=0.032). Post-hoc
analyses of the striatal structures separately, revealed
smaller caudate (Z=x2.76, p=0.006) and accumbens
(Z=x2.52, p=0.012), but not putamen follow-up
volumes (Z=1.04, p=0.30).
Striatum, dose-dependent medication effect
In the voxel-wise analyses bilateral striatal volume
loss was significant in Loque, but not in Hique patients,
Table 2. Results of the voxel-wise analyses
Region Subregion Contrast Side Z score p value
MNI coordinates
(x, y, z)
Cluster
size
Striatum Cau PtallrHC Left 3.66 0.003 x15, 8, 22 2680
Cau Right 3.01 0.004 19, 18, 15 2590
Put Left 3.35 0.003 x30,x8, 10 2110
Put Right 3.56 0.003 24, 1, 12 2180
– HiquerHC – – n.s. – –
Cau LoquerHC Left 3.51 0.004 x16, 18, 11 5530
Cau Right 3.36 0.004 18, 14, 13 3020
Put Left 3.20 0.003 x26,x7, 9 2230
Put Right 3.67 0.004 26, 2, 10 2610
– LoquerHique – – n.s. – –
Hippocampus – PtallrHC Left 3.04 0.006 x22,x34,x4 3140
– Right 3.09 0.006 15,x38,x1 2070
– Right 2.44 0.02 14,x10,x17 75
– HiquerHC Left 3.39 0.00 x33,x31,x10 2970
– Right 3.73 0.007 23,x33,x5 1500
– Right 2.18 0.03 15,x12,x17 47
– LoquerHC – – n.s. – –
– HiquerLoque – – n.s. – –
Ventricles – PtallrHC – – n.s. – –
– HiquerHC – – n.s. – –
– LoquerHC – – n.s. – –
– LoquerHique – – n.s. – –
Results of small volume correction with the study-specific masks applied to the different contrasts.
Loque, Patients treated with quetiapine<538 mg/d; Hique, patients treated with quetiapinei538 mg/d; Ptall, all patients ;
HC, healthy control subjects ; Cau, caudate nucleus ; Put, putamen; MNI, Montreal Neurological Institute coordinates
(cluster sizes are in mm3).
The displayed contrasts test for volume loss between the groups ; however, in the ventricles, enlargement is tested. The opposite
contrasts were also tested, but all were non-significant (data not shown). Contrasts were performed with total brain volume
(TBV) change as a covariate. However, the contrast HiquerLoque was performed with both TBV change and percentage weight
change as covariates. All significant contrasts are displayed (p<0.05). Non-significant contrasts are assigned n.s.
Entering age, gender and MR scan interval as covariates did not change the results. Exclusion of the five subjects with a lifetime
substance abuse diagnosis did not alter the results.
p values are false discovery rate-corrected (p<0.05).
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compared to HC. Direct comparison between Hique
and Loque patients was not significant (Table 2).
The volumetric analyses paralleled the voxel-wise
results (Table 3). Loque patients had significant striatal
volume loss over time as compared to HC (Z=x2.22,
p=0.027). Hique and HC did not differ in total striatal
volume change (p=0.23). Comparison between Hique
and Loque patients was not significant (Z=x0.50,
p=0.62). In post-hoc analyses the volume loss in Loque
patients was accounted for by significant volume
loss in caudate (Z=x2.55, p=0.010) and putamen
(Z=x1.99, p=0.047), but not in accumbens (Z=x1.37,
p=0.17).
At follow-up Loque (Z=x2.10, p=0.036), but not
Hique (Z=x1.24, p=0.22) patients had significantly
smaller striatal volumes compared to HC. In direct
comparison the patient groups did not differ signifi-
cantly (Z=x1.30, p=0.19). In post-hoc analyses the
follow-up volume reduction in the Loque group ap-
peared in the caudate (Z=x2.35, p=0.019) and in the
accumbens (Z=x2.47, p=0.014), but not in the pu-
tamen (Z=x1.18, p=0.24).
The percentage striatal volume loss (corrected for
total brain change) in the different groups were:
Ptall=0.8%, Loque=1.0%, Hique=0.5%, HC=x0.6%
(Fig. 1).
In Ptall no significant linear correlations were ob-
served between quetiapine dose and striatal volume
loss or follow-upvolume, respectively (pvalues>0.46).
Ventricles
Neither the voxel-wise (Table 2) nor the volumetric
analyses revealed ventricle differences between any
of the groups (p values>0.27). Exploratory analyses
testing for group differences for third and lateral
ventricle volumes separately were not significant. In
Ptall no linear correlation between mean quetiapine
dose and ventricle volumes were observed (p values
>0.19).
Hippocampus
Significant bilateral hippocampal volume loss in Ptall
compared to HC was revealed both by the voxel-wise
analyses (Table 2) and the volumetric analyses
(Z=x3.23, p=0.002) (Table 3). At follow-up Ptall had
significantly smaller hippocampal volumes than HC
(Z=x2.13, p=0.033).
Hippocampus, dose-dependent medication effect
In the voxel-wise analyses bilateral hippocampal
volume loss was significant in Hique, but not in Loque
patients compared to HC. Direct comparison between
Hique and Loque patients was not significant (Table 2).
The volumetric analyses paralleled the voxel-wise
results by showing significant hippocampal volume
loss in Hique (Z=x3.22, p=0.001), and trend-level
volume loss in Loque (Z=x1.93, p=0.053) patients
compared to HC. There was no difference between the
two patient groups (Z=x1.37, p=0.17).
At follow-up Hique (Z=x2.90, p=0.004), but
not Loque (Z=x0.76, p=0.45) patients had smaller
hippocampal volumes compared to HC; however,
this difference was not significant (Z=x97, p=0.33)
between the patient groups.
The percentage hippocampal volume loss (cor-
rected for total brain change) in the different groups
were : Ptall=0.6%, Loque=0.3%, Hique=1.0%, HC=
x0.4% (Fig. 2).
In Ptall no linear correlations were observed be-
tween quetapine dose and hippocampal volume loss
or follow-up volume, respectively (p values>0.21).
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Fig. 1. Boxplot of percentage striatal volume loss in the three
subject groups. Volumes are corrected for total brain volume
(TBV) change. Positive values indicate more volume loss over
time. In the box-and-whisker plot, the central box represents
the values from the lower to upper quartile. The transverse
line in the box represents the median corrected volume.
The vertical line extends from the minimum to the maximum
value, excluding outside values. Outside values are defined
as values smaller or larger than the lower quartile minus
1.5 times the interquartile range and are displayed as separate
points (#). No outliers were identified. See text for the results
of the statistical comparisons.
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Whole brain
Exploratory voxel-wise whole-brain analyses did not
reveal additional regional GM, WM or CSF volume
loss between groups.
Psychopathology
From baseline to follow-up patients improved sig-
nificantly on positive (t20=5.74, p<0.001) and total
symptoms (t20=2.88, p=0.009), but not on negative
symptoms (t20=1.56, p=0.14). There were no signifi-
cant correlations between mean quetiapine doses and
baseline, follow-up or changes in PANSS positive,
negative and total scores (p values>0.15).
A positive correlation between baseline positive
symptoms and striatal volume loss over time (r=0.44,
p=0.042) was found (Fig. 3a). Post-hoc analyses re-
vealed positive correlations with volume loss in all
three striatal structures separately (caudate : r=0.51,
p=0.016 ; accumbens : r=0.52, p=0.013; putamen:
r=0.43, p=0.047). Further, we found a positive cor-
relation between baseline positive symptoms and
hippocampal volume loss over time (r=0.51, p=
0.016) (Fig. 3b). Finally, ventricle increase over time
was associated with less improvement in negative
symptoms (r=x0.46, p=0.038) (Fig. 4). The correla-
tions did not survive a correction for multiple
comparisons. No other linear correlations between
volumetric changes or follow-up volumes, and posi-
tive, negative or total symptoms were observed.
Adding age, gender and MR interval as covariates
did not change the above results significantly.
Similarly, exclusion of the five subjects with lifetime
substance abuse diagnosis did not significantly alter
the results.
Discussion
In this longitudinal TBM study we investigated
medication and psychopathological effects on brain
Table 3. Volume estimates for regions of interest (mm3)
Region Time-point Loque (n=13) Hique (n=9) Ptall (n=22) HC (n=28)
Striatum B 16203.8 (1859.6) 17055.0 (2225.4) 16552.0 (2011.5) 17155.1 (1240.3)
F 15868.7 (1992.5) 16801.9 (2328.1) 16250.6 (2134.0) 17117.6 (1318.5)
Caudate nucleus B 7170.5 (814.8) 7465.8 (1065.2) 7291.3 (913.1) 7691.1 (687.5)
F 6998.7 (864.3) 7335.9 (1099.8) 7136.6 (957.3) 7688.6 (715.0)
Nucleus accumbens B 687.9 (79.5) 739.5 (119.7) 709.0 (98.7) 760.0 (74.4)
F 679.8 (82.3) 734.1 (125.0) 702.0 (102.8) 760.0 (78.7)
Putamen B 8345.5 (1019.5) 8849.6 (1136.1) 8551.7 (1072.4) 8703.9 (695.7)
F 8190.2 (1086.1) 8731.9 (1189.1) 8411.8 (1134.7) 8671.0 (724.7)
Hippocampus B 8845.7 (878.6) 8810.1 (789.1) 8831.1 (823.8) 9077.2 (666.3)
F 8758.6 (914.1) 8665.2 (859.7) 8720.4 (872.5) 9071.9 (677.1)
Ventricles B 15584.7 (5629.3) 18773.3 (7821.3) 16889.1 (6882.9) 15350.7 (6034.3)
F 15606.2 (5696.9) 18353.2 (7821.3) 16730.0 (6615.1) 15305.0 (6034.3)
Loque, Patients treated with quetiapine<538 mg/d; Hique, patients treated with quetiapinei538 mg/d; Ptall, all patients ;
HC, healthy control subjects ; B, baseline ; F, follow-up.
Values are mean (S.D.).
5
4
3
2
1
0
–1
–2
Loque
(n = 13)
Hique
(n = 9)
HC
(n = 28)
H
ip
po
ca
m
pa
l l
os
s 
(%
), 
co
rr
ec
te
d 
fo
r T
BV
 c
ha
ng
e
Fig. 2. Boxplot of percentage hippocampal volume loss in
the three subject groups. Volumes are corrected total brain
volume (TBV) change. Grubbs’ test detected one outlier in
the high quetiapine group. Exclusion of this outlier did not
change the results significantly. See text for the results of
the statistical comparisons. (Information about
interpretation of the boxplot is provided in Fig. 1.)
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structure in 22 initially antipsychotic-naive, first-
episode schizophrenia patients after treatment with
quetiapine for approximately 6 months. The main
finding was that patients had significant bilateral
striatal and hippocampal volume loss during the
treatment period. The striatal volume loss was most
pronounced in patients treated with low quetiapine
doses whereas the volume loss was less apparent in
patients treated with high doses. Conversely, hippo-
campal volume loss appeared more pronounced in
patients treated with high quetiapine doses than in
patients treated with low doses. However, the dose-
dependent differences were only apparent in patient
subgroups when compared to HC. Clinically, higher
baseline positive symptoms were associated with
more striatal and hippocampal volume loss over time.
Although patients’ ventricles did not change signifi-
cantly over time, ventricular increases were associated
with less improvement on negative symptoms. No
significant changes in global brain measures (TBV,
GM, WM) were observed.
Quetiapine treatment has previously been associ-
ated with striatal volume loss in already medicated
patients (Stip et al. 2008). However, in the present
study patients were initially antipsychotic-naive and
therefore quetiapine in itself may be associated with
striatal volume reduction. One previous study in
antipsychotic-naive patients reported no significant
caudate volume reduction in 10 patients following
12 wk of quetiapine treatment (mean dose 494 mg/d)
(Tauscher-Wisniewski et al. 2005). Nevertheless, they
observed that the absolute caudate volume decreased
over time. Their failure to observe significant effects
might be related to the small subject sample and the
relative short treatment period.
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Fig. 3. Positive symptoms and striatal and hippocampal loss. Positive correlations between baseline Positive and Negative
Syndrome Scale (PANSS) positive symptoms and (a) striatal (r=0.44, p=0.042), and (b) hippocampal (r=0.51, p=0.016)
volume loss (in mm3) over time. Volumes were corrected for changes in total brain volume (TBV) and percentage weight
change. The correlations did not survive a correction for multiple comparisons. Note, that grey-matter loss is indicated
with higher values on the y-axis. See text for details.
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Fig. 4. Negative symptoms and ventricular volume increase.
A negative correlation between improvement in negative
symptoms [Positive and Negative Syndrome Scale (PANSS)
negative baseline – follow-up] and ventricle increase (inmm3)
over time (r=x0.46, p=0.038). Volumes were corrected
for changes in TBV and percentage weight change. The
correlation did not survive a correction for multiple
comparisons. Note that symptom improvement is indicated
with higher values on the x-axis and that ventricular
increase is indicated with higher values on the y-axis.
See text for details.
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Our data suggest that high quetiapine doses may
attenuate the striatal volume loss. Dose-dependent
volumetric effects of quetiapine have not previously
been described. Interestingly, clinical studies with ris-
peridone have associated striatal volume increases
with high doses of risperidone (6.05 mg/d) (Massana
et al. 2005), whereas moderate (3.64 mg/d) (Glenthoj
et al. 2007) and low (2.7 mg/d) (Lang et al. 2001)
risperidone doses caused marginal increases or no
striatal volume changes, respectively. According to a
hypothesis put forward by Kapur & Seeman (2001),
a transiently high striatal D2 blockade may drive the
antipsychotic effect in SGAs. We infer that our obser-
vation of relative striatal volume increases with high
quetiapine doses could reflect this transiently high
D2 occupancy. Conversely, in low doses the clinical
effect may be more related to 5-HT2A occupancy as
suggested by our previous PET data (Rasmussen et al.
2010). From the present study it is not possible to
determine whether the observed striatal volume re-
duction is a consequence of the disease progress per se
or of the 5-HT2A blockade. However, post-mortem
studies have indicated that 5-HT2A receptor density in
striatum is low (Dwivedi & Pandey, 1998) and that the
striatal volume and neuron number decrease over the
course of the illness regardless of chronic treatment
with FGAs (Kreczmanski et al. 2007).
Since we did not asses D2 blockade, inferences
from the present data must be made cautiously.
Nevertheless, the absence of linear correlations be-
tween quetiapine dose and striatal and hippocampal
changes, respectively, supports the hypothesis of a
threshold of 5-HT2A- and D2-mediated clinical effects.
Although quetiapine doses of 400–450 mg have re-
sulted in dopamine D2 occupancies ofy60% 2 h post-
dose (Kapur et al. 2000; Tauscher-Wisniewski et al.
2002) also lower occupancies of 44% and 30% 2 h post-
450 mg quetiapine have been reported (Gefvert et al.
1998, 2001). Indisputably, a dose of 538 mg/d as ap-
plied in our study may not address the ‘true’ thresh-
old. Larger sample sizes, preferably including PET
data are required to confirm this possible dose-
dependent effect of quetiapine and to identify a more
precise threshold. Finally, the mechanisms behind
striatal volume increase after sustained blockade of
the D2 receptors are still elusive, but up-regulation of
the D2 receptors (Burt et al. 1977; Seeman, 1987), axonal
sprouting (Benes et al. 1983) and increased striatal
blood flow (Corson et al. 2002; Miller et al. 1997) have
been suggested.
Contrary to findings in preclinical studies, quetia-
pine did not seem to protect against hippocampal
volume loss (Bi et al. 2009; Park et al. 2006). No linear
correlation between mean dose and volume loss was
observed and the hippocampal volume loss appeared
most pronounced in the high-dose group compared
to HC. Interestingly, this inverted dose-dependent
association is supported by a preclinical study on
rat hippocampi in which low doses of clozapine
(0.5 mg/kg) increased markers of DNA synthesis in
hippocampus whereas high doses (20 mg/kg) had no
effect (Halim et al. 2004).
Accumulating evidence suggests that ventricular
enlargement occurs during the early course of schizo-
phrenia (Steen et al. 2006; Van Haren et al. 2008;
Vita et al. 2006). Although antipsychotic treatment
may exert a preserving effect on ventricular volume
(Lieberman et al. 2001), a recent review has suggested
that antipsychotic treatment may on the contrary be
associated with ventricular enlargement (Moncrieff &
Leo, 2010). Similarly, the long-term effects of anti-
psychotic compounds on global brain volume are
unclear (Moncrieff & Leo, 2010). The present results
suggest that quetiapine may protect against ventri-
cular enlargement and global brain loss in the early
course of illness.
Treatment with quetiapine improved PANSS posi-
tive and total scores although negative symptoms did
not improve significantly. The absence of correlations
between mean quetiapine dose and any of the PANSS
measures, allowed for independent investigations
of mediation effects and psychopathology. On the
other hand, this absence of an association between
medication dose and psychopathology renders it
controversial whether regional GM changes induced
by antipsychotics are clinically beneficial (Navari &
Dazzan, 2009 ; Smieskova et al. 2009). The clinical
complexity of schizophrenia combined with the
pharmacological complexity of quetiapine may partly
explain why a dose–response relationship is not well-
established (Kinon et al. 2004) and an optimal thera-
peutic range for quatiapine remains to be identified
(Mauri et al. 2007).
MRI studies have previously associated striatal
volume reductions with positive symptoms (Crespo-
Facorro et al. 2007; Scheepers et al. 2001) ; however,
the present study is the first to show that the severity
of positive symptoms in the antipsychotic-naive
state may predict progressive striatal volume loss.
Interestingly, in subjects at high risk for developing
psychosis, progressive hippocampal volume reduc-
tions have been associated with later transition to
schizophrenia, although also reduced activation in
prefrontal cortex, reduced neuronal density, and in-
creased membrane turnover in frontal and cingulate
cortex seem implicated in transition (Smieskova et al.
10 B. H. Ebdrup et al.
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2010; Wood et al. 2008). Our finding of a positive cor-
relation between baseline positive symptoms and
progressive hippocampal loss could therefore suggest
that the hippocampus is particularly sensitive to
positive symptoms around and right after transition
to psychosis. We speculate that this hippocampal
sensitivity might reflect a higher level of stress ac-
companying a psychotic state possibly related to
disturbances in the hypothalamic–pituitary–adrenal
(HPA) axis (Phillips et al. 2006). Although we did not
find ventricular enlargement over time a significant
correlation between ventricular increase and less
negative symptom improvement was observed. As
such our data are consistent with the growing body of
evidence which has associated negative symptoms
and poor prognosis with ventricular enlargement
(Hulshoff Pol & Kahn, 2008).
The present study is limited by several factors. First,
the attrition was considerable during the 6-month
period (42%). Notably, only 6/16 dropouts were di-
rectly related to quetiapine. Only ventricular volumes
were significantly different (smaller) and no other
demographic, clinical or structural differences be-
tween the dropouts and re-scanned patients were
found. This suggests that our results were not biased
by baseline differences. In our analyses of dose-
dependent effects the patient subgroups are small and
the observed differences appear in comparison with
HC, whereas direct comparisons between the sub-
groups are non-significant. Nevertheless, the direction
of the dose-dependent effect on striatum was a-priori
hypothesized, rather than a result of a post-hoc
comparison. Hence our failure to detect significant
changes in direct comparison between the patient
subgroups could be attributable to lack of power
(a type II error). Moreover, a potential inaccuracy in
our threshold of 538 mg/d would also reduce the dif-
ferences between the patient groups. Ideally, a study
of dose-dependent medication effects should apply
a double-blind, randomized design; however, for
ethical reasons this was not performed. The absence of
correlations between our obtained clinical measures
and medication dose indicate that the patient sub-
groups were not biased by illness severity. Finally,
it should be emphasized that although clinically
meaningful, our findings regarding structural changes
and psychopathology appeared among several corre-
lations and they would not survive a correction for
multiple comparisons.
In conclusion we found that 6 months’ treat-
ment with quetiapine in antipsychotic-naive, first-
episode schizophrenia patients was associated with
progressive bilateral volume loss in striatum and
hippocampus. The progressive volumetric loss may
be dose-dependent and clinically relevant. The mech-
anisms underlying associations between progressive
brain changes and specific antipsychotic compounds
and clinical symptoms warrant further clarification.
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